var title_f10_33_10768="CTCAE grading scale for skin and subcutaneous disorders";
var content_f10_33_10768=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F86990&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F86990&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Common terminology criteria for adverse events (CTCAE) version 4.0. Grading scale for skin and subcutaneous tissue disorders.",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup span=\"6\" width=\"16%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        CTCAEv4 term",
"       </td>",
"       <td class=\"subtitle1\">",
"        Grade 1",
"       </td>",
"       <td class=\"subtitle1\">",
"        Grade 2",
"       </td>",
"       <td class=\"subtitle1\">",
"        Grade 3",
"       </td>",
"       <td class=\"subtitle1\">",
"        Grade 4",
"       </td>",
"       <td class=\"subtitle1\">",
"        Grade 5",
"       </td>",
"      </tr>",
"      <tr class=\"divider_bottom\">",
"       <td>",
"        Alopecia",
"       </td>",
"       <td>",
"        Hair loss of &lt;50 percent normal for that individual that is not obvious from distance but only on close inspection; different hair style may be required to cover hair loss but it does not require wig or hairpiece to camouflage",
"       </td>",
"       <td>",
"        Hair loss of &ge;50 percent normal for that individual that is readily apparent to others; wig or hairpiece is necessary if patient desires to completely camouflage hair loss; associated with psychosocial impact",
"       </td>",
"       <td class=\"centered\">",
"        &mdash;",
"       </td>",
"       <td class=\"centered\">",
"        &mdash;",
"       </td>",
"       <td class=\"centered\">",
"        &mdash;",
"       </td>",
"      </tr>",
"      <tr class=\"divider_bottom\">",
"       <td>",
"        Body odor",
"       </td>",
"       <td>",
"        Mild odor; physician intervention not indicated; self-care interventions",
"       </td>",
"       <td>",
"        Pronounced odor; psychosocial impact; patient seeks medical intervention",
"       </td>",
"       <td class=\"centered\">",
"        &mdash;",
"       </td>",
"       <td class=\"centered\">",
"        &mdash;",
"       </td>",
"       <td class=\"centered\">",
"        &mdash;",
"       </td>",
"      </tr>",
"      <tr class=\"divider_bottom\">",
"       <td>",
"        Bullous dermatitis",
"       </td>",
"       <td>",
"        Asymptomatic; blisters covering &lt;10 percent BSA",
"       </td>",
"       <td>",
"        Blisters covering 10 to 30 percent BSA; painful blisters; limiting instrumental ADL",
"       </td>",
"       <td>",
"        Blisters covering &gt;30 percent BSA; limiting self-care ADL",
"       </td>",
"       <td>",
"        Blisters covering &gt;30 percent BSA; associated with fluid or electrolyte abnormalities; ICU care or burn unit indicated",
"       </td>",
"       <td>",
"        Death",
"       </td>",
"      </tr>",
"      <tr class=\"divider_bottom\">",
"       <td>",
"        Dry skin",
"       </td>",
"       <td>",
"        Covering &lt;30 percent BSA and no associated erythema or pruritus",
"       </td>",
"       <td>",
"        Covering 10 to 30 percent BSA and associated with erythema or pruritus; limiting instrumental ADL",
"       </td>",
"       <td>",
"        Covering &gt;30 percent BSA and associated with pruritus; limiting self-care ADL",
"       </td>",
"       <td class=\"centered\">",
"        &mdash;",
"       </td>",
"       <td class=\"centered\">",
"        &mdash;",
"       </td>",
"      </tr>",
"      <tr class=\"divider_bottom\">",
"       <td>",
"        Erythema multiforme",
"       </td>",
"       <td>",
"        Target lesions covering &lt;10 percent BSA and not associated with skin tenderness",
"       </td>",
"       <td>",
"        Target lesions covering 10 to 30 percent BSA and associated with skin tenderness",
"       </td>",
"       <td>",
"        Target lesions covering &gt;30 percent BSA and associated with oral or genital erosions",
"       </td>",
"       <td>",
"        Target lesions covering &gt;30 percent BSA; associated with fluid or electrolyte abnormalities; ICU care or burn unit indicated",
"       </td>",
"       <td>",
"        Death",
"       </td>",
"      </tr>",
"      <tr class=\"divider_bottom\">",
"       <td>",
"        Erythroderma",
"       </td>",
"       <td class=\"centered\">",
"        &mdash;",
"       </td>",
"       <td>",
"        Erythema covering &gt;90 percent BSA without associated symptoms; limiting instrumental ADL",
"       </td>",
"       <td>",
"        Erythema covering &gt;90 percent BSA with associated symptoms (eg, pruritus or tenderness); limiting self-care ADL",
"       </td>",
"       <td>",
"        Erythema covering &gt;90 percent BSA with associated fluid or electrolyte abnormalities; ICU care or burn unit indicated",
"       </td>",
"       <td>",
"        Death",
"       </td>",
"      </tr>",
"      <tr class=\"divider_bottom\">",
"       <td>",
"        Fat atrophy",
"       </td>",
"       <td>",
"        Covering &lt;10 percent BSA and asymptomatic",
"       </td>",
"       <td>",
"        Covering 10 to 30 percent BSA and associated with erythema or tenderness; limiting instrumental ADL",
"       </td>",
"       <td>",
"        Covering &gt;30 percent BSA; associated with erythema or tenderness; limiting self-care ADL",
"       </td>",
"       <td class=\"centered\">",
"        &mdash;",
"       </td>",
"       <td class=\"centered\">",
"        &mdash;",
"       </td>",
"      </tr>",
"      <tr class=\"divider_bottom\">",
"       <td>",
"        Hirsutism",
"       </td>",
"       <td>",
"        In women, increase in length, thickness, or density of hair in male distribution that patient is able to camouflage by periodic shaving, bleaching, or removal of hair",
"       </td>",
"       <td>",
"        In women, increase in length, thickness, or density of hair in male distribution that requires daily shaving or consistent destructive means of hair removal to camouflage; associated with psychosocial impact",
"       </td>",
"       <td class=\"centered\">",
"        &mdash;",
"       </td>",
"       <td class=\"centered\">",
"        &mdash;",
"       </td>",
"       <td class=\"centered\">",
"        &mdash;",
"       </td>",
"      </tr>",
"      <tr class=\"divider_bottom\">",
"       <td>",
"        Hyperhidrosis",
"       </td>",
"       <td>",
"        Limited to one site (palms, soles, or axillae); self-care interventions",
"       </td>",
"       <td>",
"        Involving &gt;1 site; patient seeks medical intervention; associated with psychosocial impact",
"       </td>",
"       <td>",
"        Generalized involving sites other than palms, soles, or axillae; associated with electrolyte/ hemodynamic imbalance",
"       </td>",
"       <td class=\"centered\">",
"        &mdash;",
"       </td>",
"       <td class=\"centered\">",
"        &mdash;",
"       </td>",
"      </tr>",
"      <tr class=\"divider_bottom\">",
"       <td>",
"        Hypertrichosis",
"       </td>",
"       <td>",
"        Increase in length, thickness, or density of hair that patient is either able to camouflage by periodic shaving or removal of hairs or is not concerned enough about overgrowth to use any form of hair removal",
"       </td>",
"       <td>",
"        Increase in length, thickness, or density of hair at least on usual exposed areas of body (face [not limited to beard/ moustache area], arms) that requires frequent shaving or use of destructive means of hair removal to camouflage; associated with psychosocial impact",
"       </td>",
"       <td class=\"centered\">",
"        &mdash;",
"       </td>",
"       <td class=\"centered\">",
"        &mdash;",
"       </td>",
"       <td class=\"centered\">",
"        &mdash;",
"       </td>",
"      </tr>",
"      <tr class=\"divider_bottom\">",
"       <td>",
"        Hypohidrosis",
"       </td>",
"       <td class=\"centered\">",
"        &mdash;",
"       </td>",
"       <td>",
"        Symptomatic; limiting instrumental ADL",
"       </td>",
"       <td>",
"        Increase in body temperature; limiting self-care ADL",
"       </td>",
"       <td>",
"        Heat stroke",
"       </td>",
"       <td>",
"        Death",
"       </td>",
"      </tr>",
"      <tr class=\"divider_bottom\">",
"       <td>",
"        Lipohypertrophy",
"       </td>",
"       <td>",
"        Asymptomatic and covering &lt;10 percent BSA",
"       </td>",
"       <td>",
"        Covering 10 to 30 percent BSA and associated tenderness; limiting instrumental ADL",
"       </td>",
"       <td>",
"        Covering &gt;30 percent BSA and associated tenderness and narcotics or NSAIDs indicated; lipohypertrophy; limiting self-care ADL",
"       </td>",
"       <td class=\"centered\">",
"        &mdash;",
"       </td>",
"       <td class=\"centered\">",
"        &mdash;",
"       </td>",
"      </tr>",
"      <tr class=\"divider_bottom\">",
"       <td>",
"        Nail discoloration",
"       </td>",
"       <td>",
"        Asymptomatic; clinical or diagnostic observations only; intervention not indicated",
"       </td>",
"       <td class=\"centered\">",
"        &mdash;",
"       </td>",
"       <td class=\"centered\">",
"        &mdash;",
"       </td>",
"       <td class=\"centered\">",
"        &mdash;",
"       </td>",
"       <td class=\"centered\">",
"        &mdash;",
"       </td>",
"      </tr>",
"      <tr class=\"divider_bottom\">",
"       <td>",
"        Nail loss",
"       </td>",
"       <td>",
"        Asymptomatic separation of nail bed from nail plate or nail loss",
"       </td>",
"       <td>",
"        Symptomatic separation of nail bed from nail plate or nail loss; limiting instrumental ADL",
"       </td>",
"       <td class=\"centered\">",
"        &mdash;",
"       </td>",
"       <td class=\"centered\">",
"        &mdash;",
"       </td>",
"       <td class=\"centered\">",
"        &mdash;",
"       </td>",
"      </tr>",
"      <tr class=\"divider_bottom\">",
"       <td>",
"        Nail ridging",
"       </td>",
"       <td>",
"        Asymptomatic; clinical or diagnostic observations only; intervention not indicated",
"       </td>",
"       <td class=\"centered\">",
"        &mdash;",
"       </td>",
"       <td class=\"centered\">",
"        &mdash;",
"       </td>",
"       <td class=\"centered\">",
"        &mdash;",
"       </td>",
"       <td class=\"centered\">",
"        &mdash;",
"       </td>",
"      </tr>",
"      <tr class=\"divider_bottom\">",
"       <td>",
"        Pain of skin",
"       </td>",
"       <td>",
"        Mild pain",
"       </td>",
"       <td>",
"        Moderate pain; limiting instrumental ADL",
"       </td>",
"       <td>",
"        Severe pain; limiting self-care ADL",
"       </td>",
"       <td class=\"centered\">",
"        &mdash;",
"       </td>",
"       <td class=\"centered\">",
"        &mdash;",
"       </td>",
"      </tr>",
"      <tr class=\"divider_bottom\">",
"       <td>",
"        Palmar-plantar erythrodysesthesia syndrome",
"       </td>",
"       <td>",
"        Minimal skin changes or dermatitis (eg, erythema, edema, or hyperkeratosis) without pain",
"       </td>",
"       <td>",
"        Skin changes (eg, peeling, blisters, bleeding, edema, or hyperkeratosis) with pain; limiting instrumental ADL",
"       </td>",
"       <td>",
"        Severe skin changes (eg, peeling, blisters, bleeding, edema, or hyperkeratosis) with pain; limiting self-care ADL",
"       </td>",
"       <td class=\"centered\">",
"        &mdash;",
"       </td>",
"       <td class=\"centered\">",
"        &mdash;",
"       </td>",
"      </tr>",
"      <tr class=\"divider_bottom\">",
"       <td>",
"        Periorbital edema",
"       </td>",
"       <td>",
"        Soft or nonpitting",
"       </td>",
"       <td>",
"        Indurated or pitting edema; topical intervention indicated",
"       </td>",
"       <td>",
"        Edema associated with visual disturbance; increased intraocular pressure, glaucoma, or retinal hemorrhage; optic neuritis; diuretics indicated; operative intervention indicated",
"       </td>",
"       <td class=\"centered\">",
"        &mdash;",
"       </td>",
"       <td class=\"centered\">",
"        &mdash;",
"       </td>",
"      </tr>",
"      <tr class=\"divider_bottom\">",
"       <td>",
"        Photosensitivity",
"       </td>",
"       <td>",
"        Painless erythema; erythema covering &lt;10 percent BSA",
"       </td>",
"       <td>",
"        Tender erythema covering 10 to 30 percent BSA",
"       </td>",
"       <td>",
"        Erythema covering &gt;30 percent BSA; erythema with blistering; photosensitivity; oral corticosteroid therapy indicated; pain control indicated (eg, narcotics or NSAIDs)",
"       </td>",
"       <td>",
"        Life-threatening consequences; urgent intervention indicated",
"       </td>",
"       <td>",
"        Death",
"       </td>",
"      </tr>",
"      <tr class=\"divider_bottom\">",
"       <td>",
"        Pruritus",
"       </td>",
"       <td>",
"        Mild or localized; topical intervention indicated",
"       </td>",
"       <td>",
"        Intense or widespread; intermittent; skin changes from scratching (eg, edema, papulation, excoriations, lichenification, oozing/crusts); oral intervention indicated; limiting instrumental ADL",
"       </td>",
"       <td>",
"        Intense or widespread; constant; limiting self-care ADL or sleep; oral corticosteroid or immunosuppressive therapy indicated",
"       </td>",
"       <td class=\"centered\">",
"        &mdash;",
"       </td>",
"       <td class=\"centered\">",
"        &mdash;",
"       </td>",
"      </tr>",
"      <tr class=\"divider_bottom\">",
"       <td>",
"        Purpura",
"       </td>",
"       <td>",
"        Combined area of lesions covering &lt;10 percent BSA",
"       </td>",
"       <td>",
"        Combined area of lesions covering 10 to 30 percent BSA; bleeding with trauma",
"       </td>",
"       <td>",
"        Combined area of lesions covering &gt;30 percent BSA; spontaneous bleeding",
"       </td>",
"       <td class=\"centered\">",
"        &mdash;",
"       </td>",
"       <td class=\"centered\">",
"        &mdash;",
"       </td>",
"      </tr>",
"      <tr class=\"divider_bottom\">",
"       <td>",
"        Rash acneiform",
"       </td>",
"       <td>",
"        Papules and/or pustules covering &lt;10 percent BSA, which may or may not be associated with symptoms of pruritus or tenderness",
"       </td>",
"       <td>",
"        Papules and/or pustules covering 10 to 30 percent BSA, which may or may not be associated with symptoms of pruritus or tenderness; associated with psychosocial impact; limiting instrumental ADL",
"       </td>",
"       <td>",
"        Papules and/or pustules covering &gt;30 percent BSA, which may or may not be associated with symptoms of pruritus or tenderness; limiting self-care ADL; associated with local superinfection with oral antibiotics indicated",
"       </td>",
"       <td>",
"        Papules and/or pustules covering any BSA percent, which may or may not be associated with symptoms of pruritus or tenderness and are associated with extensive superinfection with IV antibiotics indicated; lifethreatening consequences",
"       </td>",
"       <td>",
"        Death",
"       </td>",
"      </tr>",
"      <tr class=\"divider_bottom\">",
"       <td>",
"        Rash maculopapular",
"       </td>",
"       <td>",
"        Macules/papules covering &lt;10 percent BSA with or without symptoms (eg, pruritus, burning, tightness)",
"       </td>",
"       <td>",
"        Macules/papules covering 10 to 30 percent BSA with or without symptoms (eg, pruritus, burning, tightness); limiting instrumental ADL",
"       </td>",
"       <td>",
"        Macules/papules covering &gt;30 percent BSA with or without associated symptoms; limiting self-care ADL",
"       </td>",
"       <td class=\"centered\">",
"        &mdash;",
"       </td>",
"       <td class=\"centered\">",
"        &mdash;",
"       </td>",
"      </tr>",
"      <tr class=\"divider_bottom\">",
"       <td>",
"        Scalp pain",
"       </td>",
"       <td>",
"        Mild pain",
"       </td>",
"       <td>",
"        Moderate pain; limiting instrumental ADL",
"       </td>",
"       <td>",
"        Severe pain; limiting self-care ADL",
"       </td>",
"       <td class=\"centered\">",
"        &mdash;",
"       </td>",
"       <td class=\"centered\">",
"        &mdash;",
"       </td>",
"      </tr>",
"      <tr class=\"divider_bottom\">",
"       <td>",
"        Skin atrophy",
"       </td>",
"       <td>",
"        Covering &lt;10 percent BSA; associated with telangiectasias or changes in skin color",
"       </td>",
"       <td>",
"        Covering 10 to 30 percent BSA; associated with striae or adnexal structure loss",
"       </td>",
"       <td>",
"        Covering &gt;30 percent BSA; associated with ulceration",
"       </td>",
"       <td class=\"centered\">",
"        &mdash;",
"       </td>",
"       <td class=\"centered\">",
"        &mdash;",
"       </td>",
"      </tr>",
"      <tr class=\"divider_bottom\">",
"       <td>",
"        Skin hyperpigmentation",
"       </td>",
"       <td>",
"        Hyperpigmentation covering &lt;10 percent BSA; no psychosocial impact",
"       </td>",
"       <td>",
"        Hyperpigmentation covering &gt;10 percent BSA; associated psychosocial impact",
"       </td>",
"       <td class=\"centered\">",
"        &mdash;",
"       </td>",
"       <td class=\"centered\">",
"        &mdash;",
"       </td>",
"       <td class=\"centered\">",
"        &mdash;",
"       </td>",
"      </tr>",
"      <tr class=\"divider_bottom\">",
"       <td>",
"        Skin hypopigmentation",
"       </td>",
"       <td>",
"        Hypopigmentation or depigmentation covering &lt;10 percent BSA; no psychosocial impact",
"       </td>",
"       <td>",
"        Hypopigmentation or depigmentation covering &gt;10 percent BSA; associated psychosocial impact",
"       </td>",
"       <td class=\"centered\">",
"        &mdash;",
"       </td>",
"       <td class=\"centered\">",
"        &mdash;",
"       </td>",
"       <td class=\"centered\">",
"        &mdash;",
"       </td>",
"      </tr>",
"      <tr class=\"divider_bottom\">",
"       <td>",
"        Skin induration",
"       </td>",
"       <td>",
"        Mild induration, able to move skin parallel to plane (sliding) and perpendicular to skin (pinching up)",
"       </td>",
"       <td>",
"        Moderate induration, able to slide skin, unable to pinch skin; limiting instrumental ADL",
"       </td>",
"       <td>",
"        Severe induration, unable to slide or pinch skin; limiting joint movement or orifice (eg, mouth, anus); limiting selfcare ADL",
"       </td>",
"       <td>",
"        Generalized; associated with signs or symptoms of impaired breathing or feeding",
"       </td>",
"       <td>",
"        Death",
"       </td>",
"      </tr>",
"      <tr class=\"divider_bottom\">",
"       <td>",
"        Skin ulceration",
"       </td>",
"       <td>",
"        Combined area of ulcers &lt;1 cm; nonblanchable erythema of intact skin with associated warmth or edema",
"       </td>",
"       <td>",
"        Combined area of ulcers 1 to 2 cm; partial-thickness skin loss involving skin or subcutaneous fat",
"       </td>",
"       <td>",
"        Combined area of ulcers &gt;2 cm; fullthickness skin loss involving damage to or necrosis of subcutaneous tissue that may extend down to fascia",
"       </td>",
"       <td>",
"        Any size ulcer with extensive destruction, tissue necrosis, or damage to muscle, bone, or supporting structures with or without fullthickness skin loss",
"       </td>",
"       <td>",
"        Death",
"       </td>",
"      </tr>",
"      <tr class=\"divider_bottom\">",
"       <td>",
"        Stevens-Johnson syndrome",
"       </td>",
"       <td class=\"centered\">",
"        &mdash;",
"       </td>",
"       <td class=\"centered\">",
"        &mdash;",
"       </td>",
"       <td>",
"        Skin sloughing covering &lt;10 percent BSA with associated signs (eg, erythema, purpura, epidermal detachment, and mucous membrane detachment",
"       </td>",
"       <td>",
"        Skin sloughing covering 10 to 30 percent BSA with associated signs (eg, erythema, purpura, epidermal detachment, and mucous membrane detachment)",
"       </td>",
"       <td>",
"        Death",
"       </td>",
"      </tr>",
"      <tr class=\"divider_bottom\">",
"       <td>",
"        Telangiectasia",
"       </td>",
"       <td>",
"        Telangiectasias covering &lt;10 percent BSA",
"       </td>",
"       <td>",
"        Telangiectasias covering &gt;10 percent BSA; associated with psychosocial impact",
"       </td>",
"       <td class=\"centered\">",
"        &mdash;",
"       </td>",
"       <td class=\"centered\">",
"        &mdash;",
"       </td>",
"       <td class=\"centered\">",
"        &mdash;",
"       </td>",
"      </tr>",
"      <tr class=\"divider_bottom\">",
"       <td>",
"        Toxic epidermal necrolysis",
"       </td>",
"       <td class=\"centered\">",
"        &mdash;",
"       </td>",
"       <td class=\"centered\">",
"        &mdash;",
"       </td>",
"       <td class=\"centered\">",
"        &mdash;",
"       </td>",
"       <td>",
"        Skin sloughing covering &ge;30 percent BSA with associated symptoms (eg, erythema, purpura, or epidermal detachment",
"       </td>",
"       <td>",
"        Death",
"       </td>",
"      </tr>",
"      <tr class=\"divider_bottom\">",
"       <td>",
"        Urticaria",
"       </td>",
"       <td>",
"        Urticarial lesions covering &lt;10 percent BSA; topical intervention indicated",
"       </td>",
"       <td>",
"        Urticarial lesions covering 10 to 30 percent BSA; oral intervention indicated",
"       </td>",
"       <td>",
"        Urticarial lesions covering &gt;30 percent BSA; IV intervention indicated",
"       </td>",
"       <td class=\"centered\">",
"        &mdash;",
"       </td>",
"       <td class=\"centered\">",
"        &mdash;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Other, specify",
"       </td>",
"       <td>",
"        Asymptomatic or mild symptoms; clinical or diagnostic observations only; intervention not indicated",
"       </td>",
"       <td>",
"        Moderate; minimal, local, or noninvasive intervention indicated; limiting age-appropriate instrumental ADL",
"       </td>",
"       <td>",
"        Severe or medically significant but not immediately life threatening; hospitalization or prolongation of existing hospitalization indicated; disabling; limiting self-care ADL",
"       </td>",
"       <td>",
"        Life-threatening consequences; urgent intervention indicated",
"       </td>",
"       <td>",
"        Death",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    Semicolon indicates \"or\" within description of grade. Single dash (-) indicates grade is not available. Instrumental ADL refer to preparing meals, shopping for groceries or clothes, using telephone, managing money, etc. Self-care ADL refer to bathing, dressing and undressing, feeding self, using toilet, taking medications, and not bedridden. Not all grades are appropriate for all adverse events. Therefore, some adverse events are listed with fewer than&nbsp;five options for grade selection.",
"    <div class=\"footnotes\">",
"     ADL: activities of daily living; BSA: body surface area; CTCAEv4: Common Terminology Criteria for Adverse Events Version 4; ICU: intensive care unit; IV: intravenous; NSAIDs: nonsteroidal anti-inflammatory drugs.",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced from: Chen AP, Setser A, Anadkat MJ, et al. Grading dermatologic adverse events of cancer treatments: The Common Terminology Criteria for Adverse Events Version 4.0. J Am Acad Dermatol 2012; 67:1025. Table used with the permission of Elsevier Inc. All rights reserved.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_33_10768=[""].join("\n");
var outline_f10_33_10768=null;
var title_f10_33_10769="Rabies virus vaccine: Patient drug information";
var content_f10_33_10769=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Rabies virus vaccine: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/55/16246?source=see_link\">",
"     see \"Rabies virus vaccine: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?20/49/21269?source=see_link\">",
"     see \"Rabies virus vaccine: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F216827\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Imovax&reg; Rabies;",
"     </li>",
"     <li>",
"      RabAvert&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F216828\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Imovax&reg; Rabies;",
"     </li>",
"     <li>",
"      RabAvert&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt adi-os drugH1Div\" id=\"F10026002\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     CDC Information",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705779",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Vaccine Information Statements (VIS) are made by the staff of the Centers for Disease Control and Prevention (CDC). Each VIS gives information to properly inform the adult receiving the vaccine or, in the case of a minor, the child's parent or legal representative about the risks and benefits of each vaccine. Before a doctor vaccinates a child or an adult, the provider is required by the National Childhood Vaccine Injury Act to give a copy of the VIS. You can also get foreign language versions.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2706003",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <a href=\"file://www.immunize.org/vis/vis_rabies.asp\" target=\"_blank\">",
"        Vaccine Information Statements (VIS)",
"       </a>",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11902 Version 29.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0502-201.77.166.39-AB2AAAC1E4-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_33_10769=[""].join("\n");
var outline_f10_33_10769=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F216827\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F216828\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026002\">",
"      CDC Information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?15/55/16246?source=related_link\">",
"      Rabies virus vaccine: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?20/49/21269?source=related_link\">",
"      Rabies virus vaccine: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f10_33_10770="MRI acetabular labral tear";
var content_f10_33_10770=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F82814&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F82814&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Magnetic resonance imaging arthrogram of acetabular labral tear",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 403px; height: 504px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Coronal MR arthrogram of the right hip shows linear hyperintense signal within the acetabular labrum, consistent with labral tear (arrow).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Cecilia M Jude, MD, and Shahla Modarresi, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_33_10770=[""].join("\n");
var outline_f10_33_10770=null;
var title_f10_33_10771="Colonizing flora head and neck";
var content_f10_33_10771=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F56883&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F56883&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Diagrammatic illustration of the anatomic relationship of head and neck structures and distribution of the indigenous microflora",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 388px; height: 510px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Roscoe, DL, Chow, AW. Normal flora and mucosal immunity of the head and neck. In: Infectious Syndromes of the Head and Neck, Infect Dis Clin N Am, Vol. 2, Chow, AW, Moellering, RC (Eds), WB Saunders, Philadelphia 1988. p. 5. Copyright &copy; 1988 Elsevier Science.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_33_10771=[""].join("\n");
var outline_f10_33_10771=null;
var title_f10_33_10772="Teduglutide: Drug information";
var content_f10_33_10772=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Teduglutide: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?28/26/29092?source=see_link\">",
"    see \"Teduglutide: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F16116959\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Gattex&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F15846420\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Glucagon-Like Peptide-2 (GLP-2) Analog",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F16136127\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Short bowel syndrome:",
"     </b>",
"     SubQ: 0.05 mg/kg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <i>",
"      Missed doses:",
"     </i>",
"     If a dose is missed, take as soon as possible on that day; do",
"     <b>",
"      NOT",
"     </b>",
"     take 2 doses on the same day.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F16136128\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F16136129\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &ge;50 mL/minute: No dosage adjustment necessary.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;50 mL/minute: Administer 50% of the usual dose.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ESRD: Administer 50% of the usual dose.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F16136130\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mild-to-moderate impairment (Child-Pugh class B): No dosage adjustment necessary.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Severe impairment: No dosage adjustment provided in manufacturer&rsquo;s labeling (has not been studied).",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F16116960\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, powder for reconstitution [rDNA origin, preservative free]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gattex&reg;: 5 mg [supplied with diluent]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F16136196\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block meg drugH1Div\" id=\"F15878138\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Guide",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     An FDA-approved patient medication guide, which is available with the product information and at",
"     <a href=\"file://www.fda.gov/downloads/Drugs/DrugSafety/UCM333533.pdf\" target=\"_blank\">",
"      file://www.fda.gov/downloads/Drugs/DrugSafety/UCM333533.pdf",
"     </a>",
"     , must be dispensed with this medication.",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F16136131\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     SubQ: Rotate injection site between thighs, upper arms, and quadrants of the abdomen. Do not administer I.M. or I.V.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F15845564\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of short bowel syndrome (SBS) in patients requiring parenteral nutrition support",
"    </p>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F16136038\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     &gt;10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Central nervous system: Headache (16%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Endocrine &amp; metabolic: Fluid overload (12%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Gastrointestinal: Stoma complications (42%), abdominal pain (30% to 38%), nausea (18% to 25%), abdominal distension (14% to 20%), vomiting (12%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Local: Injection site reaction (12% to 22%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Respiratory: Upper respiratory tract infection (12% to 26%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Central nervous system: Sleep disturbances (5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Dermatologic: Cutaneous hemorrhage (5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Gastrointestinal: Flatulence (9%), appetite disorders (7%), intestinal obstruction/stenosis (4%), colorectal polyps (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Respiratory: Cough (5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Miscellaneous: Hypersensitivity reactions (8%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     &lt;1% (Limited to important or life-threatening): Cholecystitis, cholelithiasis, cholestasis, congestive heart failure, gallbladder perforation, malignancy, pancreatic pseudocyst, pancreatitis",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F16136004\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no contraindications listed in the manufacturer&rsquo;s labeling.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F16136005\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Colorectal polyps: Development of colorectal polyps has been described in patients receiving teduglutide. A baseline colonoscopy of the entire colon with polyp removal is recommended &le;6 months prior to initiation of therapy. Follow-up colonoscopy (or alternative imaging) should be performed at 1 year and at least every 5 years, thereafter.  Discontinue teduglutide in patients who develop colorectal cancer.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Fluid overload: Increased fluid absorption and subsequent fluid overload/congestive heart failure has been reported; consider modification of parenteral support in patients who develop fluid overload, especially in patients with underlying cardiovascular disease. If significant cardiac deterioration develops, reassess the need for continued teduglutide treatment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Gallbladder/biliary tract disease: Cholecystitis, cholangitis, and cholelithiasis have been reported; monitor serum bilirubin and alkaline phosphatase at least every 6 months for duration of therapy. If clinically meaningful changes are detected, perform gallbladder/biliary tract imaging and reassess the need for continued teduglutide treatment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Intestinal obstruction: Temporarily discontinue treatment in patients that develop intestinal or stomal obstruction (onset usually 1 day to 7 months); teduglutide may be resumed (if clinically indicated) once the obstruction is resolved.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Malignancy: Teduglutide may increase the risk of hyperplastic changes, including neoplasia. In patients at increased risk for malignancy, consider treatment only if benefits outweigh the risks. Discontinue treatment in patients with active gastrointestinal malignancy (GI tract, hepatobiliary, pancreatic); evaluate risk versus benefit in patients with active non-GI malignancy. Monitor for small bowel neoplasia; remove any benign neoplasm.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Pancreatitis: Pancreatitis has been reported; monitor serum lipase and amylase at least every 6 months for duration of therapy. If clinically meaningful changes are detected, evaluate for pancreatitis and  reassess the need for continued teduglutide treatment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Oral medications: Teduglutide may increase absorption of oral medications; monitor therapy of medications with a narrow therapeutic index.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Discontinuation: Treatment discontinuation may result in fluid and electrolyte imbalance. Carefully monitor fluid/electrolyte status.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F16162330\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F16162328\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no known significant interactions.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F16136000\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     B (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F16136001\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events were not observed in animal reproduction studies.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F16136002\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F16136003\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     It is not known if teduglutide is excreted into breast milk. Due to the potential for serious adverse reactions in the nursing infant, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of treatment to the mother.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16570465\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Kit",
"     </b>",
"     (Gattex Subcutaneous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     5 mg (1): $1114.80",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F16136136\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Serum bilirubin, alkaline phosphatase, lipase and amylase (baseline [within 6 months prior to initiation] and every 6 months thereafter); colonoscopy of entire colon and removal of polyps (baseline [within 6 months prior to initiation], 1 year, and &le;5 years thereafter); monitor fluid status in patients with cardiovascular disease; signs/symptoms of intestinal obstruction; signs/symptoms suggestive of gall bladder disease or pancreatitis",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F16136098\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Teduglutide is an analog of glucagon-like peptide-2 (GLP-2), which is secreted in the distal intestine. Endogenous GLP-2 increases intestinal and portal blood flow while inhibiting gastric acid secretion and reducing gastric motility, thereby reducing intestinal losses and improving intestinal absorption. Teduglutide binds and activates GLP-2 receptors, resulting in release of mediators including insulin-like growth factor (IGF)-1, nitric oxide and keratinocyte growth factor (KGF).",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F16136100\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Distribution: 0.1 L/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metabolism: Similar to endogenous catabolism of GLP-2 but slower due to a single amino acid substitution (Ferrone, 2006)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bioavailability: SubQ: 88%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Half-life elimination: 1.3 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Time to peak, plasma: 3-5 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Excretion: Urine",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Ferrone M and Scolapio JS, &ldquo;Teduglutide for the Treatment of Short Bowel Syndrome,&rdquo;",
"      <i>",
"       Ann Pharmacother",
"      </i>",
"      , 2006, 40(6):1105-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/33/10772/abstract-text/16705029/pubmed\" id=\"16705029\" target=\"_blank\">",
"        16705029",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Jeppesen PB, Gilroy R, Pertkiewicz M, et al, &ldquo;Randomised Placebo-Controlled Trial of Teduglutide in Reducing Parenteral Nutrition and/or Intravenous Fluid Requirements in Patients With Short Bowel Syndrome,&rdquo;",
"      <i>",
"       Gut",
"      </i>",
"      , 2011, 60(7):902-14.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/33/10772/abstract-text/21317170/pubmed\" id=\"21317170\" target=\"_blank\">",
"        21317170",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Jeppesen PB, Pertkiewicz M, Messing B, et al, &ldquo;Teduglutide Reduces Need for Parenteral Support Among Patients With Short Bowel Syndrome With Intestinal Failure,&rdquo;",
"      <i>",
"       Gastroenterology",
"      </i>",
"      , 2012, 143(6):1473-81.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/33/10772/abstract-text/22982184/pubmed\" id=\"22982184\" target=\"_blank\">",
"        22982184",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 87469 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0602-61.234.146.186-83C710A96E-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_33_10772=[""].join("\n");
var outline_f10_33_10772=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16116959\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15846420\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16136127\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16136128\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16136129\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16136130\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16116960\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16136196\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15878138\">",
"      Medication Guide",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16136131\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15845564\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16136038\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16136004\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16136005\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16162330\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16162328\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16136000\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16136001\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16136002\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16136003\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16570465\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16136136\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16136098\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16136100\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/87469\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/87469|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?28/26/29092?source=related_link\">",
"      Teduglutide: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f10_33_10773="Mitomycin (systemic): Patient drug information";
var content_f10_33_10773=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Mitomycin (systemic): Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/32/28166?source=see_link\">",
"     see \"Mitomycin (systemic): Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F13895014\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Mitomycin For Injection;",
"     </li>",
"     <li>",
"      Mitomycin For Injection USP;",
"     </li>",
"     <li>",
"      Mutamycin&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F13905624\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700694",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug may have unsafe effects on the bone marrow. The bone marrow may not be able to make cells found in the blood as well as it used to.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3652750",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug may cause a health problem called Hemolytic-uremic syndrome.  Very bad problems may happen in some patients who get this health problem. Call your doctor right away if you are not able to pass urine, are feeling very tired or weak, have any signs of bleeding or bruising, have a fever,  or have swelling of the face, hands, feet or body.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700794",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug may cause tissue damage if the drug leaks from the vein. Tell your nurse if you have any redness, burning, pain, swelling, or leaking of fluid where the drug is going into your body.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F13905626\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691672",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat cancer.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F13905625\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702537",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to mitomycin or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703347",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any of these health problems: Bleeding problems or low platelet count.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701080",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are pregnant or may be pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701047",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are breast-feeding.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F13905630\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697282",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have kidney disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697247",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have had radiation, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698465",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood work checked. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697633",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell dentists, surgeons, and other doctors that you use this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697795",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       You may bleed more easily. Be careful and avoid injury. Use a soft toothbrush and an electric razor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697613",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with your doctor before getting any vaccines. Use with this drug may either raise the chance of an infection or make the vaccine not work as well.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697622",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with your doctor before using products that have aspirin, blood thinners, garlic, ginseng, ginkgo, ibuprofen or like products, pain drugs, or vitamin E.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697740",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use birth control that you can trust to stop pregnancy while taking this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697022",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are a man and have sex, protect your partner from pregnancy. Use birth control that you can trust.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F13905631\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698315",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       You may have more chance of getting an infection. Wash hands often. Stay away from people with infections, colds, or flu.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697876",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Anemia, low white blood cell count, and low platelet count.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698237",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Mouth and lip irritation. Using a soft toothbrush or cotton swabs and rinsing the mouth may help. Do not use mouth rinses that have alcohol in them.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698114",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Hair loss. Hair most often grows back when this drug is stopped.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698984",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Not hungry.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697898",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Bladder irritation.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F13905632\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699077",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of infection. These include a fever of 100.5&deg;F (38&deg;C) or higher, chills, very bad sore throat, ear or sinus pain, cough, more sputum or change in color of sputum, pain with passing urine, mouth sores, wound that will not heal, or anal itching or pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699023",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad dizziness or passing out.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698640",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Trouble breathing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699018",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very loose stools (diarrhea), even after drug is stopped.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699105",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any bruising or bleeding.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699050",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad swelling or pain of hands or feet.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699104",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Not able to pass urine.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698658",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling very tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699049",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad skin irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F13905628\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695991",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is given as a shot into a vein.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695989",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is given as a shot into a vein over a period of time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3652751",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It may also be given into your bladder.  You will hold it in your bladder for a few hours.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F13905634\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 83356 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1003-61.234.146.186-D438A33F91-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_33_10773=[""].join("\n");
var outline_f10_33_10773=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13895014\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13905624\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13905626\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13905625\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13905630\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13905631\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13905632\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13905628\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13905634\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?0/33/532?source=related_link\">",
"      Mitomycin (ophthalmic): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?13/62/14307?source=related_link\">",
"      Mitomycin (ophthalmic): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?27/32/28166?source=related_link\">",
"      Mitomycin (systemic): Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f10_33_10774="Erythema annulare centrifugum - light skin";
var content_f10_33_10774=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F80998%7EDERM%2F59741&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F80998%7EDERM%2F59741&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Superficial erythema annulare centrifugum",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Annular erythematous plaques with \"trailing scale\" are classic features of superficial erythema annulare centrifugum.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Superficial erythema annulare centrifugum",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Erythematous annular plaques with \"trailing scale\" are classic features of superficial erythema annulare centrifugum.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_33_10774=[""].join("\n");
var outline_f10_33_10774=null;
var title_f10_33_10775="Maintaining water quality for hemodialysis";
var content_f10_33_10775=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Maintaining water quality for hemodialysis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/33/10775/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/33/10775/contributors\">",
"     Richard A Ward, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/33/10775/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/33/10775/contributors\">",
"     Steve J Schwab, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/33/10775/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/33/10775/contributors\">",
"     Alice M Sheridan, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?10/33/10775/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 1, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hemodialysis patients are particularly vulnerable to contaminants in the water used to prepare concentrate and dialysate, or in water used for reprocessing dialyzers. Compared to healthy individuals, hemodialysis patients are exposed to extremely large volumes of water, have inadequate barriers to such toxins, and cannot easily eliminate contaminants:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The estimated water intake of a healthy individual is 2 liters per day or 14 liters per week. By comparison, a hemodialysis patient may be exposed to 350 to 500 liters of water per week, depending upon their treatment time and dialysate flow rate.",
"     </li>",
"     <li>",
"      With normal individuals, the gastrointestinal tract separates blood from contaminants in the water. By comparison, the barrier between blood and water in hemodialysis patients is a thin membrane, through which transfer of contaminants is limited only by the size of the contaminant.",
"     </li>",
"     <li>",
"      When dialyzers are reused, water is introduced into the blood compartment of the dialyzer during reprocessing. Contaminants in this water may be trapped in the blood compartment and the patient directly exposed to them during the next dialysis treatment.",
"     </li>",
"     <li>",
"      Hemodialysis patients are unable to renally excrete any contaminants taken up from the dialysate.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Accumulated experience, combined with the observation that some of the most toxic contaminants arise from municipal water treatment practices, suggest that",
"    <strong>",
"     no",
"    </strong>",
"    municipal water can be considered safe for direct use in hemodialysis applications. All dialysis facilities therefore require a properly designed and maintained water treatment system to safeguard patients [",
"    <a class=\"abstract\" href=\"UTD.htm?10/33/10775/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The methods of assuring that the water treatment system consistently provides suitable water for dialysis, including the maintenance and monitoring of the various water treatment devices, will be reviewed here. The different water-borne contaminants to which hemodialysis patients are exposed and the various water treatment systems available to the clinician are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/32/29190?source=see_link\">",
"     \"Contaminants in water used for hemodialysis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/51/42805?source=see_link\">",
"     \"Water purification systems in hemodialysis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     MAINTAINING WATER QUALITY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Maintenance of water quality begins with the proper installation and verification of the water treatment and distribution system according to pre-determined specifications and quality standards. Responsibility for installation verification is shared by the vendor of the system and the dialysis facility. However, once the water treatment and distribution system are installed and performance verified, responsibility for continued maintenance according to minimum quality standards rests solely with the hemodialysis facility.",
"   </p>",
"   <p>",
"    The key to maintaining water quality is the establishment of a facility-specific quality management program for the water treatment and distribution system [",
"    <a class=\"abstract\" href=\"UTD.htm?10/33/10775/abstract/2\">",
"     2",
"    </a>",
"    ]. That quality management program should detail maintenance practices, describe a structured monitoring program designed to verify satisfactory operation of the system, and identify the actions to be taken in the event that deviations from normal operation are observed. The quality management system should be fully documented with clearly delineated lines of responsibility; the medical director of the facility should provide regular oversight.",
"   </p>",
"   <p>",
"    Appropriate maintenance practices should be provided by the vendor of a new system when it is installed or when an existing system is modified. It is the responsibility of the hemodialysis facility to ensure that those practices are made part of the quality management program and are properly implemented. Monitoring is intended to demonstrate that the maintenance practices ensure the delivery of high quality water and should be performed according to a pre-determined schedule. If monitoring suggests that the performance of the system, or of any individual system component, is inferior to specification, reassessment and, if necessary, modification of the system or of relevant maintenance practices should ensue. This process should be iterative and continue until monitoring demonstrates restoration of adequate performance.",
"   </p>",
"   <p>",
"    Although outside vendors are required for maintenance tasks including the replacement of deionizers and carbon beds, trained dialysis staff members should perform day-to-day maintenance and monitoring. Because failure of a water treatment system can lead to serious adverse events, the individuals responsible for day-to-day operation of the water treatment system should be well trained to recognize system failures and have the authority to act immediately based upon their findings. As an example, a technician who observes the exhaustion of a deionizer must be authorized to order the cessation of all dialysis treatments until the exhausted deionizer is replaced.",
"   </p>",
"   <p>",
"    It is useful to include monitoring of the feed water in the quality management program since the ability of a water treatment system to continuously provide product water that meets the applicable standards may change in response to variations in quality of the water supply. The quality of many municipal water supplies fluctuates seasonally. In addition, changes in water treatment practices may lead to changes in water quality. As an example, in response to an Environmental Protection Agency requirement to decrease lead and copper concentrations in drinking water, many water suppliers in the United States have increased the pH of the water supply. This increase in pH may adversely affect the removal of chloramine by granular activated carbon. Thus, monitoring of feed water should include both direct measurement of contaminant levels and regular communication with the municipal water supplier.",
"   </p>",
"   <p>",
"    Secondary disinfectants have been introduced to control Legionella in hospital water supplies. So far, the few available data suggest that existing water treatment systems are adequate to protect hemodialysis patients from one of these secondary disinfectants, chlorine dioxide [",
"    <a class=\"abstract\" href=\"UTD.htm?10/33/10775/abstract/3\">",
"     3",
"    </a>",
"    ]. However, monitoring for chlorine dioxide and its daughter products, chlorate and chlorite, and additional carbon may be necessary when chlorine dioxide is present in the water supplied to a dialysis water treatment system. On the other hand, existing water treatment systems may not be effective in protecting patients from another secondary disinfectant,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?40/41/41617?source=see_link\">",
"     hydrogen peroxide",
"    </a>",
"    , which can cause methemoglobinemia [",
"    <a class=\"abstract\" href=\"UTD.htm?10/33/10775/abstract/4,5\">",
"     4,5",
"    </a>",
"    ] and hemolysis [",
"    <a class=\"abstract\" href=\"UTD.htm?10/33/10775/abstract/6\">",
"     6",
"    </a>",
"    ] and may be poorly removed by reverse osmosis because of its small size. These latter reports underscore the importance of establishing good lines of communication with all entities responsible for supplying feed water to a dialysis facility as part of the quality management program.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     MAINTENANCE AND MONITORING GUIDELINES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Maintenance practices for individual components of the water treatment system should be based on the manufacturer&rsquo;s instructions for use. Those practices may be modified as necessary based upon device performance. For example, the frequency with which it is necessary to clean reverse osmosis membranes depends on the quality of the feed water and is facility-specific.",
"   </p>",
"   <p>",
"    Proper monitoring includes measurement of a variety of physical, chemical, and microbiological parameters; these data should then be charted to allow trend analysis of the performance of equipment and overall water quality. The primary purpose of monitoring is to assure that the system delivers high quality water.",
"   </p>",
"   <p>",
"    In general, monitoring can be divided into two categories:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      On-line measurements of physical parameters, such as flow rate, pressure, conductivity, and temperature.",
"     </li>",
"     <li>",
"      Off-line measurement of the concentrations of specific chemical and microbiological contaminants.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     On-line measurements",
"    </span>",
"    &nbsp;&mdash;&nbsp;Flow rate, pressure, and temperature are measured with standard gauges and meters and their outputs usually recorded manually. Conductivity (or resistivity) is used as a convenient on-line measure of the total concentration of ionized species in the water. All conductivity meters must be temperature-compensated.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Off-line measurements",
"    </span>",
"    &nbsp;&mdash;&nbsp;Levels of chemical and microbiologic contaminants are determined on samples of water collected at various places throughout the water treatment and distribution system. All sample ports should provide direct access to the stream to be sampled; they should not be placed in an area of stagnant flow, such as at the end of a long length of dead-end tubing. The water treatment system should also have been in continuous operation for at least 20 to 30 minutes before samples are obtained to ensure that the values reflect steady state operation of the system. Water should be allowed to flow from the sample port for about 30 seconds before samples intended for microbiological assays are collected.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Chemical contaminant assays",
"    </span>",
"    &nbsp;&mdash;&nbsp;The assay for each chemical contaminant must have a minimum detection level below the maximum allowable level for that contaminant. Most chemical contaminants can be determined off-site, well after sample collection, providing the sample container is clean and does not contribute contaminants to the sample. Chloramine is an exception to this rule. Since chloramine concentrations decrease with time, they must be determined immediately after sampling. Traditionally, the chloramine concentration was determined by measuring both the total chlorine concentration and the free chlorine concentration and calculating the difference. The current recommendation is to simply measure the total chlorine concentration and set the maximum allowable level at 0.1",
"    <span class=\"nowrap\">",
"     mg/L,",
"    </span>",
"    the maximum allowable level for chloramine [",
"    <a class=\"abstract\" href=\"UTD.htm?10/33/10775/abstract/2\">",
"     2",
"    </a>",
"    ]. This measurement can be made using a DPD (N.N-diethyl-o-phenylenediamine) assay or a \"dip and read\" test strip based on Michler&rsquo;s thioketone (MTK). The test method must have a minimum detection limit of less than 0.1",
"    <span class=\"nowrap\">",
"     mg/L.",
"    </span>",
"    Because test strips can be sensitive to heat and humidity, careful attention should be paid to following the manufacturer's instructions for storage and use of test strips, including implementation of a quality control program if that is recommended. Alternatively, on-line monitors are available that allow chloramine to be monitored continuously.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Microbial contaminant assays",
"    </span>",
"    &nbsp;&mdash;&nbsp;Monitoring of microbiological contaminants requires careful attention to sample collection and the choice of assay [",
"    <a class=\"abstract\" href=\"UTD.htm?10/33/10775/abstract/7\">",
"     7",
"    </a>",
"    ]. Samples should be collected into sterile, pyrogen-free containers and assayed within 30 minutes, or refrigerated and assayed within 24 hours. Samples transported to a remote laboratory for analysis should be packed in ice in an insulated container and shipped so that they arrive and are analyzed within 24 hours. Samples intended for bacterial cultures should not be allowed to freeze.",
"   </p>",
"   <p>",
"    The choice of assay for bacteria is important. Commonly used clinical laboratory techniques are not suitable for detecting water borne organisms. The preferred assay methods are the membrane filtration, spread plate, or pour plate techniques. The use of commercially available water testers is not recommended. These devices are subject to errors in inoculation, incubation, and interpretation, particularly when used by untrained operators, and quality control is difficult when they are used in a dialysis facility.",
"   </p>",
"   <p>",
"    If the spread plate technique is used, the sample must not be applied with a calibrated loop. Calibrated loops are commonly used in clinical laboratories for culturing body fluids and apply a very small volume (typically 0.001 to 0.01 mL) to the culture plate. Since plates are generally not read as positive unless several colonies are observed, the minimum sensitivity of the calibrated loop technique is on the order of 1000 colony-forming units",
"    <span class=\"nowrap\">",
"     (CFU)/mL.",
"    </span>",
"    This sensitivity is unacceptable when the maximum allowable level of bacteria is 100",
"    <span class=\"nowrap\">",
"     CFU/mL",
"    </span>",
"    and the action level is 50",
"    <span class=\"nowrap\">",
"     CFU/mL.",
"    </span>",
"    As a result, when assaying water intended for hemodialysis applications, a pipette must be used to apply 0.1 to 0.3 mL of sample to the plate.",
"   </p>",
"   <p>",
"    Ultrapure dialysate, generally considered to have a bacterial count &lt;0.1",
"    <span class=\"nowrap\">",
"     CFU/mL",
"    </span>",
"    and an endotoxin level &lt;0.03 endotoxin units",
"    <span class=\"nowrap\">",
"     (EU)/mL,",
"    </span>",
"    is required for on-line convective therapies, such as hemodiafiltration, and its use has been recommended for all hemodialysis therapies [",
"    <a class=\"abstract\" href=\"UTD.htm?10/33/10775/abstract/2,8-10\">",
"     2,8-10",
"    </a>",
"    ]. Monitoring microbial contamination in ultrapure dialysate requires that the membrane filtration method be used. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/19/3383?source=see_link\">",
"     \"Ultrapure dialysate\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The choice of culture medium is also important. The medium must be low in nutrients and suitable for growing fastidious water borne organisms. Blood agars must not be used since they are too rich in nutrients for growth of organisms adapted to the nutrient-poor environment of purified water. Until 2011, the Association for Advancement of Medical Instrumentation (AAMI) standard specified use of tryptic soy agar (TSA) in combination with incubation at 35 to 37&deg;C for 48 hours [",
"    <a class=\"abstract\" href=\"UTD.htm?10/33/10775/abstract/11\">",
"     11",
"    </a>",
"    ]. However, it became clear that those culturing conditions",
"    <strong>",
"     underestimated",
"    </strong>",
"    the number of bacteria present [",
"    <a class=\"abstract\" href=\"UTD.htm?10/33/10775/abstract/12\">",
"     12",
"    </a>",
"    ]. Other media, such as Reasoner's 2A agar or tryptone glucose extract agar (TGEA), provide a higher recovery of bacteria, particularly if combined with a lower incubation temperature (25&ordm;C) and a longer incubation time (seven days) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/33/10775/abstract/13,14\">",
"     13,14",
"    </a>",
"    ] and are the culturing conditions recommended by the AAMI [",
"    <a class=\"abstract\" href=\"UTD.htm?10/33/10775/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The standard test for determining endotoxin concentrations is the Limulus amebocyte lysate (LAL) assay.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     MONITORING OF SPECIFIC PURIFICATION PROCESSES",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Reverse osmosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Reverse osmosis systems should be monitored:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      To ensure continued removal of contaminants at the desired level",
"     </li>",
"     <li>",
"      To ensure production of sufficient product water",
"     </li>",
"     <li>",
"      To indicate when the membranes should be cleaned or replaced",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The following figure shows the typical monitoring points for a reverse osmosis system (",
"    <a class=\"graphic graphic_figure graphicRef63776 \" href=\"UTD.htm?40/52/41793\">",
"     figure 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/51/42805?source=see_link&amp;anchor=H5#H5\">",
"     \"Water purification systems in hemodialysis\", section on 'Reverse osmosis'",
"    </a>",
"    .) Measurements of conductivity and flow rate are used to calculate the percent solute rejection (a measure of contaminant removal) and the percent recovery of product water (a measure of membrane fouling) (",
"    <a class=\"graphic graphic_figure graphicRef57198 \" href=\"UTD.htm?5/0/5133\">",
"     figure 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Some reverse osmosis systems recycle some of the reject water stream to the feed water stream. In these systems, the absolute value of percent solute rejection depends upon the point at which the feed water conductivity is measured:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      If the measurement is made before the point at which the recycle water enters the feed water stream, the calculated solute rejection provides a measure of the overall performance of the reverse osmosis system.",
"     </li>",
"     <li>",
"      If the measurement is made after the point at which the recycle water enters the feed water stream, the calculated solute rejection provides a measure of the performance of the reverse osmosis membranes and the value may be slightly lower than that obtained when the measurement is obtained before the point at which the recycle water enters the feed water stream.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    When the product water flow rate or percent recovery of product water changes by some predetermined amount, typically 10 percent, at constant temperature, pressure and feed water flow rate, the membrane modules should be cleaned using the manufacturer's recommended method. An increase in pressure drop of 10 percent should also prompt cleaning of the membranes. If cleaning fails to restore performance, the membrane modules might need to be replaced. The life of reverse osmosis membranes can be prolonged by pretreatment of the feed water. As an example, softening the feed water will help minimize fouling with calcium and magnesium salts. In addition, removal of chlorine by carbon can protect membranes from degradation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Deionizers",
"    </span>",
"    &nbsp;&mdash;&nbsp;Deionizers are monitored to ensure product water quality and to indicate when new resin beds are needed. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/51/42805?source=see_link&amp;anchor=H6#H6\">",
"     \"Water purification systems in hemodialysis\", section on 'Deionization'",
"    </a>",
"    .) Because undetected failure of a deionizer can be extremely hazardous to patients, the resistivity of the product water must be monitored continuously with a temperature-compensated meter. The monitor should be coupled to an alarm system that is audible in the patient treatment area and which diverts product water to drain if the resistivity falls",
"    <strong>",
"     below",
"    </strong>",
"    1 megOhm-cm.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Carbon",
"    </span>",
"    &nbsp;&mdash;&nbsp;Carbon beds are monitored to detect exhaustion of their capacity to remove a key contaminant (usually chloramine or total chlorine). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/51/42805?source=see_link&amp;anchor=H7#H7\">",
"     \"Water purification systems in hemodialysis\", section on 'Carbon filtration'",
"    </a>",
"    .) Although carbon can remove a wide range of organic contaminants by adsorption, removal of chloramine takes place via an oxidation&ndash;reduction reaction at active sites on the carbon surface. With time, access to these active sites is diminished by adsorption of soluble organic molecules and by trapping of suspended material present in the water. Finally, chloramine molecules reach the outlet of the bed without finding an active site. This phenomenon is known as breakthrough.",
"   </p>",
"   <p>",
"    Patients are protected from exposure to chloramine resulting from breakthrough by placing two carbon beds in series and monitoring the chloramine concentration after the first bed. When exchangeable carbon beds are used, the first bed is discarded when breakthrough is detected, the second bed is moved into the first position, and a new bed is installed in the second position. When permanent carbon beds are used, it is often simpler to replace the carbon in both beds.",
"   </p>",
"   <p>",
"    Monitoring the pressure drop between the inlet and outlet of a carbon bed provides information on fouling (an increase in pressure drop at a constant flow rate) or channeling (a decrease in pressure drop at a constant flow rate). Fouling of a carbon bed occurs when suspended matter in the water is trapped in the bed by depth filtration. This trapped material increases the resistance to flow through the bed, and reduces the feed pressure to the next element in the purification cascade. Channeling occurs when the packing of carbon particles in a bed becomes non-uniform. Under such conditions, open passages form in the bed. Water passes through these channels, decreasing contact between the water and the carbon particles, and thereby reducing the ability of the bed to remove contaminants. If either condition is detected, back-flushing may prolong bed life. However, back-flushing does not regenerate exhausted bed capacity.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Softeners",
"    </span>",
"    &nbsp;&mdash;&nbsp;Softeners are monitored to ensure that they continue to remove calcium and magnesium ions. Calcium and magnesium concentrations in the product water can be determined indirectly using a kit to measure the hardness of the water. Since softeners are often automatically regenerated at night when no dialysis is being performed, the hardness of the product water should be measured towards the end of the day to ensure the softener has adequate capacity to remove calcium and magnesium ions throughout its operating cycle. In general, the hardness of product water from a softener should not exceed 10",
"    <span class=\"nowrap\">",
"     mg/L",
"    </span>",
"    of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/32/42504?source=see_link\">",
"     calcium carbonate",
"    </a>",
"    . Values above this level should prompt an evaluation of the softener for loss of resin, fouling of the resin by iron, an inadequate regeneration cycle, or inadequate capacity due to an increase in water throughput.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Filters",
"    </span>",
"    &nbsp;&mdash;&nbsp;Filters are monitored for evidence of fouling by measuring the pressures at the inlet and outlet of the filter. These pressures are used to calculate the pressure drop, delta P, across the filter (delta P equals [Inlet pressure minus Outlet pressure]). An increase in pressure drop above some predetermined value, usually provided by the filter manufacturer, indicates that the filter should be replaced or cleaned. Failure to monitor the pressure drop and replace the filter when indicated can lead to a reduction in the pressure downstream of the filter. This may lead to an inadequate pressure at the inlet of subsequent purification devices and a generalized degradation of the performance of the water treatment system.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     MAINTENANCE AND MONITORING SCHEDULES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Maintenance practices and monitoring schedules depend upon the design of the water treatment system and the uses to which the water is put; however, some general guidelines can be given. Frequency of monitoring should be based upon the consequences of failure of a given purification process and the accumulated history of the performance of the water treatment and distribution system. As an example, since exhaustion of a deionizer may acutely expose patients to high concentrations of contaminants, deionizers must be monitored continuously and the monitor must be connected to appropriate safety systems. Similarly, if the feed water contains chloramine, carbon beds must be monitored at least daily because of the risk of acute hemolysis if patients are exposed to chloramine.",
"   </p>",
"   <p>",
"    Parameters that are measured continuously on-line should also be recorded daily; these include the water production rate, the percent rejection and product water recovery of a reverse osmosis unit, and pressures throughout the water treatment and distribution system.",
"   </p>",
"   <p>",
"    The final determinant of the adequacy of any water treatment and distribution system is the composition of the final product water and whether or not it meets the requirements of all applicable standards. The concentrations of chemical contaminants in the final product water should be determined when systems are newly installed or modified as part of installation verification. Analysis for chemical contaminants might also be necessary when changes in supply water or component performance, such as a decrease in reverse osmosis rejection rate, are detected. In the latter cases, it may be sufficient to analyze for a single contaminant, such as aluminum, rather than for all contaminants (",
"    <a class=\"graphic graphic_table graphicRef64883 \" href=\"UTD.htm?39/3/39995\">",
"     table 1",
"    </a>",
"    ). The observation that parameters measured on-line remain stable over time provides some additional assurance that water quality is being maintained independent of the measurement of concentrations of individual contaminants. However, a complete analysis of all contaminants should be performed at least annually.",
"   </p>",
"   <p>",
"    Bacteria are very difficult to remove once they have colonized a water distribution system, particularly if they form a mature biofilm on the interior surfaces of the distribution system. To minimize biofilm formation, all water distribution systems should be disinfected on a regular basis using a schedule designed to limit bacterial proliferation, rather than to eliminate bacteria once proliferation has occurred.",
"   </p>",
"   <p>",
"    Experience suggests that an approach based on regular, frequent disinfection helps limit biofilm formation [",
"    <a class=\"abstract\" href=\"UTD.htm?10/33/10775/abstract/11\">",
"     11",
"    </a>",
"    ]. With this strategy, levels of bacteria and endotoxin are monitored to validate the effectiveness of the disinfection procedure, not to indicate when disinfection should be performed. Samples for surveillance cultures and endotoxin testing should be collected before the system is disinfected, when the highest levels of contamination are likely to be present. When a new system is installed or the integrity of an existing system is broken, frequent disinfection and monitoring should be performed until consistently low levels of bacteria are observed. The frequency of disinfection and monitoring may be decreased if the accumulated data consistently show low levels of contamination; however, at least monthly disinfection and monitoring is recommended.",
"   </p>",
"   <p>",
"    With new systems, it is important to recognize that biofilm takes some time to form and mature. Therefore, little or no growth might be seen in fluid samples taken during the first month of operation even if no disinfection is performed. For that reason, caution should be exercised in extending the disinfection interval based on culture results obtained during the first few months of operation of a new system.",
"   </p>",
"   <p>",
"    Traditionally, disinfection has been performed using chemicals, such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/23/29042?source=see_link\">",
"     sodium hypochlorite",
"    </a>",
"    (bleach) and peracetic",
"    <span class=\"nowrap\">",
"     acid/",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?40/41/41617?source=see_link\">",
"      hydrogen peroxide",
"     </a>",
"     .",
"    </span>",
"    Frequent disinfection can be difficult with chemical agents because of the lengthy period of rinsing required to remove residual disinfection from a distribution system. Disinfection with hot water or ozonated water is increasingly seen as a preferable alternative since these methods leave no chemical residues (hot water) or residues with a short half-life (ozone).",
"   </p>",
"   <p>",
"    In cases where biofilm has formed and is resistant to disinfection, cleaning the system with 2 to 3 percent citric acid before disinfection may help in biofilm removal, in the setting in which the materials of the system are compatible with exposure to the acid [",
"    <a class=\"abstract\" href=\"UTD.htm?10/33/10775/abstract/15,16\">",
"     15,16",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10421440\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      To maintain acceptable water quality, a dialysis facility must institute a formal quality management program for its water treatment and distribution system. The medical director should provide regular oversight as part of the facility&rsquo;s quality",
"      <span class=\"nowrap\">",
"       assurance/performance",
"      </span>",
"      improvement program. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Maintaining water quality'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Even a well functioning water treatment system might not ensure consistently adequate water quality if the quality of the water supplied to the dialysis facility changes. Facilities should establish a relationship with their water supplier and consider regular testing of the water supply if fluctuations in the quality of the incoming water are likely to occur. Proper monitoring includes measurement of a variety of physical, chemical, and microbiological parameters; these data should then be charted to allow trend analysis of the performance of equipment and overall water quality. In general, monitoring can be divided into on-line measurements of physical parameters (such as flow rate, pressure, conductivity, and temperature) and off-line measurement of the concentrations of specific chemical and microbiological contaminants. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Maintenance and monitoring guidelines'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Monitoring should encompass measurement of physical, chemical and microbiological parameters that allow both water quality and equipment performance to be assessed. The water treatment system should be allowed to operate for 20 to 30 minutes before measurements are made to ensure the data reflect normal, steady-state operating conditions. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Off-line measurements'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H3\">",
"       'Maintenance and monitoring guidelines'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Monitoring for chloramine must be performed immediately following sample collection. It is generally simpler to monitor chloramine concentrations by measuring the total chlorine concentration and setting the maximum allowable level at 0.1",
"      <span class=\"nowrap\">",
"       mg/L.",
"      </span>",
"      (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Chemical contaminant assays'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Monitoring bacterial contamination should be performed using the membrane filtration, spread plate or pour plate techniques, with at least 0.1 mL of sample applied to the plate. Use of nutrient-poor media (TGEA or Reasoner&rsquo;s 2A agar), together with incubation at room temperature for seven days, enhances bacterial recovery and provides a more stringent assessment of microbial contamination. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Microbial contaminant assays'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      It is important to effectively monitor the specific purification processes. These processes include the reverse osmosis system, deionizers, carbon, softeners, and filters. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Monitoring of specific purification processes'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Monitoring and maintenance schedules depend upon the design of the water treatment system and the uses to which the water is put. However, there are some general guidelines. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Maintenance and monitoring schedules'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Regular, frequent disinfection is required to minimize biofilm formation in the water distribution system and control microbial contamination of the water. Surveillance cultures and endotoxin testing serve to demonstrate the adequacy of the disinfection schedule and should not be used to decide when disinfection is required. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Maintenance and monitoring schedules'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/33/10775/abstract/1\">",
"      Martin K, Laydet E, Canaud B. Design and technical adjustment of a water treatment system: 15 years of experience. Adv Ren Replace Ther 2003; 10:122.",
"     </a>",
"    </li>",
"    <li>",
"     Association for the Advancement of Medical Instrumentation. Guidance for the preparation and quality management of fluids for hemodialysis and related therapies, ANSI/AAMI/ISO 23500:2011, Association for the Advancement of Medical Instrumentation, Arlington, VA 2011.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/33/10775/abstract/3\">",
"      Srinivasan A, Bova G, Ross T, et al. A 17-month evaluation of a chlorine dioxide water treatment system to control Legionella species in a hospital water supply. Infect Control Hosp Epidemiol 2003; 24:575.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/33/10775/abstract/4\">",
"      Newbigging, N, Peel, W, Bell, E, Isles, C. Unexpected cyanosis in a haemodialysis patient - did someone add hydrogen peroxide to the dialysis water? NDT Plus 2009; 2:158.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/33/10775/abstract/5\">",
"      Bek MJ, Laule S, Reichert-J&uuml;nger C, et al. Methemoglobinemia in critically ill patients during extended hemodialysis and simultaneous disinfection of the hospital water supply. Crit Care 2009; 13:R162.",
"     </a>",
"    </li>",
"    <li>",
"     NHS National Patient Safety Agency. Risks to hemodialysis patients from water supply (hydrogen peroxide). NPSA/2008/RRR007. https://www.cas.dh.gov.uk/ViewandAcknowledgment/ViewAttachment.aspx?Attachment_id=50485 (Accessed on April 1, 2009).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/33/10775/abstract/7\">",
"      Bland LA. Microbiological and endotoxin assays of hemodialysis fluids. Adv Ren Replace Ther 1995; 2:70.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/33/10775/abstract/8\">",
"      Bommer J, Jaber BL. Ultrapure dialysate: facts and myths. Semin Dial 2006; 19:115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/33/10775/abstract/9\">",
"      Section IV. Dialysis fluid purity. European Best Practice Guidelines for Haemodialysis (Part 1). European Dialysis and Transplant Association. Nephrol Dial Transplant 2002; 17 Suppl 7:45.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/33/10775/abstract/10\">",
"      Ledebo I. Ultrapure dialysis fluid--how pure is it and do we need it? Nephrol Dial Transplant 2007; 22:20.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/33/10775/abstract/11\">",
"      Smeets E, Kooman J, van der Sande F, et al. Prevention of biofilm formation in dialysis water treatment systems. Kidney Int 2003; 63:1574.",
"     </a>",
"    </li>",
"    <li>",
"     Association for the Advancement of Medical Instrumentation. Water Treatment Equipment for Hemodialysis Applications, ANSI/AAMI RD62:2001, Association for the Advancement of Medical Instrumentation, Arlington, VA 2001.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/33/10775/abstract/13\">",
"      Pass T, Wright R, Sharp B, Harding GB. Culture of dialysis fluids on nutrient-rich media for short periods at elevated temperatures underestimate microbial contamination. Blood Purif 1996; 14:136.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/33/10775/abstract/14\">",
"      Ledebo I, Nystrand R. Defining the microbiological quality of dialysis fluid. Artif Organs 1999; 23:37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/33/10775/abstract/15\">",
"      Marion-Ferey K, Pasmore M, Stoodley P, et al. Biofilm removal from silicone tubing: an assessment of the efficacy of dialysis machine decontamination procedures using an in vitro model. J Hosp Infect 2003; 53:64.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/33/10775/abstract/16\">",
"      Cappelli G, Sereni L, Scialoja MG, et al. Effects of biofilm formation on haemodialysis monitor disinfection. Nephrol Dial Transplant 2003; 18:2105.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1900 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-61.234.146.186-7D7969DF47-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_33_10775=[""].join("\n");
var outline_f10_33_10775=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H10421440\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      MAINTAINING WATER QUALITY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      MAINTENANCE AND MONITORING GUIDELINES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      On-line measurements",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Off-line measurements",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Chemical contaminant assays",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Microbial contaminant assays",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      MONITORING OF SPECIFIC PURIFICATION PROCESSES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Reverse osmosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Deionizers",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Carbon",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Softeners",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Filters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      MAINTENANCE AND MONITORING SCHEDULES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10421440\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEPH/1900\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEPH/1900|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?40/52/41793\" title=\"figure 1\">",
"      Reverse osmosis for water purification",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?5/0/5133\" title=\"figure 2\">",
"      Formula for reverse osmosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEPH/1900|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?39/3/39995\" title=\"table 1\">",
"      Water contaminants in HD",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/32/29190?source=related_link\">",
"      Contaminants in water used for hemodialysis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/19/3383?source=related_link\">",
"      Ultrapure dialysate",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/51/42805?source=related_link\">",
"      Water purification systems in hemodialysis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f10_33_10776="Nonspecific ST changes tutorial";
var content_f10_33_10776=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F60478&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F60478&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 538px\">",
"   <div class=\"ttl\">",
"    Nonspecific ST and T wave changes",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 518px; height: 211px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The types of abnormalities include ST segment depression or elevation (leads I, aVL, V4-V6), flattening of the T wave (leads I, aVR, aVL, V5, V6), or T wave inversion (I, V2-V4).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_33_10776=[""].join("\n");
var outline_f10_33_10776=null;
var title_f10_33_10777="Causes of rhabdomyolysis";
var content_f10_33_10777=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"0\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Causes of rhabdomyolysis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/33/10777/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/33/10777/contributors\">",
"     Marc L Miller, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/33/10777/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/33/10777/contributors\">",
"     Ira N Targoff, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/33/10777/contributors\">",
"     Jeremy M Shefner, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/33/10777/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/33/10777/contributors\">",
"     Paul L Romain, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?10/33/10777/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jun 12, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H31734773\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Rhabdomyolysis is a syndrome characterized by muscle necrosis and the release of intracellular muscle constituents into the circulation. Creatine kinase (CK) levels are typically markedly elevated, and muscle pain and myoglobinuria may be present. The severity of illness ranges from asymptomatic elevations in serum muscle enzymes to life-threatening disease associated with extreme enzyme elevations, electrolyte imbalances, and acute kidney injury.",
"   </p>",
"   <p>",
"    The causes of rhabdomyolysis will be reviewed here. The clinical manifestations and diagnosis of rhabdomyolysis; the clinical features and diagnosis of acute kidney injury due to rhabdomyolysis; the management of patients with rhabdomyolysis, including methods to prevent acute kidney injury and related metabolic complications; and the prevention and management of acute compartment syndrome are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/55/32632?source=see_link\">",
"     \"Clinical manifestations and diagnosis of rhabdomyolysis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/6/22632?source=see_link\">",
"     \"Clinical features and diagnosis of heme pigment-induced acute kidney injury (acute renal failure)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/21/21847?source=see_link\">",
"     \"Prevention and treatment of heme pigment-induced acute kidney injury (acute renal failure)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/0/15369?source=see_link\">",
"     \"Crush-related acute kidney injury (acute renal failure)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/57/8090?source=see_link\">",
"     \"Acute compartment syndrome of the extremities\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31734780\">",
"    <span class=\"h1\">",
"     PATHOPHYSIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinical manifestations and complications of rhabdomyolysis result from muscle cell death, which may be triggered by any of a variety of initiating events. The final common pathway for injury is an increase in intracellular free ionized cytoplasmic and mitochondrial calcium. This may be caused by depletion of ATP, the cellular source of energy,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    by direct injury and rupture of the plasma membrane [",
"    <a class=\"abstract\" href=\"UTD.htm?10/33/10777/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. The latter pathway of injury also results in ATP depletion.",
"   </p>",
"   <p>",
"    The increased intracellular calcium leads to activation of proteases, increased skeletal muscle cell contractility, mitochondrial dysfunction, and the production of reactive oxygen species, resulting in skeletal muscle cell death [",
"    <a class=\"abstract\" href=\"UTD.htm?10/33/10777/abstract/1\">",
"     1",
"    </a>",
"    ]. ATP depletion causes dysfunction of the",
"    <span class=\"nowrap\">",
"     Na/K-ATPase",
"    </span>",
"    and Ca",
"    <sup>",
"     2+",
"    </sup>",
"    ATPase pumps that are essential to maintaining integrity of the myocyte. ATP depletion leads to myocyte injury and the release of intracellular muscle constituents, including creatine kinase and other muscle enzymes, myoglobin, and various electrolytes.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31734787\">",
"    <span class=\"h1\">",
"     CAUSES",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are multiple potential causes of rhabdomyolysis [",
"    <a class=\"abstract\" href=\"UTD.htm?10/33/10777/abstract/3-6\">",
"     3-6",
"    </a>",
"    ]; these can be broadly divided into three categories (",
"    <a class=\"graphic graphic_table graphicRef60404 \" href=\"UTD.htm?6/11/6332\">",
"     table 1",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Traumatic or muscle compression (eg, crush syndrome or prolonged immobilization)",
"     </li>",
"     <li>",
"      Nontraumatic exertional (eg, marked exertion in untrained individuals, hyperthermia, or metabolic myopathies)",
"     </li>",
"     <li>",
"      Nontraumatic nonexertional (eg, drugs or toxins, infections, or electrolyte disorders)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The specific cause is frequently evident from the history or from the immediate circumstances preceding the disorder, such as crush injury, a comatose or postictal state, postoperative surgical trauma, or extraordinary physical exertion. In other cases, however, the precipitant may not be as immediately evident but is identified through a careful history and physical and laboratory evaluation [",
"    <a class=\"abstract\" href=\"UTD.htm?10/33/10777/abstract/4,5,7\">",
"     4,5,7",
"    </a>",
"    ]. The specific causes within each of the three major categories are discussed in detail in the sections below.",
"   </p>",
"   <p>",
"    The relative frequency of the different etiologies among patients with rhabdomyolysis is illustrated by two large series of hospitalized patients [",
"    <a class=\"abstract\" href=\"UTD.htm?10/33/10777/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. The most common causes in the larger and more recent series of 475 patients were exogenous toxins (46 percent), including alcohol and illicit drugs (34 percent) and medical drugs (11 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/33/10777/abstract/4\">",
"     4",
"    </a>",
"    ]. Underlying myopathy or muscle metabolic defects were seen in 10 percent of the cases in this study, usually as the sole etiologic factor. There was a higher rate of recurrence in those with an underlying myopathy or metabolic muscle defect (26 percent) than in patients with other etiologies, except for neuroleptic malignant syndrome, which had a similar rate of recurrence. (See",
"    <a class=\"local\" href=\"#H31734829\">",
"     'Drugs'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Up to 60 percent of patients had more than one etiologic factor in the two large studies; however, no cause was identified in 3 to 7 percent of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?10/33/10777/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. Other series with more than 50 patients have included one focused on patients with infectious causes [",
"    <a class=\"abstract\" href=\"UTD.htm?10/33/10777/abstract/8\">",
"     8",
"    </a>",
"    ] and another limited to patients with marked creatine kinase (CK) elevations [",
"    <a class=\"abstract\" href=\"UTD.htm?10/33/10777/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31734794\">",
"    <span class=\"h2\">",
"     Trauma or muscle compression",
"    </span>",
"    &nbsp;&mdash;&nbsp;Trauma or muscle compression is a common cause of rhabdomyolysis and can be seen in the following settings:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A crush syndrome in victims of multiple traumata, particularly individuals trapped in cars after crashes or in collapsed buildings from earthquakes [",
"      <a class=\"abstract\" href=\"UTD.htm?10/33/10777/abstract/10-13\">",
"       10-13",
"      </a>",
"      ]. Many of these patients also experience a compartment syndrome. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?15/0/15369?source=see_link\">",
"       \"Crush-related acute kidney injury (acute renal failure)\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Individuals struggling against restraints, torture victims, or abused children [",
"      <a class=\"abstract\" href=\"UTD.htm?10/33/10777/abstract/14,15\">",
"       14,15",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Immobilization due to coma of any cause or in conscious individuals forced to lie in one position for hours, such as elderly hip fracture victims [",
"      <a class=\"abstract\" href=\"UTD.htm?10/33/10777/abstract/16,17\">",
"       16,17",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Surgical procedures in which there is either prolonged muscle compression due to positioning during a long procedure [",
"      <a class=\"abstract\" href=\"UTD.htm?10/33/10777/abstract/13,18,19\">",
"       13,18,19",
"      </a>",
"      ], or vascular occlusion because of tourniquet use in orthopedic or vascular reconstruction procedures [",
"      <a class=\"abstract\" href=\"UTD.htm?10/33/10777/abstract/13,20\">",
"       13,20",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Acute lower extremity compartment syndrome, with tibial fractures being the most common cause (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?7/57/8090?source=see_link&amp;anchor=H2#H2\">",
"       \"Acute compartment syndrome of the extremities\", section on 'Epidemiology and risk factors'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      High-voltage electrical injury (eg, from lightning or high-voltage power supplies) or extensive third-degree burns, causing direct myofibrillar injury [",
"      <a class=\"abstract\" href=\"UTD.htm?10/33/10777/abstract/2,21\">",
"       2,21",
"      </a>",
"      ] (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?4/19/4410?source=see_link\">",
"       \"Environmental electrical injuries\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31734801\">",
"    <span class=\"h2\">",
"     Nontraumatic exertional rhabdomyolysis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Rhabdomyolysis occurs in individuals with normal muscles when the energy supply to muscle is insufficient to meet demands. Examples include extreme exertion or exertion under conditions in which muscle oxygenation is impaired, including metabolic myopathies.",
"   </p>",
"   <p>",
"    Subclinical myoglobinemia, myoglobinuria, and elevation in serum CK are common following physical exertion. As an example, myoglobinemia was found in 25 of 44 participants (57 percent) in an ultra-marathon race of 99 kilometers [",
"    <a class=\"abstract\" href=\"UTD.htm?10/33/10777/abstract/22\">",
"     22",
"    </a>",
"    ]. The serum CK rose 16-fold from pre-race levels to a mean of 2060 international",
"    <span class=\"nowrap\">",
"     units/L.",
"    </span>",
"    Myoglobin was detected in the urine of five individuals, but acute kidney injury did not occur. In a second study, 39 percent of 337 military recruits developed myoglobinemia during the first six days of basic training, but none had pigmenturia or reported muscle symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?10/33/10777/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Massive rhabdomyolysis may arise with marked physical exertion, particularly when one of more of the following risk factors is present:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The individual is physically untrained.",
"     </li>",
"     <li>",
"      Exertion occurs in extremely hot, humid conditions, which may lead to exertional heat stroke [",
"      <a class=\"abstract\" href=\"UTD.htm?10/33/10777/abstract/24,25\">",
"       24,25",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?15/40/16007?source=see_link\">",
"       \"Severe hyperthermia (heat stroke) in adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Normal heat loss through sweating is impaired, as with the use of anticholinergic medications or heavy football equipment [",
"      <a class=\"abstract\" href=\"UTD.htm?10/33/10777/abstract/25,26\">",
"       25,26",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?15/40/16007?source=see_link\">",
"       \"Severe hyperthermia (heat stroke) in adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Sickle cell trait occurs in an individual who exercises at high altitude, a setting in which the decreased partial pressure of oxygen causes erythrocyte sickling with subsequent vascular occlusion and muscle ischemia [",
"      <a class=\"abstract\" href=\"UTD.htm?10/33/10777/abstract/27,28\">",
"       27,28",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?13/40/13960?source=see_link&amp;anchor=H14#H14\">",
"       \"Sickle cell trait\", section on 'Risk for sudden death and athletic participation'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Hypokalemia caused by potassium loss from sweating occurs [",
"      <a class=\"abstract\" href=\"UTD.htm?10/33/10777/abstract/29,30\">",
"       29,30",
"      </a>",
"      ]. The role of potassium in the regulation of skeletal muscle blood flow appears to be important in the pathogenesis in this setting [",
"      <a class=\"abstract\" href=\"UTD.htm?10/33/10777/abstract/31\">",
"       31",
"      </a>",
"      ]. During exercise, there is normally an appropriate increase in muscle perfusion to meet enhanced energy demands. This hyperemic response is mediated in part by the release of potassium from skeletal muscle cells. The ensuing local elevation in the potassium concentration causes vasodilation, which enhances regional blood flow [",
"      <a class=\"abstract\" href=\"UTD.htm?10/33/10777/abstract/31,32\">",
"       31,32",
"      </a>",
"      ]. However, the cellular release of potassium is impaired by potassium depletion. As a result, there is a lesser increase in blood flow, possibly resulting in cramps, ischemic necrosis, and rhabdomyolysis [",
"      <a class=\"abstract\" href=\"UTD.htm?10/33/10777/abstract/31\">",
"       31",
"      </a>",
"      ]. Hypokalemia-induced impairment in muscle metabolism also may contribute to muscle dysfunction [",
"      <a class=\"abstract\" href=\"UTD.htm?10/33/10777/abstract/30\">",
"       30",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Rhabdomyolysis can also occur in trained individuals following physical exertion in the absence of these risk factors [",
"    <a class=\"abstract\" href=\"UTD.htm?10/33/10777/abstract/22,33\">",
"     22,33",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In addition, pathologic hyperkinetic states can lead to rhabdomyolysis in individuals with normal muscles [",
"    <a class=\"abstract\" href=\"UTD.htm?10/33/10777/abstract/3,34\">",
"     3,34",
"    </a>",
"    ]. Examples include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Grand mal seizures",
"     </li>",
"     <li>",
"      Delirium tremens",
"     </li>",
"     <li>",
"      Psychotic agitation",
"     </li>",
"     <li>",
"      Amphetamine overdose",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31734808\">",
"    <span class=\"h3\">",
"     Metabolic myopathies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Rhabdomyolysis may develop in patients with abnormal muscle, such as individuals with inherited disorders of glycogenolysis, glycolysis, or lipid metabolism (",
"    <a class=\"graphic graphic_table graphicRef61324 \" href=\"UTD.htm?24/58/25515\">",
"     table 2",
"    </a>",
"    ). These disorders are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/36/21065?source=see_link\">",
"     \"Causes of metabolic myopathies\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/16/4356?source=see_link\">",
"     \"Overview of inherited disorders of glucose and glycogen metabolism\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The metabolic myopathies represent a very small percentage of cases of rhabdomyolysis overall but are relatively common causes among patients with recurrent episodes of rhabdomyolysis after exertion [",
"    <a class=\"abstract\" href=\"UTD.htm?10/33/10777/abstract/35,36\">",
"     35,36",
"    </a>",
"    ]. In a series of 77 patients evaluated for \"idiopathic\" myoglobinuria in whom muscle biopsies were performed, specific enzyme deficiencies were identified in 36 (47 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/33/10777/abstract/36\">",
"     36",
"    </a>",
"    ].",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/16/21766?source=see_link\">",
"     Carnitine",
"    </a>",
"    palmitoyltransferase deficiency was the most common disorder, occurring in 17 of the 36 patients, followed by muscle phosphorylase deficiency (McArdle disease) in 10. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/36/21065?source=see_link&amp;anchor=H11#H11\">",
"     \"Causes of metabolic myopathies\", section on 'Fatty acid transport defects'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/23/23928?source=see_link\">",
"     \"Muscle phosphorylase deficiency (glycogen storage disease V, McArdle disease)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The precise mechanism of muscle necrosis in the metabolic myopathies has not yet been established, but it is likely that insufficient energy production in exercising muscle leads to depletion of adenosine triphosphate (ATP) and creatine phosphate. The maintenance of muscle cell integrity is thereby compromised [",
"    <a class=\"abstract\" href=\"UTD.htm?10/33/10777/abstract/37\">",
"     37",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/56/905?source=see_link&amp;anchor=H5#H5\">",
"     \"Approach to the metabolic myopathies\", section on 'Myoglobinuria and rhabdomyolysis'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/63/6134?source=see_link\">",
"     \"Energy metabolism in muscle\"",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H31734780\">",
"     'Pathophysiology'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Postexertional rhabdomyolysis has also been described in individuals with mitochondrial myopathies due to defects in respiratory chain enzymes [",
"    <a class=\"abstract\" href=\"UTD.htm?10/33/10777/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31734815\">",
"    <span class=\"h3\">",
"     Thermal extremes and dysregulation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Rhabdomyolysis may occur with hyperthermia associated with heat stroke (see",
"    <a class=\"local\" href=\"#H31734801\">",
"     'Nontraumatic exertional rhabdomyolysis'",
"    </a>",
"    above). Other causes of rhabdomyolysis in the setting of temperature dysregulation or thermal extremes include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Malignant hyperthermia &mdash; Rhabdomyolysis is considered a later perioperative manifestation of malignant hyperthermia. Susceptibility is usually due to an inherited abnormality in the ryanodine receptor that causes the unregulated passage of calcium from the sarcoplasmic reticulum into the intracellular space. The most common trigger is the use of inhalation anesthetics. The persistent elevation of calcium causes sustained muscle contraction and results in ATP depletion, which causes hyperkalemia and rhabdomyolysis. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?36/3/36921?source=see_link\">",
"       \"Susceptibility to malignant hyperthermia\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?32/13/32984?source=see_link\">",
"       \"Malignant hyperthermia: Clinical diagnosis and management of acute crisis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Neuroleptic malignant syndrome &mdash; The neuroleptic malignant syndrome is a disorder in which high fever (with or without generalized muscle contraction or tremor) develops after exposure to neuroleptic drugs and anti-Parkinsonian drugs. Rhabdomyolysis has been reported [",
"      <a class=\"abstract\" href=\"UTD.htm?10/33/10777/abstract/39\">",
"       39",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?20/4/20553?source=see_link\">",
"       \"Neuroleptic malignant syndrome\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Near",
"      <span class=\"nowrap\">",
"       drowning/hypothermia",
"      </span>",
"      &mdash; Rhabdomyolysis with myoglobinuric acute renal failure can occur after prolonged immersion [",
"      <a class=\"abstract\" href=\"UTD.htm?10/33/10777/abstract/40\">",
"       40",
"      </a>",
"      ]. The mechanism of rhabdomyolysis in this setting may involve hypothermia with muscle injury from marked vasoconstriction or from excessive shivering",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      generalized hypoxia. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?26/11/26809?source=see_link\">",
"       \"Drowning (submersion injuries)\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31734822\">",
"    <span class=\"h2\">",
"     Nonexertional and nontraumatic rhabdomyolysis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nonexertional and nontraumatic causes of rhabdomyolysis include drugs and toxins, infections, electrolyte abnormalities, endocrinopathies, inflammatory myopathies, and others [",
"    <a class=\"abstract\" href=\"UTD.htm?10/33/10777/abstract/2,4-6\">",
"     2,4-6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31734829\">",
"    <span class=\"h3\">",
"     Drugs",
"    </span>",
"    &nbsp;&mdash;&nbsp;A large number of prescription drugs and drugs of abuse can cause rhabdomyolysis [",
"    <a class=\"abstract\" href=\"UTD.htm?10/33/10777/abstract/5\">",
"     5",
"    </a>",
"    ]. In addition to alcohol, other drugs of abuse that have been implicated as causes include heroin, cocaine, amphetamines,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/57/36761?source=see_link\">",
"     methadone",
"    </a>",
"    , and D-lysergic acid diethylamide (LSD). In one large series, the prescription drugs most commonly responsible were antipsychotics, followed by statins, selective serotonin reuptake inhibitors,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/28/24008?source=see_link\">",
"     zidovudine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/13/32983?source=see_link\">",
"     colchicine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/11/23736?source=see_link\">",
"     lithium",
"    </a>",
"    , antihistamines, and several others [",
"    <a class=\"abstract\" href=\"UTD.htm?10/33/10777/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The illicit and prescribed agents cause rhabdomyolysis through several different mechanisms [",
"    <a class=\"abstract\" href=\"UTD.htm?10/33/10777/abstract/41,42\">",
"     41,42",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Coma induced by alcohol, opioid overdose, or other CNS depressants leads to immobilization and ischemic compression of muscle.",
"     </li>",
"     <li>",
"      Some drugs, including statins and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/13/32983?source=see_link\">",
"       colchicine",
"      </a>",
"      , are direct myotoxins. In addition, statins can increase the risk of rhabdomyolysis in patients with other predisposing conditions, such as hypothyroidism or an inflammatory myopathy [",
"      <a class=\"abstract\" href=\"UTD.htm?10/33/10777/abstract/43-45\">",
"       43-45",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?33/0/33802?source=see_link\">",
"       \"Statin myopathy\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Drug-induced agitation states, drug-induced seizures, dystonic reactions, and cocaine-induced hyperthermia are associated with excess muscle energy demands. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?6/44/6856?source=see_link&amp;anchor=H9#H9\">",
"       \"Drug-induced myopathies\", section on 'Cocaine'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Drug-drug interactions may be responsible for rhabdomyolysis in some individuals. The nature of the interactions varies. As an example, some drugs interfere with the clearance of statins and lead to elevated plasma levels; offending agents include macrolide antibiotics (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/29/36304?source=see_link\">",
"       erythromycin",
"      </a>",
"      ),",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"       cyclosporine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?42/42/43686?source=see_link\">",
"       gemfibrozil",
"      </a>",
"      , and some protease inhibitors used in the treatment of HIV infection. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?6/44/6856?source=see_link\">",
"       \"Drug-induced myopathies\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?33/0/33802?source=see_link\">",
"       \"Statin myopathy\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      In some individuals exposed to drugs, multiple mechanisms may contribute to muscle damage; as an example, rhabdomyolysis with alcoholic binges may result from a combination of hypokalemia, hypophosphatemia, coma, agitation, and direct muscle toxicity.",
"     </li>",
"     <li>",
"      Dietary supplements used for weight loss or enhanced physical performance, which typically contain multiple ingredients, may lead to rhabdomyolysis, possibly as a result of metabolic stress [",
"      <a class=\"abstract\" href=\"UTD.htm?10/33/10777/abstract/46,47\">",
"       46,47",
"      </a>",
"      ]. In one report, nutritional supplements used in strength training caused rhabdomyolysis in otherwise healthy individuals [",
"      <a class=\"abstract\" href=\"UTD.htm?10/33/10777/abstract/46\">",
"       46",
"      </a>",
"      ]. Nutritional supplements containing ephedra, creatine, and large doses of caffeine have been implicated, but these findings have also been reported in patients using supplements lacking these compounds [",
"      <a class=\"abstract\" href=\"UTD.htm?10/33/10777/abstract/47\">",
"       47",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Patients undergoing isolated limb perfusion for locally recurrent melanoma may develop rhabdomyolysis as a complication of therapy [",
"      <a class=\"abstract\" href=\"UTD.htm?10/33/10777/abstract/48,49\">",
"       48,49",
"      </a>",
"      ]. The degree of injury is influenced by the specific drug administered and other factors, possibly including ischemia and hyperthermia. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?33/13/34007?source=see_link&amp;anchor=H16#H16\">",
"       \"Cutaneous melanoma: Management of local recurrence\", section on 'Isolated limb perfusion'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31734836\">",
"    <span class=\"h3\">",
"     Toxins",
"    </span>",
"    &nbsp;&mdash;&nbsp;Rhabdomyolysis may result from exposures to toxins other than medications [",
"    <a class=\"abstract\" href=\"UTD.htm?10/33/10777/abstract/5\">",
"     5",
"    </a>",
"    ]. These include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Metabolic poisons, such as carbon monoxide, which lead to insufficient muscle energy production (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?10/6/10345?source=see_link\">",
"       \"Carbon monoxide poisoning\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Snake venoms, which occur from certain snake bites and are most often reported from Asia, Africa, and South America [",
"      <a class=\"abstract\" href=\"UTD.htm?10/33/10777/abstract/50,51\">",
"       50,51",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Insect venoms, including wasp and bee stings [",
"      <a class=\"abstract\" href=\"UTD.htm?10/33/10777/abstract/5,52,53\">",
"       5,52,53",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Mushroom poisoning [",
"      <a class=\"abstract\" href=\"UTD.htm?10/33/10777/abstract/54-57\">",
"       54-57",
"      </a>",
"      ] (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?16/2/16426?source=see_link&amp;anchor=H29#H29\">",
"       \"Food poisoning in children\", section on 'Mushroom ingestions'",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31734843\">",
"    <span class=\"h3\">",
"     Infections",
"    </span>",
"    &nbsp;&mdash;&nbsp;Rhabdomyolysis has been associated with a variety of infections, both viral and bacterial [",
"    <a class=\"abstract\" href=\"UTD.htm?10/33/10777/abstract/8,58-60\">",
"     8,58-60",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Acute viral infections associated with rhabdomyolysis include influenza A and B, Coxsackievirus, Epstein-Barr, herpes simplex, parainfluenza, adenovirus, echovirus, human immunodeficiency virus, and cytomegalovirus [",
"    <a class=\"abstract\" href=\"UTD.htm?10/33/10777/abstract/58-60\">",
"     58-60",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/41/9879?source=see_link&amp;anchor=H4#H4\">",
"     \"Viral myositis\", section on 'Viral myositis with rhabdomyolysis'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/37/4695?source=see_link\">",
"     \"Muscle disease in HIV-infected patients\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The mechanism of muscle damage due to viral infections has not been established, as the presence of virus in affected muscle has been difficult to demonstrate consistently.",
"   </p>",
"   <p>",
"    Other infections associated with rhabdomyolysis include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Bacterial pyomyositis [",
"      <a class=\"abstract\" href=\"UTD.htm?10/33/10777/abstract/61\">",
"       61",
"      </a>",
"      ] (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?32/11/32950?source=see_link\">",
"       \"Pyomyositis\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Bacterial infections with a variety of microbial organisms, including legionella, tularemia, streptococcus and salmonella, E. coli, leptospirosis, Coxiella burnetii (Q fever), and staphylococcal infection [",
"      <a class=\"abstract\" href=\"UTD.htm?10/33/10777/abstract/5,8\">",
"       5,8",
"      </a>",
"      ]",
"      <br/>",
"      <br/>",
"      In patients with septicemia without direct muscle infection, muscle damage may be caused by a toxin, or from associated fever, rigors, and dehydration [",
"      <a class=\"abstract\" href=\"UTD.htm?10/33/10777/abstract/62,63\">",
"       62,63",
"      </a>",
"      ]. Toxic shock syndrome, most commonly caused by circulating streptococcal or staphylococcal exotoxins, may also result in rhabdomyolysis [",
"      <a class=\"abstract\" href=\"UTD.htm?10/33/10777/abstract/64,65\">",
"       64,65",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?6/29/6616?source=see_link\">",
"       \"Epidemiology, clinical manifestations, and diagnosis of streptococcal toxic shock syndrome\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?7/52/8010?source=see_link\">",
"       \"Staphylococcal toxic shock syndrome\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Human granulocytic anaplasmosis (ehrlichiosis) [",
"      <a class=\"abstract\" href=\"UTD.htm?10/33/10777/abstract/66\">",
"       66",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Falciparum malaria [",
"      <a class=\"abstract\" href=\"UTD.htm?10/33/10777/abstract/67\">",
"       67",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31734850\">",
"    <span class=\"h3\">",
"     Electrolyte disorders",
"    </span>",
"    &nbsp;&mdash;&nbsp;Rhabdomyolysis has been associated with a variety of electrolyte disorders, particularly hypokalemia [",
"    <a class=\"abstract\" href=\"UTD.htm?10/33/10777/abstract/68,69\">",
"     68,69",
"    </a>",
"    ] and hypophosphatemia [",
"    <a class=\"abstract\" href=\"UTD.htm?10/33/10777/abstract/70,71\">",
"     70,71",
"    </a>",
"    ]. The latter association is most often seen in alcoholic patients and those receiving hyperalimentation without phosphate supplementation [",
"    <a class=\"abstract\" href=\"UTD.htm?10/33/10777/abstract/70\">",
"     70",
"    </a>",
"    ]. Cases associated with hyperosmolality due to diabetic ketoacidosis or nonketotic hyperglycemia have also been described, and hypophosphatemia may contribute to the risk of rhabdomyolysis in some of these patients [",
"    <a class=\"abstract\" href=\"UTD.htm?10/33/10777/abstract/72-74\">",
"     72-74",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/2/9258?source=see_link&amp;anchor=H3819896#H3819896\">",
"     \"Clinical manifestations and treatment of hypokalemia\", section on 'Severe muscle weakness or rhabdomyolysis'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/57/32659?source=see_link&amp;anchor=H5#H5\">",
"     \"Signs and symptoms of hypophosphatemia\", section on 'Skeletal and smooth muscle'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/48/15114?source=see_link&amp;anchor=H19#H19\">",
"     \"Treatment of diabetic ketoacidosis and hyperosmolar hyperglycemic state in adults\", section on 'Phosphate depletion'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Potassium release from muscle cells during exercise normally mediates vasodilation and the appropriately increased blood flow to muscles. Decreased potassium release due to profound hypokalemia (serum potassium less than 2.5",
"    <span class=\"nowrap\">",
"     mEq/L)",
"    </span>",
"    may promote the development of rhabdomyolysis by decreasing blood flow to muscles in response to exertion.",
"   </p>",
"   <p>",
"    In both hypokalemic and hypophosphatemic rhabdomyolysis, the serum potassium and phosphate levels may underestimate or mask the underlying total body depletion because of the release of these electrolytes from intracellular stores due to the myonecrosis [",
"    <a class=\"abstract\" href=\"UTD.htm?10/33/10777/abstract/70\">",
"     70",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Other electrolyte disorders have been occasionally associated with rhabdomyolysis. These include hypocalcemia [",
"    <a class=\"abstract\" href=\"UTD.htm?10/33/10777/abstract/75\">",
"     75",
"    </a>",
"    ]; hyponatremia, mostly due to primary polydipsia [",
"    <a class=\"abstract\" href=\"UTD.htm?10/33/10777/abstract/76,77\">",
"     76,77",
"    </a>",
"    ]; and hypernatremia [",
"    <a class=\"abstract\" href=\"UTD.htm?10/33/10777/abstract/78,79\">",
"     78,79",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31734857\">",
"    <span class=\"h3\">",
"     Endocrine disorders",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several endocrine disorders, including diabetes and thyroid diseases, have been associated with rhabdomyolysis, sometimes in combination with other causes. As noted in the previous section, both diabetic ketoacidosis and nonketotic hyperglycemia have been associated with rhabdomyolysis due at least in part to phosphate depletion and other electrolyte imbalances associated with this condition [",
"    <a class=\"abstract\" href=\"UTD.htm?10/33/10777/abstract/72-74\">",
"     72-74",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Hypothyroidism is frequently accompanied by myalgias and mild to moderate serum CK elevations. In addition, overt rhabdomyolysis has been described, and concurrent statin therapy may be a risk factor. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/26/29093?source=see_link&amp;anchor=H9#H9\">",
"     \"Hypothyroid myopathy\", section on 'Rhabdomyolysis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Rhabdomyolysis has also been infrequently described in several other endocrine disorders. These include hyperthyroidism [",
"    <a class=\"abstract\" href=\"UTD.htm?10/33/10777/abstract/80\">",
"     80",
"    </a>",
"    ] and pheochromocytoma [",
"    <a class=\"abstract\" href=\"UTD.htm?10/33/10777/abstract/81\">",
"     81",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31734864\">",
"    <span class=\"h3\">",
"     Inflammatory myopathies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Rhabdomyolysis has only rarely been described in patients with the inflammatory myopathies, dermatomyositis and polymyositis [",
"    <a class=\"abstract\" href=\"UTD.htm?10/33/10777/abstract/82-84\">",
"     82-84",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/4/27722?source=see_link\">",
"     \"Clinical manifestations and diagnosis of adult dermatomyositis and polymyositis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31734871\">",
"    <span class=\"h2\">",
"     Miscellaneous",
"    </span>",
"    &nbsp;&mdash;&nbsp;Rhabdomyolysis is associated with a number of other conditions in occasional patients:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Status asthmaticus, in which muscle injury may be due to respiratory muscle overexertion",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      generalized muscle hypoxia [",
"      <a class=\"abstract\" href=\"UTD.htm?10/33/10777/abstract/85\">",
"       85",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      The administration of non-depolarizing muscle blocking agents to critically ill intensive care unit patients who require mechanical ventilation. A hypothesis is that muscle was \"primed\" for such injury by the underlying disease state, the administration of high dose glucocorticoids, or the presence of an additional factor related to the critical illness [",
"      <a class=\"abstract\" href=\"UTD.htm?10/33/10777/abstract/86\">",
"       86",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?42/44/43720?source=see_link\">",
"       \"Use of neuromuscular blocking medications in critically ill patients\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The \"capillary leak syndrome,\" a rare condition in which there are sudden, recurrent episodes of markedly increased capillary permeability, causing shifts of fluid from the intravascular to interstitial compartments. This shift leads to marked edema, limb swelling and possible compartment syndrome, hypovolemia, hypotension, and, in some cases, rhabdomyolysis [",
"      <a class=\"abstract\" href=\"UTD.htm?10/33/10777/abstract/87,88\">",
"       87,88",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?0/26/426?source=see_link\">",
"       \"Idiopathic systemic capillary leak syndrome\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Abrupt withdrawal of the gamma-aminobutyric acid (GABA) agonist",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/31/36342?source=see_link\">",
"       baclofen",
"      </a>",
"      , particularly if given intrathecally, which can lead to severe muscle spasticity and muscle necrosis [",
"      <a class=\"abstract\" href=\"UTD.htm?10/33/10777/abstract/89,90\">",
"       89,90",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31738599\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The clinical manifestations and complications of rhabdomyolysis result from muscle cell death, with the release of intracellular muscle constituents into the circulation. (See",
"      <a class=\"local\" href=\"#H31734773\">",
"       'Introduction'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H31734780\">",
"       'Pathophysiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The multiple potential causes of rhabdomyolysis can be broadly divided into three categories (",
"      <a class=\"graphic graphic_table graphicRef60404 \" href=\"UTD.htm?6/11/6332\">",
"       table 1",
"      </a>",
"      ) (see",
"      <a class=\"local\" href=\"#H31734787\">",
"       'Causes'",
"      </a>",
"      above):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Traumatic or muscle compression (see",
"      <a class=\"local\" href=\"#H31734794\">",
"       'Trauma or muscle compression'",
"      </a>",
"      above)",
"     </li>",
"     <li>",
"      Nontraumatic exertional (see",
"      <a class=\"local\" href=\"#H31734801\">",
"       'Nontraumatic exertional rhabdomyolysis'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H31734808\">",
"       'Metabolic myopathies'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H31734815\">",
"       'Thermal extremes and dysregulation'",
"      </a>",
"      above)",
"     </li>",
"     <li>",
"      Nontraumatic nonexertional &mdash; (see",
"      <a class=\"local\" href=\"#H31734822\">",
"       'Nonexertional and nontraumatic rhabdomyolysis'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H31734829\">",
"       'Drugs'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H31734843\">",
"       'Infections'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H31734850\">",
"       'Electrolyte disorders'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H31734857\">",
"       'Endocrine disorders'",
"      </a>",
"      above)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The most common causes of rhabdomyolysis are drugs and toxins, including lipid-lowering agents, alcohol, and cocaine. Trauma and overexertion are also relatively common causes. The majority of patients has more than one etiologic factor, and less than 10 percent has no identifiable cause. Rhabdomyolysis rarely occurs in association with an inflammatory myopathy. (See",
"      <a class=\"local\" href=\"#H31734787\">",
"       'Causes'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H31734864\">",
"       'Inflammatory myopathies'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/33/10777/abstract/1\">",
"      Giannoglou GD, Chatzizisis YS, Misirli G. The syndrome of rhabdomyolysis: Pathophysiology and diagnosis. Eur J Intern Med 2007; 18:90.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/33/10777/abstract/2\">",
"      Khan FY. Rhabdomyolysis: a review of the literature. Neth J Med 2009; 67:272.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/33/10777/abstract/3\">",
"      Gabow PA, Kaehny WD, Kelleher SP. The spectrum of rhabdomyolysis. Medicine (Baltimore) 1982; 61:141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/33/10777/abstract/4\">",
"      Melli G, Chaudhry V, Cornblath DR. Rhabdomyolysis: an evaluation of 475 hospitalized patients. Medicine (Baltimore) 2005; 84:377.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/33/10777/abstract/5\">",
"      Huerta-Alard&iacute;n AL, Varon J, Marik PE. Bench-to-bedside review: Rhabdomyolysis -- an overview for clinicians. Crit Care 2005; 9:158.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/33/10777/abstract/6\">",
"      Bosch X, Poch E, Grau JM. Rhabdomyolysis and acute kidney injury. N Engl J Med 2009; 361:62.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/33/10777/abstract/7\">",
"      Warren JD, Blumbergs PC, Thompson PD. Rhabdomyolysis: a review. Muscle Nerve 2002; 25:332.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/33/10777/abstract/8\">",
"      Blanco JR, Zabalza M, Salcedo J, et al. Rhabdomyolysis of infectious and noninfectious causes. South Med J 2002; 95:542.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/33/10777/abstract/9\">",
"      Veenstra J, Smit WM, Krediet RT, Arisz L. Relationship between elevated creatine phosphokinase and the clinical spectrum of rhabdomyolysis. Nephrol Dial Transplant 1994; 9:637.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/33/10777/abstract/10\">",
"      Bywaters EG, Beall D. Crush Injuries with Impairment of Renal Function. Br Med J 1941; 1:427.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/33/10777/abstract/11\">",
"      Vanholder R, Sever MS, Erek E, Lameire N. Acute renal failure related to the crush syndrome: towards an era of seismo-nephrology? Nephrol Dial Transplant 2000; 15:1517.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/33/10777/abstract/12\">",
"      Sever MS, Erek E, Vanholder R, et al. The Marmara earthquake: epidemiological analysis of the victims with nephrological problems. Kidney Int 2001; 60:1114.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/33/10777/abstract/13\">",
"      Slater MS, Mullins RJ. Rhabdomyolysis and myoglobinuric renal failure in trauma and surgical patients: a review. J Am Coll Surg 1998; 186:693.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/33/10777/abstract/14\">",
"      Malik GH, Sirwal IA, Reshi AR, et al. Acute renal failure following physical torture. Nephron 1993; 63:434.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/33/10777/abstract/15\">",
"      Schwengel D, Ludwig S. Rhabdomyolysis and myoglobinuria as manifestations of child abuse. Pediatr Emerg Care 1985; 1:194.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/33/10777/abstract/16\">",
"      Penn AS, Rowland LP, Fraser DW. Drugs, coma, and myoglobinuria. Arch Neurol 1972; 26:336.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/33/10777/abstract/17\">",
"      Szewczyk D, Ovadia P, Abdullah F, Rabinovici R. Pressure-induced rhabdomyolysis and acute renal failure. J Trauma 1998; 44:384.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/33/10777/abstract/18\">",
"      Lachiewicz PF, Latimer HA. Rhabdomyolysis following total hip arthroplasty. J Bone Joint Surg Br 1991; 73:576.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/33/10777/abstract/19\">",
"      Biswas S, Gnanasekaran I, Ivatury RR, et al. Exaggerated lithotomy position-related rhabdomyolysis. Am Surg 1997; 63:361.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/33/10777/abstract/20\">",
"      Adiseshiah M, Round JM, Jones DA. Reperfusion injury in skeletal muscle: a prospective study in patients with acute limb ischaemia and claudicants treated by revascularization. Br J Surg 1992; 79:1026.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/33/10777/abstract/21\">",
"      Brumback RA, Feeback DL, Leech RW. Rhabdomyolysis following electrical injury. Semin Neurol 1995; 15:329.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/33/10777/abstract/22\">",
"      Schiff HB, MacSearraigh ET, Kallmeyer JC. Myoglobinuria, rhabdomyolysis and marathon running. Q J Med 1978; 47:463.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/33/10777/abstract/23\">",
"      Olerud JE, Homer LD, Carroll HW. Incidence of acute exertional rhabdomyolysis. Serum myoglobin and enzyme levels as indicators of muscle injury. Arch Intern Med 1976; 136:692.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/33/10777/abstract/24\">",
"      Schwaber MJ, Liss HP, Steiner I, Brezis M. Hazard of sauna use after strenuous exercise. Ann Intern Med 1994; 120:441.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/33/10777/abstract/25\">",
"      Bouchama A, Knochel JP. Heat stroke. N Engl J Med 2002; 346:1978.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/33/10777/abstract/26\">",
"      Knochel JP. Environmental heat illness. An eclectic review. Arch Intern Med 1974; 133:841.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/33/10777/abstract/27\">",
"      Sherry P. Sickle cell trait and rhabdomyolysis: case report and review of the literature. Mil Med 1990; 155:59.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/33/10777/abstract/28\">",
"      Rosenthal MA, Parker DJ. Collapse of a young athlete. Ann Emerg Med 1992; 21:1493.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/33/10777/abstract/29\">",
"      Knochel JP. Exertional rhabdomyolysis. N Engl J Med 1972; 287:927.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/33/10777/abstract/30\">",
"      Knochel JP. Neuromuscular manifestations of electrolyte disorders. Am J Med 1982; 72:521.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/33/10777/abstract/31\">",
"      Knochel JP, Schlein EM. On the mechanism of rhabdomyolysis in potassium depletion. J Clin Invest 1972; 51:1750.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/33/10777/abstract/32\">",
"      Edwards G, Dora KA, Gardener MJ, et al. K+ is an endothelium-derived hyperpolarizing factor in rat arteries. Nature 1998; 396:269.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/33/10777/abstract/33\">",
"      Lonka L, Pedersen RS. Fatal rhabdomyolysis in marathon runner. Lancet 1987; 1:857.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/33/10777/abstract/34\">",
"      Ginsberg MD, Hertzman M, Schmidt-Nowara WW. Amphetamine intoxication with coagulopathy, hyperthermia, and reversible renal failure. A syndrome resembling heatstroke. Ann Intern Med 1970; 73:81.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/33/10777/abstract/35\">",
"      Tein I, DiMauro S, DeVivo DC. Recurrent childhood myoglobinuria. Adv Pediatr 1990; 37:77.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/33/10777/abstract/36\">",
"      Tonin P, Lewis P, Servidei S, DiMauro S. Metabolic causes of myoglobinuria. Ann Neurol 1990; 27:181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/33/10777/abstract/37\">",
"      Felig P, Wahren J. Fuel homeostasis in exercise. N Engl J Med 1975; 293:1078.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/33/10777/abstract/38\">",
"      Chinnery PF, Johnson MA, Taylor RW, et al. A novel mitochondrial tRNA phenylalanine mutation presenting with acute rhabdomyolysis. Ann Neurol 1997; 41:408.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/33/10777/abstract/39\">",
"      Eiser AR, Neff MS, Slifkin RF. Acute myoglobinuric renal failure. A consequence of the neuroleptic malignant syndrome. Arch Intern Med 1982; 142:601.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/33/10777/abstract/40\">",
"      Bonnor R, Siddiqui M, Ahuja TS. Rhabdomyolysis associated with near-drowning. Am J Med Sci 1999; 318:201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/33/10777/abstract/41\">",
"      Curry SC, Chang D, Connor D. Drug- and toxin-induced rhabdomyolysis. Ann Emerg Med 1989; 18:1068.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/33/10777/abstract/42\">",
"      Prendergast BD, George CF. Drug-induced rhabdomyolysis--mechanisms and management. Postgrad Med J 1993; 69:333.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/33/10777/abstract/43\">",
"      Antons KA, Williams CD, Baker SK, Phillips PS. Clinical perspectives of statin-induced rhabdomyolysis. Am J Med 2006; 119:400.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/33/10777/abstract/44\">",
"      Kiernan TJ, Rochford M, McDermott JH. Simvastatin induced rhabdomyolysis and an important clinical link with hypothyroidism. Int J Cardiol 2007; 119:374.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/33/10777/abstract/45\">",
"      Gupta S, Blaivas M, Ike RW, Crofford LJ. Polymyositis evolving after rhabdomyolysis associated with HMG-CoA reductase inhibitors: a report of two cases. J Clin Rheumatol 2001; 7:332.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/33/10777/abstract/46\">",
"      Scroggie DA, Harris M, Sakai L. Rhabdomyolysis associated with nutritional supplement use. J Clin Rheumatol 2000; 6:328.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/33/10777/abstract/47\">",
"      Dehoney S, Wellein M. Rhabdomyolysis associated with the nutritional supplement Hydroxycut. Am J Health Syst Pharm 2009; 66:142.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/33/10777/abstract/48\">",
"      Hohenberger P, Haier J, Schlag PM. Rhabdomyolysis and renal function impairment after isolated limb perfusion--comparison between the effects of perfusion with rhTNF alpha and a 'triple-drug' regimen. Eur J Cancer 1997; 33:596.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/33/10777/abstract/49\">",
"      Vrouenraets BC, Klaase JM, Nieweg OE, Kroon BB. Toxicity and morbidity of isolated limb perfusion. Semin Surg Oncol 1998; 14:224.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/33/10777/abstract/50\">",
"      Sitprija V, Gopalakrishnakone P. Snake bite, rhabdomyolysis, and renal failure. Am J Kidney Dis 1998; 31:l.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/33/10777/abstract/51\">",
"      Isbister GK, Hooper MR, Dowsett R, et al. Collett's snake (Pseudechis colletti) envenoming in snake handlers. QJM 2006; 99:109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/33/10777/abstract/52\">",
"      George P, Pawar B, Calton N, Mathew P. Wasp sting: an unusual fatal outcome. Saudi J Kidney Dis Transpl 2008; 19:969.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/33/10777/abstract/53\">",
"      Betten DP, Richardson WH, Tong TC, Clark RF. Massive honey bee envenomation-induced rhabdomyolysis in an adolescent. Pediatrics 2006; 117:231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/33/10777/abstract/54\">",
"      Bedry R, Baudrimont I, Deffieux G, et al. Wild-mushroom intoxication as a cause of rhabdomyolysis. N Engl J Med 2001; 345:798.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/33/10777/abstract/55\">",
"      Lee PT, Wu ML, Tsai WJ, et al. Rhabdomyolysis: an unusual feature with mushroom poisoning. Am J Kidney Dis 2001; 38:E17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/33/10777/abstract/56\">",
"      Diaz JH. Evolving global epidemiology, syndromic classification, general management, and prevention of unknown mushroom poisonings. Crit Care Med 2005; 33:419.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/33/10777/abstract/57\">",
"      Saviuc P, Danel V. New syndromes in mushroom poisoning. Toxicol Rev 2006; 25:199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/33/10777/abstract/58\">",
"      Pesik NT, Otten EJ. Severe rhabdomyolysis following a viral illness: a case report and review of the literature. J Emerg Med 1996; 14:425.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/33/10777/abstract/59\">",
"      O'Connor JV, Iyer SK. Myoglobinuria associated with parainfluenza type 2 infection. N Y State J Med 1982; 82:1469.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/33/10777/abstract/60\">",
"      Ueda K, Robbins DA, Iitaka K, Linnemann CC Jr. Fatal rhabdomyolysis associated with parainfluenza type 3 infection. Hiroshima J Med Sci 1978; 27:99.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/33/10777/abstract/61\">",
"      Armstrong JH. Tropical pyomyositis and myoglobinuria. Arch Intern Med 1978; 138:1145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/33/10777/abstract/62\">",
"      Posner MR, Caudill MA, Brass R, Ellis E. Legionnaires' disease associated with rhabdomyolysis and myoglobinuria. Arch Intern Med 1980; 140:848.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/33/10777/abstract/63\">",
"      Naschitz JE, Yeshurun D, Shagrawi I. Rhabdomyolysis in pneumococcal sepsis. Am J Med 1989; 87:479.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/33/10777/abstract/64\">",
"      Bachhuber R, Parker RA, Bennett WM. Acute renal failure in toxic shock syndrome owing to rhabdomyolysis. Ann Clin Lab Sci 1983; 13:25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/33/10777/abstract/65\">",
"      McKenna UG, Meadows JA 3rd, Brewer NS, et al. Toxic shock syndrome, a newly recognized disease entity. Report of 11 cases. Mayo Clin Proc 1980; 55:663.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/33/10777/abstract/66\">",
"      Heller HM, Telford SR 3rd, Branda JA. Case records of the Massachusetts General Hospital. Case 10-2005. A 73-year-old man with weakness and pain in the legs. N Engl J Med 2005; 352:1358.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/33/10777/abstract/67\">",
"      Knochel JP, Moore GE. Rhabdomyolysis in Malaria. N Engl J Med 1993; 329:1206.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/33/10777/abstract/68\">",
"      Shintani S, Shiigai T, Tsukagoshi H. Marked hypokalemic rhabdomyolysis with myoglobinuria due to diuretic treatment. Eur Neurol 1991; 31:396.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/33/10777/abstract/69\">",
"      Dominic JA, Koch M, Guthrie GP Jr, Galla JH. Primary aldosteronism presenting as myoglobinuric acute renal failure. Arch Intern Med 1978; 138:1433.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/33/10777/abstract/70\">",
"      Singhal PC, Kumar A, Desroches L, et al. Prevalence and predictors of rhabdomyolysis in patients with hypophosphatemia. Am J Med 1992; 92:458.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/33/10777/abstract/71\">",
"      Knochel JP. Hypophosphatemia and rhabdomyolysis. Am J Med 1992; 92:455.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/33/10777/abstract/72\">",
"      Singhal PC, Abramovici M, Venkatesan J. Rhabdomyolysis in the hyperosmolal state. Am J Med 1990; 88:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/33/10777/abstract/73\">",
"      Wang LM, Tsai ST, Ho LT, et al. Rhabdomyolysis in diabetic emergencies. Diabetes Res Clin Pract 1994; 26:209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/33/10777/abstract/74\">",
"      Casteels K, Beckers D, Wouters C, Van Geet C. Rhabdomyolysis in diabetic ketoacidosis. Pediatr Diabetes 2003; 4:29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/33/10777/abstract/75\">",
"      Akmal M. Rhabdomyolysis in a patient with hypocalcemia due to hypoparathyroidism. Am J Nephrol 1993; 13:61.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/33/10777/abstract/76\">",
"      Cronin RE. Psychogenic polydipsia with hyponatremia: report of eleven cases. Am J Kidney Dis 1987; 9:410.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/33/10777/abstract/77\">",
"      Putterman C, Levy L, Rubinger D. Transient exercise-induced water intoxication and rhabdomyolysis. Am J Kidney Dis 1993; 21:206.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/33/10777/abstract/78\">",
"      Abramovici MI, Singhal PC, Trachtman H. Hypernatremia and rhabdomyolysis. J Med 1992; 23:17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/33/10777/abstract/79\">",
"      Denman JP. Hypernatraemia and rhabdomyolysis. Med J Aust 2007; 187:527.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/33/10777/abstract/80\">",
"      Bennett WR, Huston DP. Rhabdomyolysis in thyroid storm. Am J Med 1984; 77:733.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/33/10777/abstract/81\">",
"      Shemin D, Cohn PS, Zipin SB. Pheochromocytoma presenting as rhabdomyolysis and acute myoglobinuric renal failure. Arch Intern Med 1990; 150:2384.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/33/10777/abstract/82\">",
"      Caccamo DV, Keene CY, Durham J, Peven D. Fulminant rhabdomyolysis in a patient with dermatomyositis. Neurology 1993; 43:844.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/33/10777/abstract/83\">",
"      Pirovino M, Neff MS, Sharon E. Myoglobinuria and acute renal failure with acute polymyositis. N Y State J Med 1979; 79:764.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/33/10777/abstract/84\">",
"      Kim HW, Choi JR, Jang SJ, et al. Recurrent rhabdomyolysis and myoglobinuric acute renal failure in a patient with polymyositis. Nephrol Dial Transplant 2005; 20:2255.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/33/10777/abstract/85\">",
"      Barrett SA, Mourani S, Villareal CA, et al. Rhabdomyolysis associated with status asthmaticus. Crit Care Med 1993; 21:151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/33/10777/abstract/86\">",
"      Ramsay DA, Zochodne DW, Robertson DM, et al. A syndrome of acute severe muscle necrosis in intensive care unit patients. J Neuropathol Exp Neurol 1993; 52:387.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/33/10777/abstract/87\">",
"      Dolberg-Stolik OC, Putterman C, Rubinow A, et al. Idiopathic capillary leak syndrome complicated by massive rhabdomyolysis. Chest 1993; 104:123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/33/10777/abstract/88\">",
"      Balcarek P, Frosch KH, Quintel M, St&uuml;rmer KM. [Systemic capillary leak syndrome causes a compartment syndrome of both lower legs and a forearm. A case report with a review of the literature]. Unfallchirurg 2005; 108:770, 772.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/33/10777/abstract/89\">",
"      Coffey RJ, Edgar TS, Francisco GE, et al. Abrupt withdrawal from intrathecal baclofen: recognition and management of a potentially life-threatening syndrome. Arch Phys Med Rehabil 2002; 83:735.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/33/10777/abstract/90\">",
"      Mohammed I, Hussain A. Intrathecal baclofen withdrawal syndrome- a life-threatening complication of baclofen pump: a case report. BMC Clin Pharmacol 2004; 4:6.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 16414 Version 3.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0605-213.134.24.46-F1BE05E961-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_33_10777=[""].join("\n");
var outline_f10_33_10777=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H31738599\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H31734773\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H31734780\">",
"      PATHOPHYSIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H31734787\">",
"      CAUSES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H31734794\">",
"      Trauma or muscle compression",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H31734801\">",
"      Nontraumatic exertional rhabdomyolysis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H31734808\">",
"      - Metabolic myopathies",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H31734815\">",
"      - Thermal extremes and dysregulation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H31734822\">",
"      Nonexertional and nontraumatic rhabdomyolysis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H31734829\">",
"      - Drugs",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H31734836\">",
"      - Toxins",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H31734843\">",
"      - Infections",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H31734850\">",
"      - Electrolyte disorders",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H31734857\">",
"      - Endocrine disorders",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H31734864\">",
"      - Inflammatory myopathies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H31734871\">",
"      Miscellaneous",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H31738599\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"RHEUM/16414\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"RHEUM/16414|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?6/11/6332\" title=\"table 1\">",
"      Causes of rhabdomyolysis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?24/58/25515\" title=\"table 2\">",
"      Metabolic myopathy and rhabdo",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/57/8090?source=related_link\">",
"      Acute compartment syndrome of the extremities",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/56/905?source=related_link\">",
"      Approach to the metabolic myopathies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/6/10345?source=related_link\">",
"      Carbon monoxide poisoning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/36/21065?source=related_link\">",
"      Causes of metabolic myopathies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/6/22632?source=related_link\">",
"      Clinical features and diagnosis of heme pigment-induced acute kidney injury (acute renal failure)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/4/27722?source=related_link\">",
"      Clinical manifestations and diagnosis of adult dermatomyositis and polymyositis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/55/32632?source=related_link\">",
"      Clinical manifestations and diagnosis of rhabdomyolysis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/2/9258?source=related_link\">",
"      Clinical manifestations and treatment of hypokalemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/0/15369?source=related_link\">",
"      Crush-related acute kidney injury (acute renal failure)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/13/34007?source=related_link\">",
"      Cutaneous melanoma: Management of local recurrence",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/11/26809?source=related_link\">",
"      Drowning (submersion injuries)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/44/6856?source=related_link\">",
"      Drug-induced myopathies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/63/6134?source=related_link\">",
"      Energy metabolism in muscle",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/19/4410?source=related_link\">",
"      Environmental electrical injuries",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/29/6616?source=related_link\">",
"      Epidemiology, clinical manifestations, and diagnosis of streptococcal toxic shock syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/2/16426?source=related_link\">",
"      Food poisoning in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/26/29093?source=related_link\">",
"      Hypothyroid myopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/26/426?source=related_link\">",
"      Idiopathic systemic capillary leak syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/13/32984?source=related_link\">",
"      Malignant hyperthermia: Clinical diagnosis and management of acute crisis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/37/4695?source=related_link\">",
"      Muscle disease in HIV-infected patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/23/23928?source=related_link\">",
"      Muscle phosphorylase deficiency (glycogen storage disease V, McArdle disease)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/4/20553?source=related_link\">",
"      Neuroleptic malignant syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/16/4356?source=related_link\">",
"      Overview of inherited disorders of glucose and glycogen metabolism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/21/21847?source=related_link\">",
"      Prevention and treatment of heme pigment-induced acute kidney injury (acute renal failure)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/11/32950?source=related_link\">",
"      Pyomyositis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/40/16007?source=related_link\">",
"      Severe hyperthermia (heat stroke) in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/40/13960?source=related_link\">",
"      Sickle cell trait",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/57/32659?source=related_link\">",
"      Signs and symptoms of hypophosphatemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/52/8010?source=related_link\">",
"      Staphylococcal toxic shock syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/0/33802?source=related_link\">",
"      Statin myopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/3/36921?source=related_link\">",
"      Susceptibility to malignant hyperthermia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/48/15114?source=related_link\">",
"      Treatment of diabetic ketoacidosis and hyperosmolar hyperglycemic state in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/44/43720?source=related_link\">",
"      Use of neuromuscular blocking medications in critically ill patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/41/9879?source=related_link\">",
"      Viral myositis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f10_33_10778="QT dispersion: Clinical applications";
var content_f10_33_10778=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   QT dispersion: Clinical applications",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/33/10778/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/33/10778/contributors\">",
"     Velislav Batchvarov, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/33/10778/contributors\">",
"     A John Camm, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/33/10778/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/33/10778/contributors\">",
"     Bernard J Gersh, MB, ChB, DPhil, FRCP, MACC",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/33/10778/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/33/10778/contributors\">",
"     Brian C Downey, MD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?10/33/10778/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 25, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The QT interval duration varies between leads on the standard electrocardiogram (ECG), Frank orthogonal leads, and body surface potential maps [",
"    <a class=\"abstract\" href=\"UTD.htm?10/33/10778/abstract/1-6\">",
"     1-6",
"    </a>",
"    ]. These interlead differences, called QT dispersion or QT range, were proposed as an index of the spatial dispersion of the ventricular recovery times [",
"    <a class=\"abstract\" href=\"UTD.htm?10/33/10778/abstract/7\">",
"     7",
"    </a>",
"    ]. This measurement was an attempt to distinguish between myocardium that is homogeneous from myocardium that displays inhomogeneity, which is accompanied by increased dispersion of the ventricular recovery times and prolongation of repolarization. In reality, QT dispersion is a crude and approximate measure of a general abnormality of repolarization [",
"    <a class=\"abstract\" href=\"UTD.htm?10/33/10778/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    QT dispersion was developed in an effort to improve on ECG measures used in clinical practice, including the QT interval and its heart rate-corrected value (QTc) and the description of the ST-T morphology, often using vague terms such as \"non-specific ST-T wave changes.\" However, there has been much concern about the validity of the concept and the methodology of the measurement. Despite ongoing controversy, there are a number of reasonable conclusions about the reliability and applicability of the technique [",
"    <a class=\"abstract\" href=\"UTD.htm?10/33/10778/abstract/8,9\">",
"     8,9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The clinical application of QT dispersion will be reviewed here. The pathophysiology and measurement of QT dispersion are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/51/26425?source=see_link\">",
"     \"QT dispersion: Measurement and interpretation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     NORMAL VALUES AND LIMITATIONS OF QT DISPERSION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Reported values of QT dispersion vary widely, ranging from 10 to 71 msec in normal subjects [",
"    <a class=\"abstract\" href=\"UTD.htm?10/33/10778/abstract/8,10-13\">",
"     8,10-13",
"    </a>",
"    ]. In a review of 8455 healthy control subjects of various ages, including healthy children, the mean QT dispersion values ranged from 10 to 71 msec (mean 33 msec; median 37 msec) (",
"    <a class=\"graphic graphic_figure graphicRef75877 \" href=\"UTD.htm?36/59/37822\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/33/10778/abstract/8\">",
"     8",
"    </a>",
"    ]. There is little or no sex difference in QT dispersion [",
"    <a class=\"abstract\" href=\"UTD.htm?10/33/10778/abstract/14-16\">",
"     14-16",
"    </a>",
"    ]. Age-related differences, if present, appear to be small (&lt;10 msec) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/33/10778/abstract/13,17\">",
"     13,17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Similar values have been noted in large studies and literature reviews that suggested that the upper normal limit of QT dispersion in normal and healthy subjects is 65 msec [",
"    <a class=\"abstract\" href=\"UTD.htm?10/33/10778/abstract/10,18\">",
"     10,18",
"    </a>",
"    ]. In contrast, other reports claim that QT dispersion &gt;40 ms has a sensitivity and specificity of 88 and 57 percent, respectively, for predicting the inducibility of sustained ventricular tachycardia during an electrophysiology study [",
"    <a class=\"abstract\" href=\"UTD.htm?10/33/10778/abstract/19\">",
"     19",
"    </a>",
"    ]. However, in most of the studies with positive results, values for QT dispersion are well within the demonstrated measurement error of both manual and automatic methods. Another problem is that some prospective studies only provided data for the heart rate-corrected QT (QTc) dispersion [",
"    <a class=\"abstract\" href=\"UTD.htm?10/33/10778/abstract/20,21\">",
"     20,21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    QT dispersion is increased in patients with heart disease compared to healthy subjects, and prospective studies have suggested that QT dispersion has prognostic value. However, there is a great degree of overlap between healthy subjects and cardiac patients, as well as between patients with and without adverse outcomes (",
"    <a class=\"graphic graphic_figure graphicRef75877 \" href=\"UTD.htm?36/59/37822\">",
"     figure 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef68763 \" href=\"UTD.htm?18/36/19022\">",
"     figure 2",
"    </a>",
"    ). Another problem is that the reliability and reproducibility of both automatic and manual measurement of QT dispersion are low and significantly lower than that of the QT interval; the measurement error is similar to the differences among various patient groups [",
"    <a class=\"abstract\" href=\"UTD.htm?10/33/10778/abstract/8\">",
"     8",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H5\">",
"     'Prognostic value of QT dispersion in normal subjects'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H6\">",
"     'QT dispersion in cardiac disease'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/51/26425?source=see_link\">",
"     \"QT dispersion: Measurement and interpretation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     PROGNOSTIC VALUE OF QT DISPERSION IN NORMAL SUBJECTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of prospective studies have assessed the predictive value of QT dispersion for cardiac and all-cause mortality in the general population [",
"    <a class=\"abstract\" href=\"UTD.htm?10/33/10778/abstract/8,20-22\">",
"     8,20-22",
"    </a>",
"    ]. In general, a greater amount of QT dispersion is associated with higher risk of cardiac events and mortality.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The Rotterdam Study evaluated 5812 adults who were at least 55 years of age [",
"      <a class=\"abstract\" href=\"UTD.htm?10/33/10778/abstract/20\">",
"       20",
"      </a>",
"      ]. After adjusting for a history of myocardial infarction, hypertension, and overall QT interval, QTc dispersion predicted cardiac mortality during a mean follow-up of four years. Compared to subjects with QTc dispersion below 39 msec, those with values above 60 msec had a higher risk of total mortality (hazard ratio [HR] 1.4), cardiac death (HR 2.5), and sudden death (HR 1.9).",
"     </li>",
"     <li>",
"      In the Strong Heart Study of 1839 American Indians, cardiovascular mortality was significantly higher among those with QTc dispersion values above 58 msec (HR 3.4 compared to those with QTc dispersion &lt;58 msec) (",
"      <a class=\"graphic graphic_figure graphicRef68172 \" href=\"UTD.htm?2/26/2478\">",
"       figure 3",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?10/33/10778/abstract/21\">",
"       21",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The possible prognostic importance of uncorrected QT dispersion was evaluated in a preliminary report of the WOSCOPS trial of 6595 middle-aged men with moderately raised cholesterol but no previous myocardial infarction [",
"      <a class=\"abstract\" href=\"UTD.htm?10/33/10778/abstract/22\">",
"       22",
"      </a>",
"      ]. For each 10 msec increment in QT dispersion the risk of coronary death or nonfatal myocardial infarction increased by 13 percent.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     QT DISPERSION IN CARDIAC DISEASE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Increased QT dispersion has been demonstrated in patients with a variety of cardiac diseases, which is consistent with the concept that QT dispersion represents a general repolarization abnormality. However, the presence and degree of QT dispersion varies widely. This likely reflects variations in the method of measurement, interobserver variability, and other technical factors but may also result from differences in the patient groups.",
"   </p>",
"   <p>",
"    Pooled data from almost 7000 patients with cardiac diseases, including acute myocardial infarction (MI), prior MI, hypertrophic cardiomyopathy, left ventricular hypertrophy (LVH) of various causes, heart failure",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    idiopathic dilated cardiomyopathy, and long QT syndrome of various genotypes (",
"    <a class=\"graphic graphic_figure graphicRef75877 \" href=\"UTD.htm?36/59/37822\">",
"     figure 1",
"    </a>",
"    ) shows a clear tendency toward an increase in QT dispersion in each of these disorders [",
"    <a class=\"abstract\" href=\"UTD.htm?10/33/10778/abstract/8\">",
"     8",
"    </a>",
"    ]. The highest mean values occurred in patients with the long QT syndrome, which represents a global repolarization disease (",
"    <a class=\"graphic graphic_figure graphicRef68172 \" href=\"UTD.htm?2/26/2478\">",
"     figure 3",
"    </a>",
"    ). In addition, preliminary data has suggested that an increase in QT dispersion is a marker for the development of transplant vasculopathy [",
"    <a class=\"abstract\" href=\"UTD.htm?10/33/10778/abstract/23\">",
"     23",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/9/18585?source=see_link\">",
"     \"Natural history and diagnosis of cardiac allograft vasculopathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    However, the great overlap of values between patients with different cardiac diseases, between patients and normal subjects, and the wide variation of values within each cardiac disease prevents the establishment of reference values. Part of the variation results from the inclusion of patients with and without arrhythmias who are taking different medications.",
"   </p>",
"   <p>",
"    Despite these limitations, some general conclusions can be made from these data:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      QT dispersion is increased in acute MI compared to normals, although mean values from 40 to 162 ms have been described [",
"      <a class=\"abstract\" href=\"UTD.htm?10/33/10778/abstract/24,25\">",
"       24,25",
"      </a>",
"      ]. Some, but not all studies have found that QT dispersion is also increased in the chronic phase of MI and in chronic coronary heart disease compared to normals. However, the values are lower when compared to the acute phase of MI, possibly due to spontaneous dynamic changes or to the use of revascularization procedures [",
"      <a class=\"abstract\" href=\"UTD.htm?10/33/10778/abstract/26,27\">",
"       26,27",
"      </a>",
"      ]. QT dispersion is increased in post-MI diabetic patients with compared to those post-MI patients without type 2 diabetes [",
"      <a class=\"abstract\" href=\"UTD.htm?10/33/10778/abstract/28\">",
"       28",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      QT dispersion is increased in patients with heart failure and left ventricular dysfunction of various causes compared to normals [",
"      <a class=\"abstract\" href=\"UTD.htm?10/33/10778/abstract/29-32\">",
"       29-32",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      QT dispersion is increased in patients with hypertrophic cardiomyopathy and left ventricular hypertrophy of other causes, particularly hypertension [",
"      <a class=\"abstract\" href=\"UTD.htm?10/33/10778/abstract/33-43\">",
"       33-43",
"      </a>",
"      ]. There are conflicting data as to whether physiologic hypertrophy resulting from physical training in well-trained athletes is or is not associated with increased QT dispersion [",
"      <a class=\"abstract\" href=\"UTD.htm?10/33/10778/abstract/44-47\">",
"       44-47",
"      </a>",
"      ]. Androgen use may be a contributing factor [",
"      <a class=\"abstract\" href=\"UTD.htm?10/33/10778/abstract/45\">",
"       45",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?4/5/4184?source=see_link\">",
"       \"Electrocardiographic abnormalities and conduction disturbances in athletes\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      QT dispersion is increased in patients with the long QT syndrome [",
"      <a class=\"abstract\" href=\"UTD.htm?10/33/10778/abstract/48-51\">",
"       48-51",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?2/9/2202?source=see_link\">",
"       \"Clinical features of congenital long QT syndrome\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Correlation with the extent or severity of disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Attempts have been made to correlate QT dispersion with measures of extent or localization of the cardiac disease, including:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Infarct location &mdash; In acute myocardial infarction, QT dispersion may be greater in anterior compared to inferior infarcts [",
"      <a class=\"abstract\" href=\"UTD.htm?10/33/10778/abstract/52-54\">",
"       52-54",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Left ventricular ejection fraction [",
"      <a class=\"abstract\" href=\"UTD.htm?10/33/10778/abstract/55,56\">",
"       55,56",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The amount of viable myocardium in the infarct region [",
"      <a class=\"abstract\" href=\"UTD.htm?10/33/10778/abstract/57\">",
"       57",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The number of diseased vessels [",
"      <a class=\"abstract\" href=\"UTD.htm?10/33/10778/abstract/58\">",
"       58",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    There are conflicting data concerning a possible correlation between QT dispersion and left ventricular mass index in hypertensive patients with left ventricular hypertrophy [",
"    <a class=\"abstract\" href=\"UTD.htm?10/33/10778/abstract/59-61\">",
"     59-61",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    QT dispersion also varies with spontaneous or induced alterations in the pathologic process in some cardiac diseases:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      QT dispersion seems to undergo dynamic changes during the first day and the following days of acute MI [",
"      <a class=\"abstract\" href=\"UTD.htm?10/33/10778/abstract/25,52,62\">",
"       25,52,62",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      QT dispersion exhibits significant spontaneous circadian variation in healthy subjects and in patients with ischemic heart disease without myocardial infarction but not in those with previous MI and in patients with heart failure [",
"      <a class=\"abstract\" href=\"UTD.htm?10/33/10778/abstract/63,64\">",
"       63,64",
"      </a>",
"      ]. In all patient groups, however, the detection of significant circadian variation depends on the number of leads used for 24-hour Holter monitoring [",
"      <a class=\"abstract\" href=\"UTD.htm?10/33/10778/abstract/63\">",
"       63",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      QT dispersion increases significantly during ischemia induced by balloon inflation during angioplasty, by exercise stress testing or atrial pacing, or immediately after reperfusion with angioplasty [",
"      <a class=\"abstract\" href=\"UTD.htm?10/33/10778/abstract/27,65-69\">",
"       27,65-69",
"      </a>",
"      ]. One study of 273 patients found that the presence of QT dispersion &ge;60 msec immediately after exercise could detect the presence of a significant coronary stenosis with a sensitivity and specificity of 77 and 88 percent in patients who also have significant ST segment depression and 72 and 86 percent in those without ST segment depression [",
"      <a class=\"abstract\" href=\"UTD.htm?10/33/10778/abstract/70\">",
"       70",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      QT dispersion decreases significantly with improvement of left ventricular contractility after an acute MI [",
"      <a class=\"abstract\" href=\"UTD.htm?10/33/10778/abstract/71\">",
"       71",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Increased QT dispersion is related to the presence of viable myocardium demonstrated by improved contractility during",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/57/25494?source=see_link\">",
"       dobutamine",
"      </a>",
"      stress test in patients with ischemic heart disease [",
"      <a class=\"abstract\" href=\"UTD.htm?10/33/10778/abstract/72\">",
"       72",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Improvement with therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Increased QT dispersion can be reversed by effective therapy of the underlying disease. A variety of examples have been described including:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Correction of hypertension with regression of left ventricular hypertrophy [",
"      <a class=\"abstract\" href=\"UTD.htm?10/33/10778/abstract/39-43\">",
"       39-43",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Successful treatment of arterial hypertension with the angiotensin receptors antagonist",
"      <a class=\"drug drug_general\" href=\"UTD.htm?26/38/27239?source=see_link\">",
"       telmisartan",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?10/33/10778/abstract/73\">",
"       73",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Coronary reperfusion with thrombolysis, angioplasty, or coronary artery bypass grafting [",
"      <a class=\"abstract\" href=\"UTD.htm?10/33/10778/abstract/57,74-79\">",
"       57,74-79",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Beta blocker, angiotensin converting enzyme inhibitor, or angiotensin receptor blocker therapy in heart failure [",
"      <a class=\"abstract\" href=\"UTD.htm?10/33/10778/abstract/32,80\">",
"       32,80",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Beta blocker therapy or left cardiac sympathetic denervation in the congenital long QT syndrome [",
"      <a class=\"abstract\" href=\"UTD.htm?10/33/10778/abstract/48\">",
"       48",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Prognostic significance",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are conflicting results concerning the value of QT dispersion for predicting ventricular arrhythmias or other adverse events in patients with cardiac disease [",
"    <a class=\"abstract\" href=\"UTD.htm?10/33/10778/abstract/8,81,82\">",
"     8,81,82",
"    </a>",
"    ]. Data has been pooled from 23 studies involving 1831 patients with and without serious ventricular arrhythmias who had various cardiac diseases (coronary heart disease being most common) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/33/10778/abstract/8\">",
"     8",
"    </a>",
"    ]. Although most studies show significantly greater QT dispersion in patients with ventricular arrhythmias, the values overlap widely (",
"    <a class=\"graphic graphic_figure graphicRef75877 \" href=\"UTD.htm?36/59/37822\">",
"     figure 1",
"    </a>",
"    ). Furthermore, patients with adverse outcomes often had QT dispersion values well within both the measurement error and the reported range of values in healthy subjects.",
"   </p>",
"   <p>",
"    Thus, the positive results can be interpreted as indicating an \"indifferent\" QT dispersion [",
"    <a class=\"abstract\" href=\"UTD.htm?10/33/10778/abstract/83\">",
"     83",
"    </a>",
"    ]. This does not signify lack of clinical importance; it does illustrate that increased QT dispersion in these cases merely signifies a general repolarization abnormality which, in the majority of (if not all) patients, is already visible from abnormal T wave morphology",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    increased QT interval. Such QT dispersion does not necessitate a specific therapeutic action and does not help in risk stratification [",
"    <a class=\"abstract\" href=\"UTD.htm?10/33/10778/abstract/83\">",
"     83",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Postmyocardial infarction",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of studies of patients with an acute or remote MI, most of them retrospective, have found that QT dispersion is greater in those with ventricular arrhythmias [",
"    <a class=\"abstract\" href=\"UTD.htm?10/33/10778/abstract/30,84-86\">",
"     30,84-86",
"    </a>",
"    ]. However, this association has not been confirmed in prospective studies, in which QT dispersion was not predictive of ventricular arrhythmias early or late after an MI [",
"    <a class=\"abstract\" href=\"UTD.htm?10/33/10778/abstract/87-91\">",
"     87-91",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a prospective series of 280 post-MI patients, none of 26 ventricular dispersion indices had any predictive value for an adverse outcome during a 32-month follow-up [",
"      <a class=\"abstract\" href=\"UTD.htm?10/33/10778/abstract/87\">",
"       87",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Two additional prospective series of 708 and 700 post-MI patients evaluated the role of QT dispersion for risk stratification in cohorts treated with contemporary therapies including primary reperfusion and beta blockers [",
"      <a class=\"abstract\" href=\"UTD.htm?10/33/10778/abstract/90,91\">",
"       90,91",
"      </a>",
"      ]. Over follow-up periods of 24 to 43 months, QT dispersion was not predictive of sudden or non-sudden cardiac death.",
"     </li>",
"     <li>",
"      In one study on 142 patients with acute MI who underwent successful PTCA, QT dispersion measured before, but not 24 hours after PTCA was an independent predictor of mortality and major adverse cardiac events during a follow-up of 32 &plusmn; 19 months [",
"      <a class=\"abstract\" href=\"UTD.htm?10/33/10778/abstract/92\">",
"       92",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    An important limitation to the measurement of QT dispersion is the absence of objective criteria for determination of the QT interval offset in ECG leads with low amplitude T waves or T waves merged with U waves. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/51/26425?source=see_link\">",
"     \"QT dispersion: Measurement and interpretation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    It has been suggested that spontaneous ventricular premature beats, which have increased T wave amplitude, might provide predictive information. This was evaluated in a series of 148 patients with remote MI; QT dispersion was measured manually in ventricular premature beats and in the last preceding sinus beat [",
"    <a class=\"abstract\" href=\"UTD.htm?10/33/10778/abstract/93\">",
"     93",
"    </a>",
"    ]. The following findings were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      QT dispersion was significantly greater in ventricular premature beats, compared to the preceding sinus beats (83 versus 74 msec, p = 0.001).",
"     </li>",
"     <li>",
"      QT dispersion in both sinus and ventricular premature beats was significantly greater in patients with, compared to those without, major arrhythmic events (sustained ventricular tachycardia, ventricular fibrillation, or sudden death).",
"     </li>",
"     <li>",
"      Only QT dispersion &gt;100 msec, measured in ventricular premature beats, was an independent predictor of arrhythmic events in univariate and multivariate analysis, with a sensitivity, specificity, and positive and negative predictive value of 67, 75, 41, and 90 percent, respectively.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Correlation with electrophysiologic studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are conflicting data as to whether QT dispersion can or cannot be used to predict inducibility of ventricular arrhythmias during electrophysiology study in patients with coronary heart disease and a history of ventricular tachyarrhythmias (",
"    <a class=\"graphic graphic_figure graphicRef68763 \" href=\"UTD.htm?18/36/19022\">",
"     figure 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/33/10778/abstract/94-99\">",
"     94-99",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/1/3097?source=see_link\">",
"     \"Invasive cardiac electrophysiology studies: Tachyarrhythmias\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Heart failure",
"    </span>",
"    &nbsp;&mdash;&nbsp;A significant correlation between QT dispersion and outcome has been suggested in patients with heart failure [",
"    <a class=\"abstract\" href=\"UTD.htm?10/33/10778/abstract/80,100-102\">",
"     80,100-102",
"    </a>",
"    ]. However, this association has not been confirmed in sub-studies of the DIAMOND-CHF study involving",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/2/6183?source=see_link\">",
"     dofetilide",
"    </a>",
"    , the UK-HEART study, and in a prospective series of 2263 patients [",
"    <a class=\"abstract\" href=\"UTD.htm?10/33/10778/abstract/103-105\">",
"     103-105",
"    </a>",
"    ]. In patients with heart failure enrolled in the DIAMOND-CHF study, changes in QT dispersion following treatment with dofetilide did not predict all-cause or cardiac mortality [",
"    <a class=\"abstract\" href=\"UTD.htm?10/33/10778/abstract/106\">",
"     106",
"    </a>",
"    ]. In another study on 179 consecutive patients with idiopathic dilated cardiomyopathy without sustained VT or VF at enrollment, QT dispersion did not show any predictive value for major arrhythmic events (nine patients with sudden cardiac death and 15 with sustained VT or VF) during a mean follow-up of 39 months [",
"    <a class=\"abstract\" href=\"UTD.htm?10/33/10778/abstract/107\">",
"     107",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Left ventricular hypertrophy",
"    </span>",
"    &nbsp;&mdash;&nbsp;As noted above, correction of hypertension with regression of left ventricular hypertrophy is associated with improvement in QT dispersion [",
"    <a class=\"abstract\" href=\"UTD.htm?10/33/10778/abstract/39-43\">",
"     39-43",
"    </a>",
"    ]. However, there is no evidence that increased QT dispersion was an independent predictive value for sudden cardiac death and cardiac mortality in these patients [",
"    <a class=\"abstract\" href=\"UTD.htm?10/33/10778/abstract/108\">",
"     108",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/23/1401?source=see_link\">",
"     \"Left ventricular hypertrophy and arrhythmia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/34/17959?source=see_link\">",
"     \"Clinical implications and treatment of left ventricular hypertrophy in hypertension\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Hypertrophic cardiomyopathy",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are conflicting data as to whether patients with hypertrophic cardiomyopathy with ventricular arrhythmias have a significant increase in QT dispersion compared to those without arrhythmias. Some small studies noted such an association, which was not confirmed in larger series [",
"    <a class=\"abstract\" href=\"UTD.htm?10/33/10778/abstract/33,109-112\">",
"     33,109-112",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/3/22586?source=see_link\">",
"     \"Ventricular arrhythmias and sudden cardiac arrest in hypertrophic cardiomyopathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Long QT syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;As noted above, QT dispersion is increased in patients with long QT syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?10/33/10778/abstract/48-51\">",
"     48-51",
"    </a>",
"    ]. This increase in QT dispersion can be reversed with beta blockers or left cardiac sympathetic blockade in patients with congenital disease [",
"    <a class=\"abstract\" href=\"UTD.htm?10/33/10778/abstract/48\">",
"     48",
"    </a>",
"    ]. In a report on the latter, patients not responding to beta blockers had significantly greater QT dispersion than responders (137 versus 75 msec, p&lt;0.05) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/33/10778/abstract/48\">",
"     48",
"    </a>",
"    ]. However, there are no other data that QT dispersion has prognostic value in these patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     EFFECT OF CARDIAC RESYNCHRONIZATION THERAPY ON QT DISPERSION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cardiac resynchronization therapy (CRT) with biventricular pacing is used to improve symptoms and survival in patients with medically refractory advanced heart failure, nonischemic or ischemic cardiomyopathy, and left ventricular dyssynchrony. The use of CRT is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/56/18314?source=see_link\">",
"     \"Cardiac resynchronization therapy in heart failure: Indications\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a series of 75 patients with advanced heart failure treated with CRT, QT dispersion was measured before and 48 hours after commencement of biventricular pacing [",
"      <a class=\"abstract\" href=\"UTD.htm?10/33/10778/abstract/113\">",
"       113",
"      </a>",
"      ]. Pacing-induced increase in QT dispersion was a strong predictor of major arrhythmic events during an average follow-up of 807 days, independent of NYHA class, left ventricular (LV) ejection fraction, LV end-systolic and end-diastolic volume and QRS duration.",
"     </li>",
"     <li>",
"      In another study on 26 heart failure patients who underwent CRT, those who responded to therapy by &ge;1 NYHA association class improvement three months after CRT (n = 18) had significantly larger QTc dispersion before CRT compared to nonresponders (n = 8). Following CRT, QTc dispersion decreased significantly in responders, but not in nonresponders [",
"      <a class=\"abstract\" href=\"UTD.htm?10/33/10778/abstract/114\">",
"       114",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Conversely, in a study on 70 consecutive heart failure patients (37 with ischemic heart disease) with a history of syncope or sustained ventricular arrhythmias who underwent implantation of a biventricular pacemaker with implantable cardioverter-defibrillator (ICD), QT dispersion measured 30 days after implantation was not significantly different from the pre-procedure values, and was not predictive of appropriate ICD therapy (experienced in 39 percent of the patients during a follow-up of one year) [",
"      <a class=\"abstract\" href=\"UTD.htm?10/33/10778/abstract/115\">",
"       115",
"      </a>",
"      ]. Another study on 100 heart patients who have received CRT-ICD implantation also failed to show decrease in QT dispersion following device implantation both in patients with broad as well as in those narrow QRS complex, as well as any association between QT dispersion and appropriate ICD therapy (experienced in 22 patients) during a 12-month follow-up [",
"      <a class=\"abstract\" href=\"UTD.htm?10/33/10778/abstract/116\">",
"       116",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     EFFECT OF DRUGS ON QT DISPERSION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most frequently used antiarrhythmic drugs for the treatment of cardiac arrhythmias are the class IA and class III agents (",
"    <a class=\"graphic graphic_table graphicRef56600 \" href=\"UTD.htm?2/52/2892\">",
"     table 1",
"    </a>",
"    ), whose antiarrhythmic and potentially proarrhythmic effects are thought to occur via modification of ventricular repolarization. It is becoming increasingly evident that a number of other cardiac and noncardiac drugs may prolong ventricular repolarization and trigger potentially fatal torsades de pointes [",
"    <a class=\"abstract\" href=\"UTD.htm?10/33/10778/abstract/117,118\">",
"     117,118",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/55/23418?source=see_link\">",
"     \"Acquired long QT syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although some of these drugs also effect QT dispersion, hopes that QT dispersion could help predict the appearance of torsades de pointes have been largely unfulfilled [",
"    <a class=\"abstract\" href=\"UTD.htm?10/33/10778/abstract/118,119\">",
"     118,119",
"    </a>",
"    ]. Examples of the impact of antiarrhythmic drugs on QT dispersion include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?0/48/777?source=see_link\">",
"       Quinidine",
"      </a>",
"      increases QT dispersion, which, unlike the corrected QTc interval, seems to have some predictive value for development of torsades de pointes [",
"      <a class=\"abstract\" href=\"UTD.htm?10/33/10778/abstract/120-122\">",
"       120-122",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?36/9/37018?source=see_link\">",
"       \"Major side effects of class I antiarrhythmic drugs\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?21/13/21721?source=see_link\">",
"       Sotalol",
"      </a>",
"      has a variable effect on QT dispersion in patients with ischemic heart disease [",
"      <a class=\"abstract\" href=\"UTD.htm?10/33/10778/abstract/123,124\">",
"       123,124",
"      </a>",
"      ]. However, in one study of 61 patients who received sotalol for ventricular tachycardia",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      ventricular fibrillation, QT dispersion was significantly increased in the 11 patients who developed torsades de pointes compared to those who did not [",
"      <a class=\"abstract\" href=\"UTD.htm?10/33/10778/abstract/125\">",
"       125",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?28/10/28841?source=see_link\">",
"       \"Therapeutic use and major side effects of sotalol\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      In general,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"       amiodarone",
"      </a>",
"      either decreases or produces no change in QT dispersion [",
"      <a class=\"abstract\" href=\"UTD.htm?10/33/10778/abstract/120,121,124,126-128\">",
"       120,121,124,126-128",
"      </a>",
"      ]. In addition, anecdotal reports suggest that amiodarone can be safely administered to patients who have experienced torsades de pointes during therapy with other drugs; this effect is paralleled by a decrease of QT dispersion [",
"      <a class=\"abstract\" href=\"UTD.htm?10/33/10778/abstract/121,129\">",
"       121,129",
"      </a>",
"      ]. However, amiodarone can increase QT dispersion [",
"      <a class=\"abstract\" href=\"UTD.htm?10/33/10778/abstract/130\">",
"       130",
"      </a>",
"      ]. Amiodarone also increased QT dispersion and QTc in a preliminary report from the Canadian Implantable Defibrillator Study of patients with ventricular tachycardia, ventricular fibrillation, or syncope that was deemed to be secondary to arrhythmia; despite this change, amiodarone therapy was associated with low mortality [",
"      <a class=\"abstract\" href=\"UTD.htm?10/33/10778/abstract/131\">",
"       131",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?22/57/23449?source=see_link\">",
"       \"Major side effects of amiodarone\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?25/51/26423?source=see_link\">",
"       Propafenone",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/49/35607?source=see_link\">",
"       disopyramide",
"      </a>",
"      , and almokalant increase QT dispersion [",
"      <a class=\"abstract\" href=\"UTD.htm?10/33/10778/abstract/132-134\">",
"       132-134",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?6/2/6183?source=see_link\">",
"       Dofetilide",
"      </a>",
"      does not appear to increase QT dispersion [",
"      <a class=\"abstract\" href=\"UTD.htm?10/33/10778/abstract/135,136\">",
"       135,136",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Azimilide and magnesium significantly decrease QT and QTc dispersion [",
"      <a class=\"abstract\" href=\"UTD.htm?10/33/10778/abstract/137,138\">",
"       137,138",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Beta blockers appear to reduce QT dispersion in the long QT syndrome, syndrome X (angina pectoris with normal coronary arteries), and heart failure according to some studies [",
"      <a class=\"abstract\" href=\"UTD.htm?10/33/10778/abstract/32,48,139-141\">",
"       32,48,139-141",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Beta blockers do not appear to reduce QT dispersion in hypertrophic cardiomyopathy [",
"      <a class=\"abstract\" href=\"UTD.htm?10/33/10778/abstract/33\">",
"       33",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      One randomized, double-blind, cross-over study on eight patients with heart failure treated with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?25/35/26168?source=see_link\">",
"       losartan",
"      </a>",
"      alone,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?17/22/17767?source=see_link\">",
"       spironolactone",
"      </a>",
"      with an ACE-inhibitor, or losartan with spironolactone demonstrated that all three regimens significantly decreased QT dispersion [",
"      <a class=\"abstract\" href=\"UTD.htm?10/33/10778/abstract/142\">",
"       142",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/37/35417?source=see_link\">",
"       Atorvastatin",
"      </a>",
"      appears to shorten QTc dispersion in patients with heart failure secondary to ischemic heart disease [",
"      <a class=\"abstract\" href=\"UTD.htm?10/33/10778/abstract/143\">",
"       143",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Despite the evident impact of these drugs on QT dispersion, and limited evidence that patients with history of drug-induced torsades de pointes",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    QT prolongation have increased QT dispersion [",
"    <a class=\"abstract\" href=\"UTD.htm?10/33/10778/abstract/144,145\">",
"     144,145",
"    </a>",
"    ], the majority of data do not support the predictive value of QT dispersion for drug-induced torsades de pointes [",
"    <a class=\"abstract\" href=\"UTD.htm?10/33/10778/abstract/119\">",
"     119",
"    </a>",
"    ]. In a report of 27 patients with acquired long QT syndrome, those with history of torsades de pointes (n = 12) had significantly longer QT dispersion compared to those without torsades de pointes (n = 15) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/33/10778/abstract/144\">",
"     144",
"    </a>",
"    ]. Logistic regression analysis, however, found that QT dispersion was not a predictor of torsades de pointes. Some authors recommend abnormally prolonged QT dispersion (&gt;80 ms) to be used as an additional ECG predictor of increased risk of drug-induced torsades de pointes [",
"    <a class=\"abstract\" href=\"UTD.htm?10/33/10778/abstract/146\">",
"     146",
"    </a>",
"    ]. However, in the scientific statement for prevention of torsades de pointes in hospital settings by the American Heart Association and the American College of Cardiology published in 2010, QT dispersion is not even mentioned among the ECG parameters that could be useful for monitoring the risk of torsades de pointes [",
"    <a class=\"abstract\" href=\"UTD.htm?10/33/10778/abstract/147\">",
"     147",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Reasons for the discrepancy between changes in QT dispersion and the development of torsades de pointes are not clear. Experimental studies using arterially perfused ventricular wedge preparations have shown that the risk of drug-induced torsades de pointes is closely related to enhancement of the normally existing transmural dispersion of repolarization rather than to prolongation of ventricular repolarization (ie, the QT interval) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/33/10778/abstract/148-151\">",
"     148-151",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    These studies have shown that the interval from the peak to the end of the T wave (Tpe = Tpeak - Tend) reflects transmural dispersion of repolarization [",
"    <a class=\"abstract\" href=\"UTD.htm?10/33/10778/abstract/152\">",
"     152",
"    </a>",
"    ]. Thus, unlike QT dispersion, the use of the Tpe interval as a surface ECG index of dispersion of ventricular repolarization is supported by credible experimental evidence. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/51/26425?source=see_link&amp;anchor=H12#H12\">",
"     \"QT dispersion: Measurement and interpretation\", section on 'Transmural dispersion and the Tpe interval'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    However, further research on the Tpe interval is necessary to clarify its physiological background, optimal methods of measurement (eg, in which and how many leads, etc) and clinical use. The magnitude of regional and transmural dispersion of repolarization in the beating heart under normal and abnormal conditions as opposed to the wedge preparations (which measure) are also not clear and are subject to an ongoing debate [",
"    <a class=\"abstract\" href=\"UTD.htm?10/33/10778/abstract/153\">",
"     153",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The QT interval duration varies between leads on the standard electrocardiogram (ECG), Frank orthogonal leads, and body surface potential maps. The variation between the longest and shortest QT intervals is reported as QT dispersion. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Reported normal values of QT dispersion vary widely, and there is a great degree of overlap between healthy subjects and cardiac patients, as well as between patients with and without adverse outcomes. The lack of a standardized normal range and the overlap in values between healthy patients and those with cardiac disease has significantly limited the utility of QT dispersion in the clinical setting. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Normal values and limitations of QT dispersion'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Increased QT dispersion has been demonstrated in patients with a variety of cardiac diseases (eg, myocardial infarction, heart failure, long QT syndrome, etc), which is consistent with the concept that QT dispersion represents a general repolarization abnormality. However, given significant variability in QT dispersion within patients with a specific disorder, along with the marked overlap in values with healthy patients, the diagnostic and prognostic utility of QT dispersion for a specific cardiac disorder remains undetermined. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'QT dispersion in cardiac disease'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Only significantly abnormal values of QT dispersion (ie, &gt;100 msec) which are clearly outside the possible measurement error can be recommended for use as markers of generally abnormal repolarization. However, the likelihood of finding such extreme values in ECGs from patients with normal T wave morphology is uncertain, and it is unknown if QT dispersion will offer any additional information to the traditional description of the T wave. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'QT dispersion in cardiac disease'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      New parameters of ventricular repolarization have been developed, such as the Tpe interval, quantitative analysis of T wave morphology, and beat-to-beat QT interval variability. These parameters, which more directly reflect the electrophysiological substrate of ventricular arrhythmias, have better measurement properties, and seem to be better predictors of adverse clinical events than QT dispersion. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Effect of drugs on QT dispersion'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?25/51/26425?source=see_link&amp;anchor=H12#H12\">",
"       \"QT dispersion: Measurement and interpretation\", section on 'Transmural dispersion and the Tpe interval'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/33/10778/abstract/1\">",
"      Wilson FN, Macleod AG, Barker PS, Johnston FD. Determination of the significance of the areas of the ventricular deflections of the electrocardiogram. Am Heart J 1934; 10:46.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/33/10778/abstract/2\">",
"      Rudehill A, Sundqvist K, Sylv&eacute;n C. QT and QT-peak interval measurements. A methodological study in patients with subarachnoid haemorrhage compared to a reference group. Clin Physiol 1986; 6:23.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/33/10778/abstract/3\">",
"      Campbell RW, Gardiner P, Amos PA, et al. Measurement of the QT interval. Eur Heart J 1985; 6 Suppl D:81.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/33/10778/abstract/4\">",
"      Cowan JC, Yusoff K, Moore M, et al. Importance of lead selection in QT interval measurement. Am J Cardiol 1988; 61:83.",
"     </a>",
"    </li>",
"    <li>",
"     Butrous GS, Dabbas N, Patel PR, et al. Measurement of the QT Interval. In: Clinical Aspects of Ventricular Repolarization, Butrous GS, Schwartz PJ (Eds), Farrand Press, London 1989. p.41.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/33/10778/abstract/6\">",
"      Mirvis DM. Spatial variation of QT intervals in normal persons and patients with acute myocardial infarction. J Am Coll Cardiol 1985; 5:625.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/33/10778/abstract/7\">",
"      Day CP, McComb JM, Campbell RW. QT dispersion: an indication of arrhythmia risk in patients with long QT intervals. Br Heart J 1990; 63:342.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/33/10778/abstract/8\">",
"      Malik M, Batchvarov VN. Measurement, interpretation and clinical potential of QT dispersion. J Am Coll Cardiol 2000; 36:1749.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/33/10778/abstract/9\">",
"      Rautaharju PM. QT and dispersion of ventricular repolarization: the greatest fallacy in electrocardiography in the 1990s. Circulation 1999; 99:2477.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/33/10778/abstract/10\">",
"      Surawicz B. Will QT dispersion play a role in clinical decision-making? J Cardiovasc Electrophysiol 1996; 7:777.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/33/10778/abstract/11\">",
"      Kautzner J, Malik M. QT interval dispersion and its clinical utility. Pacing Clin Electrophysiol 1997; 20:2625.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/33/10778/abstract/12\">",
"      Statters DJ, Malik M, Ward DE, Camm AJ. QT dispersion: problems of methodology and clinical significance. J Cardiovasc Electrophysiol 1994; 5:672.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/33/10778/abstract/13\">",
"      Macfarlane PW, McLaughlin SC, Rodger JC. Influence of lead selection and population on automated measurement of QT dispersion. Circulation 1998; 98:2160.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/33/10778/abstract/14\">",
"      Tutar HE, Ocal B, Imamoglu A, Atalay S. Dispersion of QT and QTc interval in healthy children, and effects of sinus arrhythmia on QT dispersion. Heart 1998; 80:77.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/33/10778/abstract/15\">",
"      Challapalli S, Lingamneni R, Horvath G, et al. Twelve-lead QT dispersion is smaller in women than in men. Ann Noninvas Electrocardiol 1998; 3:25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/33/10778/abstract/16\">",
"      Savelieva I, Camm AJ, Malik M. Gender-specific differences on QT dispersion measured in 1100 healthy subjects (abstract). Pacing Clin Electrophysiol 1999; 22:885.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/33/10778/abstract/17\">",
"      Savelieva I, Camm AJ, Malik M. Do we need age-adjustment of QT dispersion? Observations from 1096 normal subjects (abstract). Heart 1999; 81:P47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/33/10778/abstract/18\">",
"      Zaidi M, Robert A, Fesler R, et al. Dispersion of ventricular repolarisation: a marker of ventricular arrhythmias in patients with previous myocardial infarction. Heart 1997; 78:371.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/33/10778/abstract/19\">",
"      Goldner B, Brandspiegel HZ, Horwitz L, et al. Utility of QT dispersion combined with the signal-averaged electrocardiogram in detecting patients susceptible to ventricular tachyarrhythmia. Am J Cardiol 1995; 76:1192.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/33/10778/abstract/20\">",
"      de Bruyne MC, Hoes AW, Kors JA, et al. QTc dispersion predicts cardiac mortality in the elderly: the Rotterdam Study. Circulation 1998; 97:467.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/33/10778/abstract/21\">",
"      Okin PM, Devereux RB, Howard BV, et al. Assessment of QT interval and QT dispersion for prediction of all-cause and cardiovascular mortality in American Indians: The Strong Heart Study. Circulation 2000; 101:61.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/33/10778/abstract/22\">",
"      Macfarlane PW. QT dispersion &mdash; Lack of discriminating power (abstract). Circulation 1998; 98:I81.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/33/10778/abstract/23\">",
"      Ali A, Mehra MR, Malik FS, et al. Insights into ventricular repolarization abnormalities in cardiac allograft vasculopathy. Am J Cardiol 2001; 87:367.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/33/10778/abstract/24\">",
"      Shah CP, Thakur RK, Reisdorff EJ, et al. QT dispersion may be a useful adjunct for detection of myocardial infarction in the chest pain center. Am Heart J 1998; 136:496.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/33/10778/abstract/25\">",
"      Glancy JM, Garratt CJ, de Bono DP. Dynamics of QT dispersion during myocardial infarction and ischaemia. Int J Cardiol 1996; 57:55.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/33/10778/abstract/26\">",
"      Ashikaga T, Nishizaki M, Arita M, et al. Effect of dipyridamole on QT dispersion in vasospastic angina pectoris. Am J Cardiol 1999; 84:807.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/33/10778/abstract/27\">",
"      Sporton SC, Taggart P, Sutton PM, et al. Acute ischaemia: a dynamic influence on QT dispersion. Lancet 1997; 349:306.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/33/10778/abstract/28\">",
"      Sakabe K, Fukuda N, Fukuda Y, et al. QT-interval dispersion in type 2 diabetic and non-diabetic patients with post-myocardial infarction. Nutr Metab Cardiovasc Dis 2008; 18:121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/33/10778/abstract/29\">",
"      Fei L, Goldman JH, Prasad K, et al. QT dispersion and RR variations on 12-lead ECGs in patients with congestive heart failure secondary to idiopathic dilated cardiomyopathy. Eur Heart J 1996; 17:258.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/33/10778/abstract/30\">",
"      Pye M, Quinn AC, Cobbe SM. QT interval dispersion: a non-invasive marker of susceptibility to arrhythmia in patients with sustained ventricular arrhythmias? Br Heart J 1994; 71:511.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/33/10778/abstract/31\">",
"      Zaidi M, Robert A, Fesler R, et al. Dispersion of ventricular repolarization in dilated cardiomyopathy. Eur Heart J 1997; 18:1129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/33/10778/abstract/32\">",
"      Bonnar CE, Davie AP, Caruana L, et al. QT dispersion in patients with chronic heart failure: beta blockers are associated with a reduction in QT dispersion. Heart 1999; 81:297.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/33/10778/abstract/33\">",
"      Yi G, Elliott P, McKenna WJ, et al. QT dispersion and risk factors for sudden cardiac death in patients with hypertrophic cardiomyopathy. Am J Cardiol 1998; 82:1514.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/33/10778/abstract/34\">",
"      Calo L, Sciarra L, Sabina F, et al. QT dispersion and late potentials in hypertrophic cardiomyopathy (abstract). J Am Coll Cardiol 1996; 27:59A.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/33/10778/abstract/35\">",
"      Dritsas A, Sbarouni E, Gilligan D, et al. QT-interval abnormalities in hypertrophic cardiomyopathy. Clin Cardiol 1992; 15:739.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/33/10778/abstract/36\">",
"      Zaidi M, Robert A, Fesler R, et al. Dispersion of ventricular repolarization in hypertrophic cardiomyopathy. J Electrocardiol 1996; 29 Suppl:89.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/33/10778/abstract/37\">",
"      Ichkhan K, Molnar J, Somberg J. Relation of left ventricular mass and QT dispersion in patients with systematic hypertension. Am J Cardiol 1997; 79:508.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/33/10778/abstract/38\">",
"      Perki&ouml;m&auml;ki JS, Ik&auml;heimo MJ, Pikkuj&auml;ms&auml; SM, et al. Dispersion of the QT interval and autonomic modulation of heart rate in hypertensive men with and without left ventricular hypertrophy. Hypertension 1996; 28:16.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/33/10778/abstract/39\">",
"      Mayet J, Shahi M, McGrath K, et al. Left ventricular hypertrophy and QT dispersion in hypertension. Hypertension 1996; 28:791.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/33/10778/abstract/40\">",
"      Lim PO, Nys M, Naas AA, et al. Irbesartan reduces QT dispersion in hypertensive individuals. Hypertension 1999; 33:713.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/33/10778/abstract/41\">",
"      Karpanou EA, Vyssoulis GP, Psichogios A, et al. Regression of left ventricular hypertrophy results in improvement of QT dispersion in patients with hypertension. Am Heart J 1998; 136:765.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/33/10778/abstract/42\">",
"      Gonz&aacute;lez-Juanatey JR, Garc&iacute;a-Acu&ntilde;a JM, Pose A, et al. Reduction of QT and QTc dispersion during long-term treatment of systemic hypertension with enalapril. Am J Cardiol 1998; 81:170.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/33/10778/abstract/43\">",
"      Tomiyama H, Doba N, Fu Y, et al. Left ventricular geometric patterns and QT dispersion in borderline and mild hypertension: their evolution and regression. Am J Hypertens 1998; 11:286.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/33/10778/abstract/44\">",
"      Muir DF, Love MW, MacGregor GD, et al. Athletic left ventricular hypertrophy is associated with increased QT dispersion: An observational study (abstract). J Am Coll Cardiol 1999; 33:510A.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/33/10778/abstract/45\">",
"      Stolt A, Karila T, Viitasalo M, et al. QT interval and QT dispersion in endurance athletes and in power athletes using large doses of anabolic steroids. Am J Cardiol 1999; 84:364.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/33/10778/abstract/46\">",
"      Halle M, Huonker M, Hohnloser SH, et al. QT dispersion in exercise-induced myocardial hypertrophy. Am Heart J 1999; 138:309.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/33/10778/abstract/47\">",
"      Mayet J, Kanagaratnam P, Shahi M, et al. QT dispersion in athletic left ventricular hypertrophy. Am Heart J 1999; 137:678.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/33/10778/abstract/48\">",
"      Priori SG, Napolitano C, Diehl L, Schwartz PJ. Dispersion of the QT interval. A marker of therapeutic efficacy in the idiopathic long QT syndrome. Circulation 1994; 89:1681.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/33/10778/abstract/49\">",
"      Gavrilescu S, Luca C. Right ventricular monophasic action potentials in patients with long QT syndrome. Br Heart J 1978; 40:1014.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/33/10778/abstract/50\">",
"      Bonatti V, Rolli A, Botti G. Recording of monophasic action potentials of the right ventricle in long QT syndromes complicated by severe ventricular arrhythmias. Eur Heart J 1983; 4:168.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/33/10778/abstract/51\">",
"      Zareba W, Moss AJ, Konecki J. TU wave area-derived measures of repolarization dispersion in the long QT syndrome. J Electrocardiol 1998; 30 Suppl:191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/33/10778/abstract/52\">",
"      Yap, YG, Yi, G, Guo, XH, et al. Dynamic changes of QT dispersion and Its relationship with clinical variables and arrhythmic events after myocardial infarction (abstract). J Am Coll Cardiol 1999; 33:107A.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/33/10778/abstract/53\">",
"      Paventi S, Bevilacqua U, Parafati MA, et al. QT dispersion and early arrhythmic risk during acute myocardial infarction. Angiology 1999; 50:209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/33/10778/abstract/54\">",
"      Bennemeier H, Hartmann F, Giannitsis E, et al. Effects of primary angioplasty on the course of QT dispersion after myocardial infarction and its association with infarct size (abstract). Pacing Clin Electrophysiol 1999; 22:A19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/33/10778/abstract/55\">",
"      Puljevic D, Smalcelj A, Durakovic Z, Goldner V. Effects of postmyocardial infarction scar size, cardiac function, and severity of coronary artery disease on QT interval dispersion as a risk factor for complex ventricular arrhythmia. Pacing Clin Electrophysiol 1998; 21:1508.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/33/10778/abstract/56\">",
"      Kluger J, Hathaway L, Giedrimiene D. Does left ventricular function influence QT dispersion in patients with previous myocardial infarction and ventricular tachyarrhythmias? (abstract). J Am Coll Cardiol 1997; 29:510A.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/33/10778/abstract/57\">",
"      Schneider CA, Voth E, Baer FM, et al. QT dispersion is determined by the extent of viable myocardium in patients with chronic Q-wave myocardial infarction. Circulation 1997; 96:3913.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/33/10778/abstract/58\">",
"      Lyras TG, Papapanagiotou VA, Foukarakis MG, et al. Evaluation of serial QT dispersion in patients with first non-Q-wave myocardial infarction: relation to the severity of underlying coronary artery disease. Clin Cardiol 2003; 26:189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/33/10778/abstract/59\">",
"      Clarkson PB, Naas AA, McMahon A, et al. QT dispersion in essential hypertension. QJM 1995; 88:327.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/33/10778/abstract/60\">",
"      Kohno I, Takusagawa M, Yin D, et al. QT dispersion in dipper- and nondipper-type hypertension. Am J Hypertens 1998; 11:280.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/33/10778/abstract/61\">",
"      Bura Z, Koylan N, Vural A, et al. Left ventricular geometric patterns and QT dispersion in untreated essential hypertension. Am J Hypertens 1998; 11:1164.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/33/10778/abstract/62\">",
"      Higham PD, Furniss SS, Campbell RW. QT dispersion and components of the QT interval in ischaemia and infarction. Br Heart J 1995; 73:32.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/33/10778/abstract/63\">",
"      Hansen S, Rasmussen V, Torp-Pedersen C, Jensen GB. QT intervals and QT dispersion determined from a 12-lead 24-hour Holter recording in patients with coronary artery disease and patients with heart failure. Ann Noninvasive Electrocardiol 2008; 13:22.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/33/10778/abstract/64\">",
"      Gunes Y, Tuncer M, Guntekin U, et al. Lack of diurnal variation of P-wave and QT dispersions in patients with heart failure. Pacing Clin Electrophysiol 2008; 31:974.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/33/10778/abstract/65\">",
"      Aytemir K, Bavafa V, Ozer N, et al. Effect of balloon inflation-induced acute ischemia on QT dispersion during percutaneous transluminal coronary angioplasty. Clin Cardiol 1999; 22:21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/33/10778/abstract/66\">",
"      Okishige K, Yamashita K, Yoshinaga H, et al. Electrophysiologic effects of ischemic preconditioning on QT dispersion during coronary angioplasty. J Am Coll Cardiol 1996; 28:70.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/33/10778/abstract/67\">",
"      Tarabey R, Sukenik D, Molnar J, Somberg JC. Effect of intracoronary balloon inflation at percutaneous transluminal coronary angioplasty on QT dispersion. Am Heart J 1998; 135:519.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/33/10778/abstract/68\">",
"      Yi G, Crook R, Guo XH, et al. Exercise-induced changes in the QT interval duration and dispersion in patients with sudden cardiac death after myocardial infarction. Int J Cardiol 1998; 63:271.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/33/10778/abstract/69\">",
"      Michelucci A, Padeletti L, Frati M, et al. Effects of ischemia and reperfusion on QT dispersion during coronary angioplasty. Pacing Clin Electrophysiol 1996; 19:1905.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/33/10778/abstract/70\">",
"      Koide Y, Yotsukura M, Yoshino H, Ishikawa K. Usefulness of QT dispersion immediately after exercise as an indicator of coronary stenosis independent of gender or exercise-induced ST-segment depression. Am J Cardiol 2000; 86:1312.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/33/10778/abstract/71\">",
"      Gabrielli F, Balzotti L, Bandiera A. QT dispersion variability and myocardial viability in acute myocardial infarction. Int J Cardiol 1997; 61:61.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/33/10778/abstract/72\">",
"      Moreno V, Mar&iacute;n F, Monmeneu JV, de la Morena G. QT-interval dispersion and myocardial viability. Rev Esp Cardiol 2009; 62:461.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/33/10778/abstract/73\">",
"      Galetta F, Franzoni F, Fallahi P, et al. Effect of telmisartan on QT interval variability and autonomic control in hypertensive patients with left ventricular hypertrophy. Biomed Pharmacother 2010; 64:516.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/33/10778/abstract/74\">",
"      Moreno FL, Villanueva T, Karagounis LA, Anderson JL. Reduction in QT interval dispersion by successful thrombolytic therapy in acute myocardial infarction. TEAM-2 Study Investigators. Circulation 1994; 90:94.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/33/10778/abstract/75\">",
"      Karagounis LA, Anderson JL, Moreno FL, Sorensen SG. Multivariate associates of QT dispersion in patients with acute myocardial infarction: primacy of patency status of the infarct-related artery. TEAM-3 Investigators. Third trial of Thrombolysis with Eminase in Acute Myocardial Infarction. Am Heart J 1998; 135:1027.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/33/10778/abstract/76\">",
"      Kelly RF, Parillo JE, Hollenberg SM. Effect of coronary angioplasty on QT dispersion. Am Heart J 1997; 134:399.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/33/10778/abstract/77\">",
"      Szydlo K, Trusz-Gluza M, Drzewiecki J, et al. Correlation of heart rate variability parameters and QT interval in patients after PTCA of infarct related coronary artery as an indicator of improved autonomic regulation. Pacing Clin Electrophysiol 1998; 21:2407.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/33/10778/abstract/78\">",
"      Bonnemeier H, Hartmann F, Wiegand UK, et al. Course and prognostic implications of QT interval and QT interval variability after primary coronary angioplasty in acute myocardial infarction. J Am Coll Cardiol 2001; 37:44.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/33/10778/abstract/79\">",
"      Jim&eacute;nez-Candil J, Hern&aacute;ndez Hern&aacute;ndez J, Aguero VL, et al. Early reduction of QT dispersion after primary percutaneous intervention in ST-segment elevation acute myocardial infarction. Mechanisms and clinical implications. Cardiology 2009; 113:172.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/33/10778/abstract/80\">",
"      Brooksby P, Robinson PJ, Segal R, et al. Effects of losartan and captopril on QT dispersion in elderly patients with heart failure. ELITE study group. Lancet 1999; 354:395.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/33/10778/abstract/81\">",
"      Wang CH, Chen CL, Hsiao CK, et al. Arsenic-induced QT dispersion is associated with atherosclerotic diseases and predicts long-term cardiovascular mortality in subjects with previous exposure to arsenic: A 17-Year follow-up study. Cardiovasc Toxicol 2010; 10:17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/33/10778/abstract/82\">",
"      Tamaki S, Yamada T, Okuyama Y, et al. Cardiac iodine-123 metaiodobenzylguanidine imaging predicts sudden cardiac death independently of left ventricular ejection fraction in patients with chronic heart failure and left ventricular systolic dysfunction: results from a comparative study with signal-averaged electrocardiogram, heart rate variability, and QT dispersion. J Am Coll Cardiol 2009; 53:426.",
"     </a>",
"    </li>",
"    <li>",
"     Surawicz B. Long QT: Good, bad, indifferent and fascinating. ACC Current J Rev 1999; pp. 19-21.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/33/10778/abstract/84\">",
"      Zaputovi L, Mavri Z, Zaninovi-Jurjevi T, et al. Relationship between QT dispersion and the incidence of early ventricular arrhythmias in patients with acute myocardial infarction. Int J Cardiol 1997; 62:211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/33/10778/abstract/85\">",
"      Zareba W, Moss AJ, le Cessie S. Dispersion of ventricular repolarization and arrhythmic cardiac death in coronary artery disease. Am J Cardiol 1994; 74:550.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/33/10778/abstract/86\">",
"      Wahab A, Zaheer MS, Rabbani MU, Wahab S. A study of heart rate variability and QT dispersion in patients of acute ST elevation myocardial infarction. Indian Heart J 2009; 61:261.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/33/10778/abstract/87\">",
"      Zabel M, Klingenheben T, Franz MR, Hohnloser SH. Assessment of QT dispersion for prediction of mortality or arrhythmic events after myocardial infarction: results of a prospective, long-term follow-up study. Circulation 1998; 97:2543.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/33/10778/abstract/88\">",
"      Tavernier R, Jordaens L. Repolarisation characteristics and sudden death after myocardial infarction: A case control study (abstract). J Am Coll Cardiol 1999; 33:146A.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/33/10778/abstract/89\">",
"      Aitchison JD, Campbell RW, Higham PD. Time dependent variability of QT dispersion after acute myocardial infarction and its relation to ventricular fibrillation: a prospective study. Heart 2000; 84:504.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/33/10778/abstract/90\">",
"      Jordaens L, Tavernier R, MIRRACLE Investigators. Determinants of sudden death after discharge from hospital for myocardial infarction in the thrombolytic era. Eur Heart J 2001; 22:1214.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/33/10778/abstract/91\">",
"      Huikuri HV, Tapanainen JM, Lindgren K, et al. Prediction of sudden cardiac death after myocardial infarction in the beta-blocking era. J Am Coll Cardiol 2003; 42:652.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/33/10778/abstract/92\">",
"      Ueda H, Hayashi T, Tsumura K, et al. QT dispersion and prognosis after coronary stent placement in acute myocardial infarction. Clin Cardiol 2007; 30:229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/33/10778/abstract/93\">",
"      Dabrowski A, Kramarz E, Piotrowicz R, Kubik L. Predictive power of increased QT dispersion in ventricular extrasystoles and in sinus beats for risk stratification after myocardial infarction. Circulation 2000; 101:1693.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/33/10778/abstract/94\">",
"      Bogun F, Chan KK, Harvey M, et al. QT dispersion in nonsustained ventricular tachycardia and coronary artery disease. Am J Cardiol 1996; 77:256.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/33/10778/abstract/95\">",
"      Lee KW, Okin PM, Kligfield P, et al. Precordial QT dispersion and inducible ventricular tachycardia. Am Heart J 1997; 134:1005.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/33/10778/abstract/96\">",
"      Gillis AM, Traboulsi M, Hii JT, et al. Antiarrhythmic drug effects on QT interval dispersion in patients undergoing electropharmacologic testing for ventricular tachycardia and fibrillation. Am J Cardiol 1998; 81:588.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/33/10778/abstract/97\">",
"      Armoundas AA, Osaka M, Mela T, et al. T-wave alternans and dispersion of the QT interval as risk stratification markers in patients susceptible to sustained ventricular arrhythmias. Am J Cardiol 1998; 82:1127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/33/10778/abstract/98\">",
"      Zabel M, Klingenheben T, Sticherling C, et al. QT-dispersion does not predict inducibility or adequate device treatment in patients with malignant ventricular tachyarrhythmias (abstract). Eur Heart J 1998; 19:600.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/33/10778/abstract/99\">",
"      De Sutter J, Tavernier R, Van De Wiele C, et al. QT dispersion is not related to infarct size or inducibility in patients with coronary artery disease and life threatening ventricular arrhythmias. Heart 1999; 81:533.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/33/10778/abstract/100\">",
"      Fu GS, Meissner A, Simon R. Repolarization dispersion and sudden cardiac death in patients with impaired left ventricular function. Eur Heart J 1997; 18:281.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/33/10778/abstract/101\">",
"      Galinier M, Vialette JC, Fourcade J, et al. QT interval dispersion as a predictor of arrhythmic events in congestive heart failure. Importance of aetiology. Eur Heart J 1998; 19:1054.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/33/10778/abstract/102\">",
"      Anastasiou-Nana MI, Nanas JN, Karagounis LA, et al. Dispersion od QRS and QT in patients with advanced congestive heart failure: relation to cardiac and sudden cardiac death mortality (abstract). Eur Heart J 1999; 20:117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/33/10778/abstract/103\">",
"      Brendorp B, Elming H, Jun L, et al. Qt dispersion has no prognostic information for patients with advanced congestive heart failure and reduced left ventricular systolic function. Circulation 2001; 103:831.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/33/10778/abstract/104\">",
"      Brooksby P, Batin PD, Nolan J, et al. The relationship between QT intervals and mortality in ambulant patients with chronic heart failure. The united kingdom heart failure evaluation and assessment of risk trial (UK-HEART). Eur Heart J 1999; 20:1335.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/33/10778/abstract/105\">",
"      Radmanabhan S, Amin J, Silvet H, Pai RG. QT dispersion has no impact on mortality in patients with moderate and severe left ventricular dysfunction: Results from a cohort of 2263 patients (abstract). J Am Coll Cardiol 1999; 33:107A.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/33/10778/abstract/106\">",
"      Brendorp B, Elming H, Jun L, et al. Effect of dofetilide on QT dispersion and the prognostic implications of changes in QT dispersion for patients with congestive heart failure. Eur J Heart Fail 2002; 4:201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/33/10778/abstract/107\">",
"      Iacoviello M, Forleo C, Guida P, et al. Ventricular repolarization dynamicity provides independent prognostic information toward major arrhythmic events in patients with idiopathic dilated cardiomyopathy. J Am Coll Cardiol 2007; 50:225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/33/10778/abstract/108\">",
"      Galinier M, Balanescu S, Fourcade J, et al. Prognostic value of arrhythmogenic markers in systemic hypertension. Eur Heart J 1997; 18:1484.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/33/10778/abstract/109\">",
"      Buja G, Miorelli M, Turrini P, et al. Comparison of QT dispersion in hypertrophic cardiomyopathy between patients with and without ventricular arrhythmias and sudden death. Am J Cardiol 1993; 72:973.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/33/10778/abstract/110\">",
"      Miorelli M, Buja G, Melacini P, et al. QT-interval variability in hypertrophic cardiomyopathy patients with cardiac arrest. Int J Cardiol 1994; 45:121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/33/10778/abstract/111\">",
"      Bayrak F, Kahveci G, Mutlu B, et al. Usefulness of surface electrocardiogram in predicting the clinical course of patients with hypertrophic cardiomyopathy. Anadolu Kardiyol Derg 2007; 7 Suppl 1:178.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/33/10778/abstract/112\">",
"      Maron BJ, Leyhe MJ 3rd, Casey SA, et al. Assessment of QT dispersion as a prognostic marker for sudden death in a regional nonreferred hypertrophic cardiomyopathy cohort. Am J Cardiol 2001; 87:114.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/33/10778/abstract/113\">",
"      Chalil S, Yousef ZR, Muyhaldeen SA, et al. Pacing-induced increase in QT dispersion predicts sudden cardiac death following cardiac resynchronization therapy. J Am Coll Cardiol 2006; 47:2486.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/33/10778/abstract/114\">",
"      Hina K, Kawamura H, Murakami T, et al. Association of corrected QT dispersion with symptoms improvement in patients receiving cardiac resynchronization therapy. Heart Vessels 2008; 23:325.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/33/10778/abstract/115\">",
"      Dilaveris P, Giannopoulos G, Synetos A, et al. Effect of biventricular pacing on ventricular repolarization and functional indices in patients with heart failure: lack of association with arrhythmic events. Europace 2009; 11:741.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/33/10778/abstract/116\">",
"      Lellouche N, De Diego C, Akopyan G, et al. Changes and predictive value of dispersion of repolarization parameters for appropriate therapy in patients with biventricular implantable cardioverter-defibrillators. Heart Rhythm 2007; 4:1274.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/33/10778/abstract/117\">",
"      Haverkamp W, Breithardt G, Camm AJ, et al. The potential for QT prolongation and proarrhythmia by non-antiarrhythmic drugs: clinical and regulatory implications. Report on a policy conference of the European Society of Cardiology. Eur Heart J 2000; 21:1216.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/33/10778/abstract/118\">",
"      Moss AJ. Drugs that prolong the QT interval: Regulatory and QT measurement issues from the United States and European perspectives. Ann Noninvas Electrocardiol 1999; 4:255.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/33/10778/abstract/119\">",
"      Shah RR. Drug-induced QT dispersion: does it predict the risk of torsade de pointes? J Electrocardiol 2005; 38:10.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/33/10778/abstract/120\">",
"      Cui G, Sager PT, Singh BN, Sen L. Different Effects of Amiodarone and Quinidine on the Homogeneity of Myocardial Refractoriness in Patients With Intraventricular Conduction Delay. J Cardiovasc Pharmacol Ther 1998; 3:201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/33/10778/abstract/121\">",
"      Hii JT, Wyse DG, Gillis AM, et al. Precordial QT interval dispersion as a marker of torsade de pointes. Disparate effects of class Ia antiarrhythmic drugs and amiodarone. Circulation 1992; 86:1376.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/33/10778/abstract/122\">",
"      Hohnloser SH, van de Loo A, Baedeker F. Efficacy and proarrhythmic hazards of pharmacologic cardioversion of atrial fibrillation: prospective comparison of sotalol versus quinidine. J Am Coll Cardiol 1995; 26:852.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/33/10778/abstract/123\">",
"      Day CP, McComb JM, Matthews J, Campbell RW. Reduction in QT dispersion by sotalol following myocardial infarction. Eur Heart J 1991; 12:423.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/33/10778/abstract/124\">",
"      Cui G, Sen L, Sager P, et al. Effects of amiodarone, sematilide, and sotalol on QT dispersion. Am J Cardiol 1994; 74:896.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/33/10778/abstract/125\">",
"      Hohnloser SH, van de Loo A, Kalusche D, et al. Does sotalol-induced alteration of QT-dispersion predict drug effectiveness or proarrhythmic hazards? (abstract). Circulation 1993; 88:397.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/33/10778/abstract/126\">",
"      Dritsas A, Gilligan D, Nihoyannopoulos P, Oakley CM. Amiodarone reduces QT dispersion in patients with hypertrophic cardiomyopathy. Int J Cardiol 1992; 36:345.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/33/10778/abstract/127\">",
"      Meierhenrich R, Helguera ME, Kidwell GA, Tebbe U. Influence of amiodarone on QT dispersion in patients with life-threatening ventricular arrhythmias and clinical outcome. Int J Cardiol 1997; 60:289.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/33/10778/abstract/128\">",
"      Grimm W, Steder U, Menz V, et al. Effect of amiodarone on QT dispersion in the 12-lead standard electrocardiogram and its significance for subsequent arrhythmic events. Clin Cardiol 1997; 20:107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/33/10778/abstract/129\">",
"      van de Loo A, Klingenheben T, Hohnloser SH. [Amiodarone therapy after sotalol-induced torsade de pointes: prolonged QT interval and QT dispersion in differentiation of pro-arrhythmic effects]. Z Kardiol 1994; 83:887.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/33/10778/abstract/130\">",
"      Tran HT, Chow MS, Kluger J. Amiodarone induced torsades de pointes with excessive QT dispersion following quinidine induced polymorphic ventricular tachycardia. Pacing Clin Electrophysiol 1997; 20:2275.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/33/10778/abstract/131\">",
"      Yadav A, Paquette M, Newman D, et al. Amiodarone is associated with increased QT dispersion but low mortality in a CIDS cohort (abstract). Pacing Clin Electrophysiol 1999; 22:896.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/33/10778/abstract/132\">",
"      Faber TS, Zehender M, Krahnefeld O, et al. Propafenone during acute myocardial ischemia in patients: a double-blind, randomized, placebo-controlled study. J Am Coll Cardiol 1997; 29:561.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/33/10778/abstract/133\">",
"      Trusz-Gluza M, Swiderska E, Smieja-Jaroczynska B, et al. Factors influencing dispersion of repolarisation under antiarrhythmic treatment (abstract). Ann Noninvas Electrocardiol 1998; 3:S18.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/33/10778/abstract/134\">",
"      Houltz B, Darp&ouml; B, Edvardsson N, et al. Electrocardiographic and clinical predictors of torsades de pointes induced by almokalant infusion in patients with chronic atrial fibrillation or flutter: a prospective study. Pacing Clin Electrophysiol 1998; 21:1044.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/33/10778/abstract/135\">",
"      Sedgwick ML, Rasmussen HS, Cobbe SM. Effects of the class III antiarrhythmic drug dofetilide on ventricular monophasic action potential duration and QT interval dispersion in stable angina pectoris. Am J Cardiol 1992; 70:1432.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/33/10778/abstract/136\">",
"      D&eacute;molis JL, Funck-Brentano C, Ropers J, et al. Influence of dofetilide on QT-interval duration and dispersion at various heart rates during exercise in humans. Circulation 1996; 94:1592.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/33/10778/abstract/137\">",
"      Brum J, Alkhalidi H, Karam R, Marcello S. Effects of azimilide, an IKs/IKr blocking anti-arrhythmic on QT and QTc dispersion, in patients with ventricular tachycardia (VT) (abstract). Pacing Clin Electrophysiol 1999; 22:A13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/33/10778/abstract/138\">",
"      Parikka H, Toivonen L, Naukkarinen V, et al. Decreases by magnesium of QT dispersion and ventricular arrhythmias in patients with acute myocardial infarction. Eur Heart J 1999; 20:111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/33/10778/abstract/139\">",
"      Leonardo F, Fragasso G, Rosano GM, et al. Effect of atenolol on QT interval and dispersion in patients with syndrome X. Am J Cardiol 1997; 80:789.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/33/10778/abstract/140\">",
"      Aygul N, Ozdemir K, Duzenli MA, Aygul MU. The comparative effects of long-term carvedilol versus bisoprolol therapy on QT dispersion in patients with chronic heart failure. Cardiology 2009; 112:168.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/33/10778/abstract/141\">",
"      Mir TS, L&auml;er S, Eiselt M, et al. Effect of Carvedilol on QT Duration in Paediatric Patients with Congestive Heart Failure. Clin Drug Investig 2004; 24:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/33/10778/abstract/142\">",
"      Shehab A, Elnour AA, Struthers AD. A randomised, controlled, double-blind, cross-over pilot study assessing the effects of spironolactone, losartan and their combination on heart rate variability and QT dispersion in patients with chronic heart failure. Cardiovasc J Afr 2008; 19:292.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/33/10778/abstract/143\">",
"      Xie RQ, Cui W, Liu F, et al. Statin therapy shortens QTc, QTcd, and improves cardiac function in patients with chronic heart failure. Int J Cardiol 2010; 140:255.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/33/10778/abstract/144\">",
"      Yamaguchi M, Shimizu M, Ino H, et al. T wave peak-to-end interval and QT dispersion in acquired long QT syndrome: a new index for arrhythmogenicity. Clin Sci (Lond) 2003; 105:671.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/33/10778/abstract/145\">",
"      Chevalier P, Rodriguez C, Bontemps L, et al. Non-invasive testing of acquired long QT syndrome: evidence for multiple arrhythmogenic substrates. Cardiovasc Res 2001; 50:386.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/33/10778/abstract/146\">",
"      Cubeddu LX. Iatrogenic QT Abnormalities and Fatal Arrhythmias: Mechanisms and Clinical Significance. Curr Cardiol Rev 2009; 5:166.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/33/10778/abstract/147\">",
"      Drew BJ, Ackerman MJ, Funk M, et al. Prevention of torsade de pointes in hospital settings: a scientific statement from the American Heart Association and the American College of Cardiology Foundation. J Am Coll Cardiol 2010; 55:934.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/33/10778/abstract/148\">",
"      Yan GX, Wu Y, Liu T, et al. Phase 2 early afterdepolarization as a trigger of polymorphic ventricular tachycardia in acquired long-QT syndrome : direct evidence from intracellular recordings in the intact left ventricular wall. Circulation 2001; 103:2851.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/33/10778/abstract/149\">",
"      Di Diego JM, Belardinelli L, Antzelevitch C. Cisapride-induced transmural dispersion of repolarization and torsade de pointes in the canine left ventricular wedge preparation during epicardial stimulation. Circulation 2003; 108:1027.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/33/10778/abstract/150\">",
"      Liu T, Brown BS, Wu Y, et al. Blinded validation of the isolated arterially perfused rabbit ventricular wedge in preclinical assessment of drug-induced proarrhythmias. Heart Rhythm 2006; 3:948.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/33/10778/abstract/151\">",
"      Fenichel RR, Malik M, Antzelevitch C, et al. Drug-induced torsades de pointes and implications for drug development. J Cardiovasc Electrophysiol 2004; 15:475.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/33/10778/abstract/152\">",
"      Yan GX, Lankipalli RS, Burke JF, et al. Ventricular repolarization components on the electrocardiogram: cellular basis and clinical significance. J Am Coll Cardiol 2003; 42:401.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/33/10778/abstract/153\">",
"      Taggart P, Sutton PM, Opthof T, et al. Transmural repolarisation in the left ventricle in humans during normoxia and ischaemia. Cardiovasc Res 2001; 50:454.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1027 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1003-190.81.197.98-C50D28AF5E-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_33_10778=[""].join("\n");
var outline_f10_33_10778=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H19\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      NORMAL VALUES AND LIMITATIONS OF QT DISPERSION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      PROGNOSTIC VALUE OF QT DISPERSION IN NORMAL SUBJECTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      QT DISPERSION IN CARDIAC DISEASE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Correlation with the extent or severity of disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Improvement with therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Prognostic significance",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Postmyocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Correlation with electrophysiologic studies",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Heart failure",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Left ventricular hypertrophy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Hypertrophic cardiomyopathy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Long QT syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      EFFECT OF CARDIAC RESYNCHRONIZATION THERAPY ON QT DISPERSION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      EFFECT OF DRUGS ON QT DISPERSION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"CARD/1027\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/1027|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?36/59/37822\" title=\"figure 1\">",
"      QT dispersion patient groups",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?18/36/19022\" title=\"figure 2\">",
"      QT dispersion VT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?2/26/2478\" title=\"figure 3\">",
"      QT dispersion mortality normals",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/1027|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?2/52/2892\" title=\"table 1\">",
"      Vaughan Williams classification of antiarrhythmic drugs",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/55/23418?source=related_link\">",
"      Acquired long QT syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/56/18314?source=related_link\">",
"      Cardiac resynchronization therapy in heart failure: Indications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/9/2202?source=related_link\">",
"      Clinical features of congenital long QT syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/34/17959?source=related_link\">",
"      Clinical implications and treatment of left ventricular hypertrophy in hypertension",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/5/4184?source=related_link\">",
"      Electrocardiographic abnormalities and conduction disturbances in athletes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/1/3097?source=related_link\">",
"      Invasive cardiac electrophysiology studies: Tachyarrhythmias",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/23/1401?source=related_link\">",
"      Left ventricular hypertrophy and arrhythmia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/57/23449?source=related_link\">",
"      Major side effects of amiodarone",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/9/37018?source=related_link\">",
"      Major side effects of class I antiarrhythmic drugs",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/9/18585?source=related_link\">",
"      Natural history and diagnosis of cardiac allograft vasculopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/51/26425?source=related_link\">",
"      QT dispersion: Measurement and interpretation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/10/28841?source=related_link\">",
"      Therapeutic use and major side effects of sotalol",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/3/22586?source=related_link\">",
"      Ventricular arrhythmias and sudden cardiac arrest in hypertrophic cardiomyopathy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f10_33_10779="ACC AHA skills internal CV II";
var content_f10_33_10779=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F65048&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F65048&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Technical skills necessary to perform internal DC cardioversion",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        Competency in performing diagnostic cardiac electrophysiology studies",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ability to place electrode catheters in appropriate locations for intracardiac synchronization and DC cardioversion",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Familiarity with the catheter characteristics, synchronization, and DC cardioversion equipment",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ability to confirm the timing and energy of the shock for safe shock delivery",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Adequate electrocardiographic and rhythm monitoring equipment",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ability to handle complications, including the use of temporary pacing and defibrillation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Proficiency in the appropriate use of sedation during procedures, including airway management",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from Tracy, CM, Akhtar, M, DiMarco, JP, et al. Circulation 2000; 102:2309.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_33_10779=[""].join("\n");
var outline_f10_33_10779=null;
var title_f10_33_10780="T cell depletion prevent GVHD";
var content_f10_33_10780=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F73755&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F73755&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Trials of T cell depletion for the prevention of acute graft-versus-host disease",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        N",
"       </td>",
"       <td class=\"subtitle1\">",
"        Antibody",
"       </td>",
"       <td class=\"subtitle1\">",
"        Other prophylaxis",
"       </td>",
"       <td class=\"subtitle1\">",
"        GVHD, percent",
"       </td>",
"       <td class=\"subtitle1\">",
"        Relapse, percent",
"       </td>",
"       <td class=\"subtitle1\">",
"        Graft failure, percent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        20",
"       </td>",
"       <td>",
"        8 monoclonals",
"       </td>",
"       <td>",
"        Cyclosporine/ methotrexate",
"       </td>",
"       <td>",
"        15",
"       </td>",
"       <td>",
"        35",
"       </td>",
"       <td>",
"        15",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        20",
"       </td>",
"       <td>",
"        Anti CD2",
"       </td>",
"       <td>",
"        Cyclosporine",
"       </td>",
"       <td>",
"        15",
"       </td>",
"       <td>",
"        25",
"       </td>",
"       <td>",
"        60",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        58",
"       </td>",
"       <td>",
"        Anti CD2,5,7 or anti CD4,5,8",
"       </td>",
"       <td>",
"        None",
"       </td>",
"       <td>",
"        5",
"       </td>",
"       <td>",
"        24",
"       </td>",
"       <td>",
"        19",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        36",
"       </td>",
"       <td>",
"        Anti CD8",
"       </td>",
"       <td>",
"        Cyclosporine",
"       </td>",
"       <td>",
"        28",
"       </td>",
"       <td>",
"        8",
"       </td>",
"       <td>",
"        11",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        282",
"       </td>",
"       <td>",
"        Campath-1",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        12",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        15",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        112",
"       </td>",
"       <td>",
"        Anti CD6",
"       </td>",
"       <td>",
"        None",
"       </td>",
"       <td>",
"        6",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        3",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        122",
"       </td>",
"       <td>",
"        SBA/E-rosette",
"       </td>",
"       <td>",
"        None",
"       </td>",
"       <td>",
"        6",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        16",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     See text for details and for references.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_33_10780=[""].join("\n");
var outline_f10_33_10780=null;
var title_f10_33_10781="Dyspnea differential";
var content_f10_33_10781=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F52926&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F52926&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Differential diagnosis of acute dyspnea",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\" class=\"container\">",
"     <tr>",
"      <td class=\"container\">",
"       <table cellspacing=\"0\">",
"        <tr>",
"         <td class=\"subtitle1_single\">",
"          HEENT",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Angiodema",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Anaphylaxis",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Pharyngeal infections",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Deep neck infections",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Foreign body",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Neck trauma",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"subtitle1_single\">",
"          Chest wall",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Rib fractures",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Flail chest",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"subtitle1_single\">",
"          Pulmonary",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          COPD exacerbation",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Asthma exacerbation",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Pulmonary embolism",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Pneumothorax",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Pulmonary infection",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          ARDS",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Pulmonary contusion or other lung injury",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Hemorrhage",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"subtitle1_single\">",
"          Cardiac",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          ACS",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          ADHF",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Flash pulmonary edema",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          High output failure",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Cardiomyopathy",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Arrhythmia",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Valvular dysfunction",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Cardiac tamponade",
"         </td>",
"        </tr>",
"       </table>",
"      </td>",
"      <td class=\"container\">",
"       <table cellspacing=\"0\">",
"        <tr>",
"         <td class=\"subtitle1_single\">",
"          Neurological",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Stroke",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Neuromuscular disease",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"subtitle1_single\">",
"          Toxic/metabolic",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Organophosphate poisoning",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Salicylate poisioning",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          CO poisoning",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Toxic ingestion",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Diabetic ketoacidosis",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Sepsis",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Anemia",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Acute chest syndrome",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"subtitle1_single\">",
"          Miscellaneous",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Hyperventilation",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Anxiety",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Pneumomediastinum",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Lung tumor",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Pleural effusion",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Intra-abdominal process",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Ascites",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Pregnancy",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Massive obesity",
"         </td>",
"        </tr>",
"       </table>",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    ACS: Acute coronary syndrome; ADHF: Acute decompensated heart failure; ARDS: Acute respiratory distress syndrome; CO: Carbon monoxide; COPD: Chronic obstructive pulmonary disease",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_33_10781=[""].join("\n");
var outline_f10_33_10781=null;
var title_f10_33_10782="Decidual hemorrhage and PTB";
var content_f10_33_10782=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F54338&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F54338&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Decidual hemorrhage",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 447px; height: 363px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     F: factor; TF: tissue factor; MMP: matrix metalloproteinases; ECM: extracellular matrix; uPA: urokinase-type plasminogen activator; tPA: tissue-type plasminogen activator.",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Charles Lockwood, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_33_10782=[""].join("\n");
var outline_f10_33_10782=null;
var title_f10_33_10783="Doppler jet patterns AS";
var content_f10_33_10783=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F77381&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F77381&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Doppler jet patterns in aortic stenosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 363px; height: 257px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The diagramatic illustration shows the shape changes in the continuous wave Doppler jet patterns associated with varying degrees of severity of aortic stenosis. Mild stenosis (A) has a rapid rising initial jet velocity whereas the more severe degrees (B and C) have progressively slower rates of rise. The pulsus tardus on physical examination is a direct correlate of these patterns.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_33_10783=[""].join("\n");
var outline_f10_33_10783=null;
